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1. Melting points were determined on a Fargo melting point apparatus and are 
uncorrected. 
2. 1H NMR & 13C NMR spectra were recorded on 600 MHz, Brucker AVANCE 
600 DRX and 400 MHz, Brucker Top-Spin spectrometers. Making a solution of 
samples in DMSO-d6 solvents using tetramethylsilane (TMS) as the internal 
standard unless otherwise mentioned, and are given in the ppm (δ) scale. The 
standard abbreviations s, d, t, q, m, dd, brs refer to singlet, doublet, triplet, 
quartet, multiplet, doublet of doublet, and broad singlet respectively. 
3. Mass spectra were recorded on Shimadzu GC MS-QP 2010 spectrometer 
operating at 70 eV using direct injection probe technique. 
4. Elemental analyses were done on a Heraeus CHN-O Rapid instrument. The 
elemental analysis of the newly synthesized derivatives was within ±0.4% range 
of the calculated C, H, N data. 
5. High performance liquid chromatography analysis for checking purity of 
synthesized compounds were recorded on a Hitachi D-2000 Elite instrument: 
column, Mightysil RP-18 GP 250-4.6 (5µm); mobile phase, MeCN/THF (50:50 
v/v); flow rate, 1 mL/min; injected sample 10µL, column temp, 27 oC; 
wavelength, 254 nm. The purity of all tested compounds was ≥ 95% based on 
analytical HPLC. 
6. Analytical thin layer chromatography (TLC) was performed on Merck precoated 
silica G60 F254 glass plates. Visualization of the spots on TLC plates was 
achieved either by exposure to iodine vapor or UV light. 
7. All evaporation of solvents was carried out under reduced pressure on Heidolph 
LABOROTA-400-efficient. 
8. All reported yields are isolated yields after chromatography or crystallization. 
9. The chemicals used for the synthesis of intermediates were purchased from 
Aldrich, Meark, Spectrochem, Sisco Research Laboratories (SRL), Thomas 
Baker, Sd fine chemicals, Loba chemie and SU-Lab. 
10. The structures and names of all compounds given in the experimental section 
and in physical data table were generated using ChemBio Draw Ultra 12.  
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1.0 Introduction 
Clinically, cancer is a name given to the large family of diseases, maybe a 
hundred or more, that vary in age of onset, rate of growth, state of cellular 
differentiation, diagnostic detectability, invasiveness, metastatic potential, and 
response to treatment and prognosis.1 Cancer occurs when cells in a part of the body 
start to grow out of control or cells become abnormal and forming new cells without 
any control or order.2 All organs of the body are made up of cells. Normally, cells 
divide to form new cells only when the body needs them. If cells divide when new 
ones does not need, they form a mass of excess tissue, called a tumor. Tumors can be 
benign (not cancer) or malignant (cancer). The cells in the malignant tumors can 
damage and invade nearby tissues and organs. Cancer cells can also break away from 
the malignant tumor and travel through the bloodstream to form new tumors in other 
parts of the body. The spread of cancer is called metastasis. 
 
Cancer is a disease that has tormented man throughout recorded history. 
Among the first to document cancer were the ancient Egyptians, whom 1600 B. C. 
years ago wrote detailed accounts of breast cancer.3,4 Continuing through the ages, 
cancer was researched and described by numerous historical figures including Greek 
physician Hippocrates (460–370 B.C.), considered the “Father of Medicine”, Galen, 
and Giovanni Morgagni. It was not until the second half of the 20th century, however, 
that cancer has been more fully researched and its molecular and cellular basis began 
to be understood. As a result, many effective treatment regimens have been 
developed. However, cancer continues to be a major killer.5,6 
 
In the world cancer is the second leading cause of death behind heart disease.7, 
8 Cancers in all forms are causing about 12 per cent of deaths throughout the world. 
While In India, Cancer has become one of the ten leading causes of death.9 It is 
estimated that there are nearly 1.5-2 million cancer cases at any given point of time. 
More than 7 lakh new cases of cancer and 3 lakh deaths occur annually due to 
cancer.10 Nearly 15 lakh patients require facilities for diagnosis, treatment and follow 
up at a given time. Data from the National Cancer Registry Programme indicate that 
the leading sites of cancer are oral cavity, lungs, esophageal, cervical and colic 
amongst men and cervix, and breast amongst women. Cancers namely those of oral 
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and lungs in males, and cervix and breast in females account for over 50% of all 
cancer deaths in India. 
 
From the average diagnosis, most common types of cancer have seen at age 
67. Although cancer is relatively rare in children, still it is a leading cause of death 
between ages 1 and 14. Millions of people alive today have had some type of cancer. 
Of these, about half are considered cured. The good news is that more and more 
people are now being cured of their cancers. This progress is due to better techniques 
of diagnosis and treatment. 
 
In many cases, the causes of cancer are not clear, but both external and 
internal factors play a role. Due to the complex nature of cancer development, it is not 
possible to pinpoint one specific agent as the cause of cancer.11-13 Rather, it is most 
likely due to a number of contributing factors. These factors include exposure to 
certain chemicals, action of viruses, exposure to radiation, and heredity. Today we 
recognize and avoid many specific substances that cause cancer: coal tars and their 
derivatives (like benzene), some hydrocarbons, aniline (a substance used to make 
dyes), asbestos, and others. Radiation from variety of sources, including the sun, is 
known to cause cancer. To ensure the public safety, the government has set standards 
for many substances, including benzene, asbestos, hydrocarbons in the air, arsenic in 
drinking water, and radiation. Collectively, these are known as risk factors. Brief risk 
factors are summarized in Table 1.1 
 
Table 1.1 Risk factors for the development of cancer. 
 
Sr. 
No. 
Risk Factor Mechanism of Action Example 
1 Chemicals  Damage DNA, 
leading  
to mutations 
 Encountered in the 
manufacture 
of dyes, chemicals, 
petroleum products 
 Associated with tobacco 
usage, 
general environmental  
pollution, diet, some 
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medicines 
2 Radiation  Damage DNA, 
leading  
to mutations 
 UV, ionizing radiation, 
radioactive elements 
3 Viruses  Not thought to induce 
Cancer 
 Participate in early 
stages leading to 
cancer 
 Epstein-Barr virus, human 
papilloma Virus, hepatitis 
B virus, HIV 
4 Heredity  Transmission of a 
single gene increases 
likelihood of cancer 
 Inherited cancers are 
commonly diseases of 
childhood: retinoblastoma, 
Wilm’s tumor 
 Adult diseases: colon and 
breast carcinoma 
 Rare hereditary 
diseases increase 
likelihood of cancer 
 Xenoderma Pigmentosum, 
Ataxia telangiectasia 
  
 
 
1.1 Cancer Prevention 
 
The best way to reduce deaths from cancer is to prevent it. Medical doctors 
generally agree that about one-third of all human cancers are directly related to 
cigarette smoking.1 For smokers, the risk of cancer is much higher than that of the 
nonsmokers. Excluding the UV rays of sunlight which cause skin cancer, the next 
most common cited cancer-causing factor is diet. The National Cancer Institute and 
the American Cancer Society recommend a diet low in fat, high in natural fiber, and 
rich in fruits and vegetables. On the other hand Chemoprevention is simply 
prevention with drugs. The word “drugs” is used to include dietary supplements, 
hormones, and vitamins etc., as well as real drugs such as aspirin and other synthetic 
agents used for therapeutic purposes. The number of chemopreventive agents is 
increasing.14 
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1.2 Cancer Treatments 
There are three main strategies for cancer treatment: surgery, radiation and 
chemotherapy, which are used to attempt the damage cancer cell. The role of each 
depends upon types of tumor and the stage of its development. 
 
1.2.1 Surgery15 
Surgery is the oldest and still the most common local treatment for cancer. 
Surgery is a procedure to remove or repair a part of the body. Surgery also can help to 
decrease the tumor bulk and, along with other treatment measures, may provide a cure 
for certain cancers. However, surgery is not always the best answer. It generally 
works best on slow-growing cancers.  
 
1.2.2 Radiation therapy16  
Similar to surgical intervention, radiation therapy is a localized treatment. 
Radiation therapy is a use of high-energy radiation from x-rays, gamma rays, 
neutrons, protons, and other sources to treat cancer cells. Radiation may come from a 
machine outside the body (external-beam radiation therapy), or it may come from 
radioactive material placed in the body near cancer cells (internal radiation therapy). 
Systemic radiation therapy uses a radioactive substance, such as a radiolabeled 
monoclonal antibody, that travels in the blood to tissues throughout the body. 
Radiation therapy is used at some point in the treatment of more than half of all 
cancer cases. 
 
1.2.3 Chemotherapy17 
Chemotherapy is the use of cancer-fighting medications to stop the growth of 
malignant cells. During Second World War, naval personnel who were exposed to 
mustard gas as a result of a military action were found to have toxic effects on the 
bone marrow cells that developed into blood cells. In the course of that observation, 
compound called nitrogen mustard was studied and found to work against a cancer of 
the lymph nodes called lymphoma. The development and use of chemotherapy drugs 
(chemo) have resulted in the successful treatment of many people with cancer. It 
works by either killing the cells or preventing them from dividing. Many of cancers 
can be controlled with chemotherapy for a long period of time, even if they are not 
cured. 
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1.2.4 Other therapies  
Targeted therapy is a type of medication that blocks the growth of cancer 
cells by interfering with specific targeted molecules needed for carcinogenesis and 
tumor growth, rather than by simply interfering with rapidly dividing cells.18 
Immunotherapy is the use of the immune system to reject cancer. The main 
premise is stimulating the patient’s immune system to attack the malignant tumor 
cells that are responsible for the disease. This can be either through immunization of 
patient (e.g., by administering a cancer vaccine) or through the administration of 
therapeutic antibodies as drugs. 19 
Hormone therapy inhibited the growth of some cancers by providing or 
blocking certain hormones. Common examples of hormone-sensitive tumors include 
certain types of breast and prostate cancers. 20 
 
1.3 Type of different cytotoxic agents 
 
Agents for cancer chemotherapy are often organized into groups according to 
their origin or mechanism of action. The six major classes of agents include the 
alkylating agents, antimetabolites and nucleoside analogs, antitumor antibiotics, 
antimitotic, hormonal, and miscellaneous agents. The mechanism of action, drug 
group, and relevant examples of each class are shown in Table 1.2 
 
Table 1.2 Classification of cytotoxic drug, including their mechanism of action, drug 
group, and example drug.21 
 
 
Sr. 
No. 
Class of 
Anticancer 
Mechanism 
of Action 
Drug Group Example Drug 
1 Alkylating 
Agents 
React with 
DNA 
Aliphatic 
Nitrogen 
Mustard 
Mechlorethamine 
Aromatic 
Nitrogen 
Mustard 
Melphalan, 
Chlorambucil 
Phospharamide Cyclophosphamide,
Ifosfamide 
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Nitrosourea Carmustine, 
Lomustine 
2 Antimetabolites  
& Nucleoside 
Analogs 
Interact with 
cellular 
Enzymes 
Pyrimidine 
Antimetabolites
5-Fluorouracil, 
Cytarabine, 
Gemcitabine 
Purine 
Antimetabolites
6-Mercaptopurine, 
6-Thioguanine 
3 Antitumor 
Antibiotics 
Intercalate 
DNA, 
formation of 
free 
radicals 
Streptomyces  Doxorubicin, 
Mitomycin C, 
E0-9, 
Bleomycin 
4 Antimitotic  Interfere with 
microtubule 
function 
Vinca 
Alkaloids 
Vincristine, 
Vinblastine, 
Vinorelbine 
Taxanes Paclitaxel, 
Docetaxel 
5 Hormonal  Bind to 
receptors 
Antiestorgenes Tamoxifen,  
Estramustine 
6 Miscellaneous 
 
Various 
interactions 
with cellular 
DNA, 
inhibiting 
replication, 
transcription 
Platinum 
Complex 
Cisplatin, 
Carboplatin, 
Tetraplatin 
Enzymes L-asparagina 
Other class Hydroxyurea, 
Mitotane, 
Camptothecins, 
Topotecan 
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1.4 Alkylating Agents 
 
Alkylating agents are the oldest class of anticancer drugs which are still 
commonly used; they play a vital role in the treatment of varieties of cancers.22-24 
Alkylating agents that induce permanent DNA damage are often exhibits potent 
antitumor activity.25 A range of DNA alkylating agents is known including 
monofunctional alkylating (reacts only one DNA strand to form genotoxic 
monoadducts) and bifunctional alkylating drugs. The latter were found to intrastrand 
cross-links, interstrand crosslinks, inter-helix or DNA-protein cross-links (ICLs) on 
DNA, which resulted in more potent and efficacious agents.26 Currently, a variety of 
bifunctional alkylating agents are widely used for the treatment of patients with 
malignant diseases. 
 
1.5 Naturally Occurring DNA Bifunctional Alkylating agents 
1.5.1 Mitomycine C and its analogues 
 
The existence of bioactive compounds in plants and other natural sources has 
played an important role in the development of new drugs.27,28 For e.g., In the 1950s, 
the Mitomycines were identified as a new and potent class of antibiotics agents.29,30 
The mitomycines displays a wide array of substitution patterns inherent to core 
structure of pyrrolo[1,2-a]indole.31-33 (Figure 1) Originally isolated from Streptomyces 
caespitosus in Japan, one of the members of the family, Mitomycine C (MMC, 1) has 
been use for antitumor antibiotic activity.34-39 They have obtained a prominent place 
in cancer chemotherapy as a DNA bifunctional alkylating agents and used to treat a 
verity of tumors.40-44 
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Figure 1. Examples of naturally occurring Mitomycine derivatives.
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The synthetic analogue of the antitumor antibiotic Mitomycin C, EO-9 (7) is a 
bioreductive alkylating agent indoloquinone which serves as a target for nucleophilic 
DNA and capable to cross-linked with DNA.45 The aziridinylquinone is a derivative 
of banzoquinone, represented perhaps the simplest of the mitomycine C like 
prodrugs.46 Most studied aziridinylquinone derivative are the simple unsubstituted 
diaziridinylquinone (DZQ, 8) and the more clinically promising quinone derivative is 
AZQ (9), active against human brain tumors.47 
 
N
N
O
O
OH
OHMe
N
O
O
N
N
O
O
N
H
N
N
H
COOEt
EtOOC
Indoloquinone EO-9, 7 DZQ, 8 AZQ, 9
Figure 2. Examples of DNA alkylating Quinone derivatives  
 
Mitomycine C itself inactive,48 which is activated by chemical (Na2S2O4,49 
NaBH4,49 H2, 49,50 NO/HCO2Na/hv51), electrochemical52,53 or enzymatic (old yellow 
enzyme,54 NADPH-cytochrome c reductase/NADPH,55,56 xanthine 
oxidase/NADH,55,56 DT-diaphorase55,57) reduction of the quinone moiety to 
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semiquinone or hydroquinone to initiate alkylation. Iyer and Szybalski49 proposed a 
mechanism for the activation and alkylation reactions, their mechanism was purely 
based on structural considerations and chemical precedent shown in Scheme 1. While 
its structure exhibits similarities to other quinone natural products, Initial One or two-
electron reduction of the quinone ring 1 to either the semiquinone or the 
hydroquinone (10).58-60  Generation of hydroquinone facilitates the loss of the 
methoxy group, leading to the formation of the hydroquinone intermediate (11). 
Tautomerization followed by the reaction with the N2-amino group of guanine 
produces monoadduct (14). Elimination of the carbamoyl group producesd the highly 
reactive vinylogous hydroquinone methide intermediate (15), which alkylates the 
guanine on the opposite strand of DNA to produce (16), after oxidation, an interstrand 
cross-link (17). 
N
O
O
NH
OCONH2
OMeH2N
H3C
Mitomycin C (MMC), 1
Scheme 1. Proposed mechanism of DNA cross-linking by two electron reductive activation of Mitomycine C.
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1.5.2 Pyrrolizidine alkaloids  
Other natural products, Pyrrolizidine alkaloids (PAs) are constituents of over 
6000 species of plants, most notably Boraginaceae, Graminae, Leguminosae and 
Compositae, insects including various species of butterflies and even animals such as 
amphibians. They elicit hepatotoxic, carcinogenic, antineoplastic and genotoxic 
activity, primarily via DNA cross-linking.61 Their ubiquitous presence, as well as their 
interesting biological activity is through the formation of DNA-protein cross-links.62 
The common structural feature of all these alkaloids is the presence of a 
functionalized pyrrolizidine moiety – the necine base.61 Although a large variety of 
necine bases have been isolated (Figure 3), most of the alkaloids contain retronecine 
(20) as their pyrrolizidine portion. 
 
 
 
The mechanism of DNA cross-linking by pyrrolizidine alkaloids (e.g. 
retrorsine, 23) has been extensively investigated. Inhibition of DNA synthesis in 
pyrrolizidine alkaloids treated liver-slices, corroborated with the lack of a similar 
effect in lung tissue cultures.63 It is well established mechanism of action involving 
oxidative activation of the pyrrolizidine moiety by chemical oxidation in vitro or 
hepatic oxidation in vivo.64 Further studies demonstrated that the retronecine portion 
of (23) is oxidized by liver cytocrome P450 to a highly reactive pyrrole (26)65 
(Scheme 2). 
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Scheme 2. Mechamism of oxidatvie pyrrolizidine alkaloid activation
 
Conjugation with the pyrrole nitrogen lone pair makes the C-7 and C-9 
positions of (26) highly reactive toward nucleophilic attack. Thus, such species is 
extremely reactive was reported by Niwa et al. 65 
 
Along with mitomycin C (1) and pyrrolizidine alkaloids (23), several other 
naturally occurring or synthetic antitumor agents contains at least one, often two or 
three, reactive electrophilic centers in the molecule through which they exert their 
anticancer activity. For examples (Figure 4), aflatoxin B1(27),66 7,8-dihydroxy-9,10-
epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE) (28),67 naphthoquinone β-
lapachone (29),68 anthramycin (30),69 azinomycin B (31),70 anthracycline derivatives 
(i.e. doxorubicin, 32),71 cyclopropylpyrroloindoles (i.e. duocarmycin, 33).72 
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Studies involving the structure-activity relationship among pyrrolizidine 
alkaloids suggest that although the presence of the unsaturated pyrrolizidine base 
(retronecine) is the most important element for the cross-linking capacity of these 
compounds, there are other, more subtle structural features modulating both the 
potency and preference of various alkaloids for different types of DNA lesions. The 
patterns of proteins crosslinked to DNA are similar to those induced by standard 
bifunctional alkylating agents such as mitomycin C.73 
 
Hopkins et al. have demonstrated that pyrrolizidine alkaloids metabolites 
target the same 5’GpC3’ DNA sequence as antitumor antibiotic mitomycin C (1) 
albeit with less selectivity.74 These findings can be explained by the structural 
similarities between the alkylating moiety of active mitomycin metabolite 34 and 
activated pyrrolizidine alkaloids the added sequence promiscuity. In the case of 
pyrrolizidine alkaloids suggest the lack of some molecular recognition constituents 
inherent to the mitomycins (Figure 5). 
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1.6 Synthetic DNA Bifunctional Alkylating agents 
 
Structure-activity relationship studies with many of these natural products are 
often limited by the small quantities of material available and by the relatively limited 
number of modifications which actually can be performed on these complex 
molecules. On the other hand, to synthesize this simple molecules for SAR study; one 
can use biological active natural products as the base template.75-77 Based on 
structural characteristics of the mitomycin C and pyrrolizidine alkaloids, Hopkins et 
al. have demonstrated that dehydroretrorsine (36), and dehydromonocrotaline (37), 
dehydroretronecine diacetate (38), 2,3-bis(acetoxymethyl)-1-methylpyrrole (39), and  
3,4-bis(acetoxymethyl)-1-methylpyrrole (40) also cross-linked with DNA in same 
manner like MMC targets, with a high degree of selectivity for 5-CpG3.78,79  
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In additionally, Anderson et al.80,81 have designed and synthesized several 
“acylated vinylogous carbinolamine” tumor inhibitors including (Figure 6); l-Phenyl-
2,5-dimethy1-3,4-bis(hydroxymethyl)-pyrrole-bis(N-methylcarbamate) (41a-j)80 and 
1,2-dimethyl-3,4-bis(hydroxymethyl)-5-phenylpyrrol bis(N-methylcarbamate) (42a-
r)81 also demonstrated to have DNA interstrand cross-linking activity as same as 
MMCs.  
 
a, X = 4'-OMe f, X = H
b, X = 4'-OEt g, X = 4'-F
c, X = 3',4'-OCH2O- h, X = 4'-Cl
d, X = 4'-CH3 i, X = 4'-Br
e, X = 4'-n-C4H9 j, X = 3', 4'-Cl2
N
OCONHMe
OCONHMe
Me
Me
X
42
Figure 6
N
MeHNOCO OCONHMe
Me
Me
X
a, X = 4'-H
b, X = 4'-Me
c, X = 4'-C(Me)3
d, X = 4'-Ph
e, X = 4'-F
f , X = 4'-Cl
g, X = 4'-Br
h, X = 4'-OMe
i, X = 4'-n-C4H9
41
j, X = 4'-SMe
k, X = 4'-SO2Me
l, X = 3', 4'-Cl2
m,X = 4'-NO2
n, X = 4'-NH2
o, X = 4'-NHCONHMe
p, X = 4'-NHCOMe
q, X = 4'-NHMe
r, X = 4'-NHEt
 
 
 The rationale design of these agents is based on the concept that these agents 
can act as bifunctional electrophiles in which [(carbamoy1)oxyl]methyl groups serve 
as reactive electrophilic centers. The SAR studies of these agents against P338 
lymphocytic leukemia revealed that the compounds having 1-substituted derivatives 
41, compounds possessed significant reproducible activity against the P-388 
lymphocytic leukemia (PS) assay with the lowest dose of 12.5 mg/kg. Activity at this 
dose ranged from %T/C = 190-132 for compounds 41e and 41c, respectively. In the 
series of C-2 substituted derivatives 42 the electronic and lipophilic properties of the 
substituent X can be varied rather extensively without loss of significant antileukemic 
activity.   
  In the course of exploring the structure-biological activity relationships of 
pyrrole-derived bifunctional alkylating agents, a series of 6,7-disubstituted pyrrolizine 
diesters have been synthesized and evaluated for antitumor studies.82 
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The potential electrophilic reactivity of the allylic esters in 43 (via O-alkyl 
cleavage) will be enhanced by participation of the ring nitrogen similar to that of 
MMC and PAs. All of these compounds exhibited significant antileukemic activity 
against P-388 in animal model. Of these derivatives, bis(methylcarbamate) derivative 
44 showed potent activity at lowest dose tested, 0.78 mg/kg and 45, afforded “cures” 
at dose levels as low as 12.5 mg/kg. Several other compounds showed high activity 
against P-388 over a four-fold dose range without appeared acute toxicity. The most 
potent compound of this class was 5-(3,4-dichloropehnyl)-2,3-dihydro-1H-
pyrrolizidine-6-7-bis(isopropylcarbamate) (46),83 which had significant reproducible 
antitumor activity against a broad range of experimental murine neoplasias and humor 
tumor xenografts in nude mice. This compound was selected for more extensive 
preclinical studies,84 but there was no further information has been published whether 
this agent was in clinical trials.  
Studies on the structure-activity relationships of derivatives of 5-
phenylpyrrolizines 43 revealed that the nature of R and R1 substituent significantly 
affected both chemical reactivity and biological activity of the system. The chemical 
reactivity of 43 toward nucleophiles was found that compounds having electron-
donating substituent(s) (OMe) on the phenyl ring were generally less cytotoxic than 
those compounds bearing electron-withdrawing substituent(s) (halogen). While, the in 
vivo antitumor activities were comparable or slightly less potent in compounds having 
an electron-donating substituent. These studies also suggested that the lipophilicity of 
compound might affect its antitumor potency. The reactivity of this system depended 
upon the π–electron density in the pyrrole ring and the ability of the C-5 substituent 
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(R) to stabilize the formation of the positive charge on the heterocyclic nitrogen atom 
during the displacement of the ester moieties (via O-alkyl cleavage). In general, the 
electrophilic reactivity can be controlled by the electronic influence of the C-5 
substituent. The size of the R1 substituent does not appear to have any significant 
effect upon potency, activity, or toxicity. 
 
  The water soluble analogues of (46, IPP) were also prepared for the oral 
availability, Anderson & co-workers have designed and synthesized several series of 
compounds to study their antitumor effect against P388 lymphocytic leukemia and 
B16 melanocarcinoma in mice.85 Among these agents, alcohol derivative 47a (where 
R = H) showed to have comparable activity to 46 with a dose of 50 mg/kg, while 47b 
(where R = COCH2N(CH3)2) showed less active and 47d with very low activity. In 
order to prepared more lipophilic compounds, the same authors have synthesized 
hetero analogues of 43 with general formula 4886 in which the C-2 methylene was 
replaced by S, SO or SO2. However, these agents were found to be less cytotoxic as 
compare to (46, IPP). The water soluble derivatives 49 were also synthesized by using 
prodrug approach in which an α-halopyridinium moiety as the pyrrolizines C-5 
substituent.87 The 4- and 5-pyrrolizinyl-2-halopyridinium iodides and the 
corresponding pyridones were evaluated against P388 lymphocytic leukemia in vivo. 
The compounds having small size (α-fluoropyridinium) were active but the α-chloro 
compounds were not. Compounds were active in the P388 screen, were evaluated in 
L1210 leukemia, M5076 carcinoma, and MX-1 mammary xenograft assays in mice. 
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From this observation, Lalezari et al. have prepared 1-Thia analogues of 46 
(IPP).88 Of these derivatives compound having Ph, F and di-Cl were equipotent (IC50 
= 1.5, 1.6, and 1.9 µM respective) against the HL-60 (human leukemia) cells as 
compare to 46 (IC50 = 1.5 µM) while 4-Cl (51) derivative showed an increase potency 
of 75% (IC50 = 0.85 µM). All derivatives were also cytotoxic against HT-29 (human 
colon carcinoma) cells as similar inhibition of 46. 
 
N
S
R
OCONH-i-Pr
OCONH-i-Pr
50
R = C6H5, 4-F-C6H4,
4-Cl-C6H4, 3,4-di-Cl-C6H3
N
S
OCONH-i-Pr
OCONH-i-Pr
Cl51
Figure 9  
 
Further Anderson and group have also synthesized a different of heterocyclic  
analogs (52-56)89 of pyrroles (41 and 42) to examine differ from one and other in 
several aspects-aromaticity, pKa, lipophilicity, dipole moments, charge-transfer 
donor/acceptor. All prepared derivatives were tested for antileukemic activity against 
murine P-338 lymphocytic leukemia. None of the compounds was active when 
compared to 41 and 42. It was shown that electrophilic reactivity is one requirement 
for antineoplastic activity in these bis(carbamates). It was also evident that the 
bis(carbamates) are not functioning as carbamoylating agents since so many of these 
nonpyrrole bis(carbamates) derivative were inactive. 
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The rational used for the design of 46 (IPP) Anderson et al. have extended to 
imidazoles nucleus to prepared water soluble derivatives.90 Appropriate electron 
donating or electron withdrawing substituents were added to the imidazole ring to 
modulate the reactivity of the two electrophilic centers. The potent advantage of the 
imidazole is that it is sufficiently basic to allow for the preparation of salts to enhance 
water solubility. All synthesized imidazole derivatives were tested against murine P-
388 lymphocytic leukemia. The structure activity relationship studies of this series of 
compounds were emerged that the electron-withdrawing susbstituents at either N-1 of 
C-2 gave rise to inactive compounds. However, the electron-donating substituents 
gave active compounds and the 2-(methylthio)-1-methyl derivatives 58 (carmethizole) 
was found to be most potent. The derivative 58, were also found to be active against 
the MX-1 mammary xenograft, the human amelanotic melanoma cell line LOX 
xenograft, the M-5076 sarcoma, and L-1210 lymphocytic leukemia. Finally, 58 was 
reached for clinical evaluation.91-93 
 
N
N
OCONHR1
OCONHR1R
X
X = H, Me, Ph, SMe, OMe;
R = H, Me, Ph, CH2Ph;
R1= Me, CHMe2
N
N
OCNHMe
OCNHMeMe
MeS
57 58
Figure 11  
 
Studies on the mechanism of action showed that the bis(carbamate)pyrroles 
(41 or 42) or pyrrolizines derivatives (43-51) exert their antitumor effect was 
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probably via a SN1 electrophilic reaction (Scheme 3).79,82 These derivatives are 
capable of forming DNA interstrand cross-link with the short oligonucleotide 5’-
ACGT at the 5’-CG residues at the minor groove region.79  
 
 
 
These agents are not carbamoylating agents; instead the carbamate moieties 
are leaving groups in an alkyl-oxygen cleavage mechanism (60). The reactions take 
place on methylenic carbons bonded directly to a heteroaromatic pyrrole nucleus (61). 
The role of the heteroaromatic system is to stabilize reaction transition states, and this 
provides a means to control the reactivity of the two electrophilic centers. Control 
may be achieved through the alteration of the heteroaromatic system.  
The degree of conjugation observed in any biaryl system is related to the 
capability of the system to adopt a coplanar conformation. Studies on comparison of 
nonbonding interactions in C-5-phenyl pyrroles (42a-r) and C-5-phenyl pyrrolizines 
(43-51) revealed that two significant nonbonded interactions exist in the 5-
phenylpyrrole derivatives (65, Figure 12) between the ortho hydrogens of the phenyl 
substituent and the hydrogens on the N-1 methyl group and the C-4 methylene.94 
While, one of these nonbonded interactions is absent in the pyrrolizine compounds 
(66, Figure 12): the pyrrolizine C-3 methylene hydrogens lie outside the van der 
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Waals radii of the ortho-hydrogen atoms of the C-5 phenyl ring and demonstrated that 
the phenyl and pyrrole rings in 43 are coplanar (or very nearly so).94  
 
 
 
On the basis of this observation, several new set of analogues that possess 
angular tricyclic structures to limit the deviation from coplanatiry of the phenyl and 
pyrrole rings. Specifically, tricyclic derivative of pyrrolo[2,1-a]isoquinolines was first 
designed and evaluated for antitumor activity against P388 lymphocytic leukemia.94 It 
was demonstrated that the pyrrolo[2,1-a]isoquinolin-bis(isopropylcarbamate) 67a 
exhibited the best activity of the compounds tested. The carbamate derivative 67a 
were also found broad spectrum of activity against the various human tumors 
xenongraft (MX-1 breast, CX-1 colon and LX-1 lung) and murine tumors (B16 
melanocarcinoma, L1210 lymphoid leukemia, CD8F1 mammary and lewis lung 
carcinoma colon 38). However, the tricyclic compounds revealed to be more potent 
than pyrrole and pyrrolizine derivatives. 
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On the potency of 67, several other angular tricyclic pyrrolo[1,2-a]quinolines 
(68a-b), pyrrolo[1,2-a]benzazepines (69a-b) and pyrrolo[2,1-a]isobenzazepines (70) 
were also synthesized and evaluated for antileukemic activity (Figure 13). The 
bis(carbamates) (68-70) were tested in vivo against P388 lymphocytic leukemia. In 
the pyrrolo[2,1-a]isoquinoline series (67a-b), the C-3 methyl group had more 
pronounced effect on activity and toxicity than the C-7 methoxy group where as 
pyrrolo[1,2-a]quinolines were less active.94,95 The pyrrolo[l,2-a]benzazepine-
bis(carbamates) 69a and 69b showed approximately equivalent activity to the 
comparable pyrrolo[1,2-a]quinolines. The fused benzazepines 70 were less potent and 
more toxic than the corresponding pyrrolo[2,1-a]isoquinoline (67a).95 It was 
concluded that ring fusion and ring substitution do alter the potency, activity and 
toxicity of the bis(carbamates) derivatives. It was also indicated that compounds with 
the phenyl ring attached directly to the pyrrole nitrogen will have different structure-
activity requirements from the compounds in which the phenyl ring is attached to the 
pyrrole α-carbon. 
Recently, Su et al. have designed and synthesized a series of DNA 
bifunctional alkylating agents (Figure 14), bis(hydroxymethyl)-8H-3a-
azacyclopenta[a]indene-1-yl derivatives and their bis(methylcarbamate) derivatives 
(71).96 These agents can be considered as “benzologues” of 
bis(hydroxymethyl)pyrrolizines and were able to cross-link to DNA double strands. It 
was demonstrated that these analogues exhibited potent antitumor activity against 
human lymphoblastic leukemia and various solid tumor cell growths in vitro and 
potent antitumor efficacy in vivo with a relatively low toxicity. Detailed SAR studies 
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were demonstrated that the size and electron properties of the substituent at C-3 
affected the cytotoxicity of these agents. Remarkably, complete tumor remission (CR) 
in nude mice bearing human breast carcinoma MX-1 xenograft by 
bis(hydroxymethyl) derivatives (72 and 73, Figure 14) and bis(methylcarbamate) 
derivatives (74 and 75) were achieved. Interestingly, compound 73 was able to 
significantly suppress against prostate adenocarcinoma PC3 xenograft in nude mice. 
Studies on the DNA interstrand cross-linking suggested that these derivatives were 
potent bifunctional DNA cross-linking agents. Furthermore, 3a-aza-
cyclopenta[a]indene derivatives were able to induce substantial G2/M phase arrest of 
the cell cycle.  
 
 
In additionally, they also demonstrated that the effect of combining alkylating 
agents 74 and arsenic trioxide (ATO, DNA repair inhibitor) significantly suppressed 
human large cell lung carcinoma H460 xenograft (>82%) and cisplatin-resistant 
NTUB1/P human bladder carcinoma xenografts (>92%) in nude mice.97 From this 
observation, it was concluded that a combination of bifunctional alkylating agents and 
ATO may be a rational approach for treating cancers with inherited or acquired drug 
resistance. These exciting results provoked to continue designing and synthesizing 
new bis(hydroxymethyl)pyrrolizine analogues for antitumor studies. 
 
1.7 Rational Drug Design of Bis(hydroxymethyl) and their 
Bis(alkylcarbamates) Derivatives. 
 
As mentioned previously, pyrrolo[2,1-a]isoquinolines (67, Figure 13) bear a 
angular tricyclic ring system and it showed best activity of the other angular tricyclic 
(68-70, Figure 13). Moreover, tricyclic derivatives do appear to be most cytotoxic 
Chapter 1                                                                                                   Introduction… 
       
 
 
24
than pyrrole and pyrrolizine derivatives. Based on the potent antitumor activities and 
mechanism of action of MMC (1) and pyrrolo[2,1-a]isoquinolines (67), to investigate 
whether analogues of 67 with a linear tricyclic ring system also possess potent 
antitumor activity. In medicinal chemistry term, the molecule differing one from 
another by only a methylene group is called homologues. By using ring enlargement 
approach in 3a-azacyclopenta[a]indene (71) derivatives to design and manipulation of 
the original B ring systems, it is great interest to synthesize a series of new linear 
bis(hydroxymethyl) of 5,10-dihydropyrrolo[1,2-b]isoquinolines and their 
bis(alkylcarbamates) (76) derivatives having structure in Figure 15. One can expect 
that the newly synthesized compounds might be able to cross-link to the 
macromolecular DNA via a similar mechanism of action as that of pyrrolizines 
derivatives. (Scheme 4) 
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X
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X
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Scheme 4. Proposed mechanism of action of 5,10-dihydro-pyrrolo[1,2-b]isoquinolin-1-yl derivatives  
 
The chemical synthesis of bis(hydroxymethyl)-5,10-dihydropyrrolo[1,2-
b]isoquinolines and their bis(alkylcarbamates) derivatives are described in the 
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Chapter 2. The antitumor activities, in vitro, in vivo evaluation and mechanism of 
action of these agents are described in the Chapter 3. 
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Section A 
 
Chapter 2. Synthesis and 
Characterization of 
bis(hydroxymethyl)-5,10-
dihydropyrrolo[1,2-b]isoquinolin-
1-yl derivatives and their 
bis(alkylcarbamate) derivatives 
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2.0 Chemistry 
 
The synthetic route for bis(hydroxymethyl)-5,10-dihydropyrrolo[1,2-
b]isoquinolin-1-yl derivatives (81) and their bis(alkylcarbamate) derivatives (82–84) 
is shown in Scheme 1. The known 3-carboxy-1,2,3,4-tetrahydroisoquinoline (78) was 
synthesized by treating the commercially available D,L-phenylalanine (77) with 
formaldehyde and conc. HCl by following the procedure developed by Dean.98 
Compound 78 was N-acylated by treating with various acid chlorides (R1COCl) in 
presence of 2N NaOH to give N-acyl-3-carboxy-1,2,3,4-tetrahydroisoquinolines (79b-
j) by following the literature procedure.99,100 Compounds 79b-j were then reacted with 
dimethyl acetylenedicarboxylate (DMAD) in acetic anhydride at 60–70 oC yielded 
5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic acid dimethyl esters (80b-j). 
The methyl ester derivative 80a (R1 = Me) was prepared in good yields directly from 
78 by reacting with acetic anhydride and DMAD.101 The ester function of 80a-j were 
reduced to bis(hydroxymethyl) derivatives 81a-j by treating with LiAlH4 in a mixture 
of ether/CH2Cl2 at 0-5 ºC. Compounds 81a-j were then further treated with methyl-, 
ethyl- or iso-propylisocyanate in presence of triethylamine (TEA) to furnish the 
desired bis(alkylcarbamate)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1-yl derivatives 
(82–84) in good to high yields. The cycloaddition reaction mechanism of 79b-j with 
DMAD is depicted in Scheme 2. The reaction of N-acyl-3-carboxy-1,2,3,4-
tetrahydroisoquinolines (79b-j) with dimethyl acetylenedicarboxylate (DMAD) in 
presence of acetic anhydride provides mesoionic oxazolone intermediates 85b-j. 1,3-
dipolar addition102 of 85b-j give 86b-j which spontaneously eliminate CO2 to give 
diester 80a-j. Table 2.1 and 2.2 show the yields and the physical data of these 
compounds. 
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2.1 Reaction Scheme 
2.1.1 Scheme 1 Synthetic routes for bis(hydroxymethyl)-5,10-dihydropyrrolo[1,2-
b]isoquinolin-1-yl derivatives (81) and their bis(alkylcarbamate) derivatives (82–84). 
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i: R1= 3',4'-di-MeO-C6H3
j: R1 = 3',4',5'-tri-MeO-C6H2
Reagents and conditions: (i) 37 % Formalin/Conc. HCl, reflux; (ii) Acid chloride, 2N NaOH/
acetone, room temperature; (iii) DMAD/Ac2O, 60-70 oC; (iv) LiAlH4, CH2Cl2/Et2O, 0-5 oC;
(v) R2NCO/ Et3N, room temperature.
 
2.1.2 Scheme 2 Plausible reaction mechanism of 1,3-dipolar cycloaddition reaction 
of 80a–j. 
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Table 2.1 Yields and physical data of the compounds 79b–j and 80a–j. 
 
 
 
Compd. BO No. Substitute R1 
Yield 
% 
MP °C Analysis 
79b 1473 Et 87 173–174 CHN 
79c 1471 C6H5 78 168–169 CHN 
79d 1477 4’-F-C6H4 98 179–180 CHN 
79e 1114 4’-Cl-C6H4 93 77–79 CHN 
79f 1110 3’,4’-di-F-C6H3 95 89–91 CHN 
79g 1507 3’,4’-di-Cl-C6H3 90 101–102 CHN 
79h 1103 4’-MeO-C6H4 86 178–180 CHN 
79i 1474 3’,4’- di-MeO-C6H3 62 235–236 CHN 
79j 1486 3’,4’,5’-tri-MeO-C6H2 98 186–189 CHN 
80aa 1105 Me 78 152–154 CHN 
80b 1489 Et 93 88–89 CHN 
80c 1472 C6H5 68 137–138 CHN 
80d 1479 4’-F-C6H4 58 149–150 CHN 
80e 1115 4’-Cl-C6H4 64 164–166 CHN 
80f 1111 3’,4’-di-F-C6H3 67 142–144 CHN 
80g 1508 3’,4’-di-Cl-C6H3 64 169–170 CHN 
80h 1104 4’-MeO-C6H4 66 155–158 CHN 
80i 1475 3’,4’- di-MeO-C6H3 81 202–203 CHN 
80j 1487 3’,4’,5’-tri-MeO-C6H2 51 165–166 CHN 
aknown compound 
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Table 2.2 Yields and physical data of the compounds 81a–j, 82, 83a–j and 84a-j. 
 
 
 
Compd. 
BO 
No. 
Substitute R1 
Yield
% 
MP °C 
HPLC 
% 
Analysis
81a 1107 Me 65 99–101 96.94 CHN 
81b 1524 Et 77 Liq. 97.09 CHN 
81c 1476 C6H5 80 150–151 99.29 CHN 
81d 1480 4’-F-C6H4 75 135–136 97.62 CHN 
81e 1116 4’-Cl-C6H4 52 170–172 99.52 CHN 
81f 1112 3’,4’-di-F-C6H3 83 145–146 99.52 CHN 
81g 1518 3’,4’-di-Cl-C6H3 72 150–151 99.54 CHN 
81h 1106 4’-MeO-C6H4 67 174–176 99.56 CHN 
81i 1492 3’,4’- di-MeO-C6H3 77 145–146 98.68 CHN 
81j 1490 3’,4’,5’-tri-MeO-C6H2 58 146–147 97.62 CHN 
82a 1108 Me 45 174–176 97.44 CHN 
82e 1117 4’-Cl-C6H4 82 194–196 99.74 CHN 
82f 1113 3’,4’-di-F-C6H3 77 190–192 99.79 CHN 
82h 1109 4’-MeO-C6H4 87 182–184 96.10 CHN 
83a 1506 Me 53 208–209 99.34 CHN 
83b 1525 Et 51 127–129 97.01 CHN 
83c 1493 C6H5 81 170–171 97.29 CHN 
83d 1491 4’-F-C6H4 76 183–184 97.92 CHN 
83e 1520 4’-Cl-C6H4 65 191–192 99.05 CHN 
83f 1517 3’,4’-di-F-C6H3 71 189–190 98.75 CHN 
83g 1519 3’,4’-di-Cl-C6H3 83 208–209 96.91 CHN 
83h 1516 4’-MeO-C6H4 65 165–166 99.05 CHN 
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83i 1501 3’,4’- di-MeO-C6H3 70 124–125 95.87 CHN 
83j 1503 3’,4’,5’-tri-MeO-C6H2 99 170–171 98.58 CHN 
84a 1528 Me 65 215–218 99.99 CHN 
84b 1532 Et 59 155–158 98.28 CHN 
84c 1504 C6H5 74 175–176 99.41 CHN 
84d 1502 4’-F-C6H4 82 190–191 97.26 CHN 
84e 1530 4’-Cl-C6H4 64 191–192 96.48 CHN 
84f 1527 3’,4’-di-F-C6H3 83 176–178 96.63 CHN 
84g 1526 3’,4’-di-Cl-C6H3 83 192–193 96.73 CHN 
84h 1529 4’-MeO-C6H4 65 199–200 97.60 CHN 
84i 1505 3’,4’- di-MeO-C6H3 56 188–189 95.84 CHN 
84j 1531 3’,4’,5’-tri-MeO-C6H2 57 189–190 97.60 CHN 
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2.2 Experimental  
2.2.1 General methods and materials 
 
All commercial chemicals and solvents were reagent grade and used without 
further purification unless otherwise specified. Melting points were determined on a 
Fargo melting point apparatus and are uncorrected. Thin-layer chromatography was 
performed on silica gel G60 F254 (Merck) with short-wavelength UV light for 
visualization. All reported yields are isolated yields after chromatography or 
crystallization. Elemental analyses were done on a Heraeus CHN-O Rapid instrument. 
1H NMR spectra were recorded on a 600 MHz, Brucker AVANCE 600 DRX and 400 
MHz, Brucker Top-Spin spectrometers in the indicated solvent. The chemical shifts 
were reported in ppm () relative to TMS and coupling constants (J) in Hertz (Hz) 
and s, d, t, m, brs, refer to singlet, doublet, triplet, multiplet, broad respectively. High 
performance liquid chromatography analysis for checking purity of synthesized 
compounds were recorded on a Hitachi D-2000 Elite instrument: column, Mightysil 
RP-18 GP 250-4.6 (5µm); mobile phase, MeCN/THF (50:50 v/v); flow rate, 1 
mL/min; injected sample 10µL, column temp, 27 oC; wavelength, 254 nm. The purity 
of all tested compounds was ≥ 95% based on analytical HPLC. 
 
All synthesized compounds were characterized by using 1H NMR and 
Elemental analysis. For compounds 80a-j, the characteristic proton signals for ester 
(COOMe) appeared at the range of 3.51–3.76 δ ppm. The 1H NMR proton signals for 
the compounds 81a-j, hydroxymethyl proton (CH2OH) appeared at the range of 4.33–
4.55 δ ppm and methylene proton of isoquinoline ring appeared at 3.96–5.03 δ ppm. 
For compounds 82–84, the 1H NMR signals for the carbamate residue (i.e., CH2OCO) 
appeared at 3.9–5.1 δ ppm. The characteristic proton for NH of alkylcarbamates 
appeared at the range of 6.7–7.0 δ ppm as multiplate and D2O exchangeable single. 
The elemental analysis of the newly synthesized derivatives was within ±0.4% range 
of the calculated C, H, N data. 
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1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid hydrochloride (78). A mixture 
of D,L-phenylalanine (77, 50 g, 3.03 mol), conc. HCl (325 mL) and 37 % formalin 
(110 mL) was heated to a gentle reflux with vigorous stirring. After 30 min, another 
portion of formalin (50 mL) and conc. HCl (110 mL) was added. The reaction mixture 
was further stirred and heated for 4 h and cooled to room temperature. The white solid 
separated out was filtered and washed with methanol (30 mL) to give 78 64.1 g, yield 
98 %; mp > 280 °C (lit.98 mp 286 –290 °C). 1H NMR (DMSO-d6)  3.15 (1H, m, 
CH), 3.32 (1H, m, CH), 4.30 (2H, m, CH2), 4.43 (1H, m, CH), 7.20 –7.35 (4H, m, 
4ArH), 9.89 (1H, brs, exchangeable, NH); 10.06 (1H, brs, exchangeable, COOH).  
 
2-Propionyl-1,2,3,4-tetrahydroisoquiniline-3-carboxylic acid (79b). To a 
suspension of 1,2,3,4-tetrahydroisoquinoline-3-carboxylicacid hydrochloride (78, 10 
g, 46.8 mmol) in acetone (60 mL) was added 2N NaOH (40 mL) solution at room 
temperature. The clear solution obtained then added dropwise into a solution of 
propionyl chloride (5.2 g, 57 mmol) in acetone (20 mL) at room temperature, 
simultaneously 2N NaOH was added dropwise and pH maintained above 10. The 
reaction mixture was stirred at room temperature for 2h, the solvent was evaporated 
under reduce pressure. The solution was acidified to pH 5-6 with 3N HCl. The white 
solid separated, filtered it and dried to give 79b 9 g, yield 87 %; mp 173–174 ºC. 1H 
NMR (DMSO-d6)  1.03 (3H, m, Me), 2.45 (2H, m, CH2), 3.13 (2H, m, CH2), 4.52 
(2H, m, CH2), 5.09 (1H, m, CH), 7.16–7.20 (4H, m, 4×ArH), 12.63 (1H, brs, 
exchangeable, COOH,). Anal. Calcd. for (C13H15NO3): C, 66.94; H, 6.48; N, 6.00. 
Found: C, 66.64; H, 6.48; N, 5.89.  
 
By following the same synthetic procedure as that for 79b, the following compounds 
were synthesized:  
 
2-Benzoyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (79c). Compound 79c 
was prepared from 78 (8.0 g, 37.4 mmol) and benzoyl chloride (6.43 g, 45.6 mmol). 
Yield, 9.9 g (77 %); mp 168–169 °C (lit.99 mp 168–169 °C). 1H NMR (DMSO-d6)   
3.18 (2H, m, CH2), 4.52 (2H, m, CH2), 5.08 (1H, m, CH), 7.14–7.22 (4H, m, 4×ArH), 
7.41–7.49 (5H, m, 5×ArH), 12.85 (1H, brs, exchangeable, COOH).  
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2-(4-Fluorobenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (79d). 
Compound 79d was prepared from 78 (10.0 g, 46.8 mmol) and 4-fluorobenzoyl 
chloride (9.91 g, 57.0 mmol). Yield, 13.5 g (97 %); mp 179–180 ºC; 1H NMR 
(DMSO-d6)   3.20 (2H, m, CH2), 4.52 (2H, m, CH2), 5.06 (1H, m, CH), 7.19–7.33 
(6H, m, 6×ArH), 7.48–7.52 (2H, m, 2×ArH), 12.76 (1H, brs, exchangeable, COOH). 
Anal. Calcd. for (C17H14FNO3): C, 68.22; H, 4.71; N, 4.68. Found: C, 68.08; H, 4.57; 
N, 4.42.  
 
2-(4-Chlorobenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (79e). 
Compound 79e was prepared from 78 (10.0 g, 46.8 mmol) and 4-chloroenzoyl 
chloride (10.1 g, 57.0 mmol). Yield, 13.8 g (93 %), mp 77−79 °C; 1H NMR (DMSO-
d6)   3.29 (2H, m, CH2), 4.49 (2H, m, CH2), 5.02 (1H, m, CH), 7.01–7.17 (4H, m, 
4×ArH), 7.40–7.58 (4H, m, 4×ArH), 12.81 (1H, brs, exchangeable, COOH). Anal. 
Calcd. for (C17H14ClNO3): C, 64.67;  H, 4.47; N, 4.44. Found: C, 64.52; H, 4.56; N, 
4.33.  
 
2-(3, 4-Difluorobenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (79f). 
Compound 79f was prepared from 78 (10.0 g, 46.8 mmol) and 3,4-difluorobenzoyl 
chloride (10.2 g, 57.0 mmol). Yield, 14.2 g (95 %); mp 89–91°C; 1H NMR (DMSO-
d6)  3.18 (2H, m, CH2), 4.48 (2H, m, CH2), 5.02 (1H, m, CH), 7.09–7.15 (4H, m, 
4×ArH), 7.33 (1H, s, ArH), 7.46–7.54 (2H, m, 2×ArH), 12.84 (1H, brs, exchangeable, 
COOH). Anal. Calcd. for (C17H13F2NO3): C, 64.35; H, 4.13; N, 4.41. Found: C, 
64.21; H, 4.26; N, 4.56.  
 
2-(3, 4-Dichlorobenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (79g). 
Compound 79g was prepared from 78 (10.0 g, 46.8 mmol) and 3,4-dichlorobenzoyl 
chloride (12.1 g, 57.0 mmol). Yield, 14.5 g (89 %); mp 101–102 °C; 1H NMR 
(DMSO-d6)  3.27 (2H, m, CH2), 4.45 (2H, m, CH2), 4.99 (1H, m,  CH), 7.08–7.13 
(4H, m, 4×ArH), 7.44–7.46 (1H, m, ArH), 7.66–7.70 (2H, m, 2×ArH), 12.67 (1H, brs, 
exchangeable, COOH). Anal. Calcd. For (C17H17Cl2NO3): C, 58.31; H, 3.74; N, 4.00. 
Found: C, 58.19; H, 4.04; N, 3.87. 
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2-(4-Methoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (79h). 
Compound 79h was prepared from 78 (10.0 g, 46.8 mmol) and 4-methoxybenzoyl 
chloride (9.8 g, 57.0 mmol). Yield, 12.6 g (86 %); mp 178– 180 °C; 1H NMR 
(DMSO-d6)  3.28 (2H, m, CH2), 3.85 (3H, s, MeO), 4.60 (2H, m, CH2), 5.02 (1H, m, 
CH), 6.90–6.94 (3H, m, 3×ArH), 7.18 –7.22 (3H, m, 3×ArH), 7.42 –7.48 (2H, m, 
2×ArH), 12.66 (1H, brs, exchangeable, COOH). Anal. Calcd. for (C18H17NO4): C, 
69.44; H, 5.50; N, 4.50. Found: C, 69.12; H, 5.62; N, 4.27. 
 
2-(3,4-Dimethoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (79i). 
Compound 79i was prepared from 78 (10.0 g, 46.8 mmol) and 3,4-dimethoxybenzoyl 
chloride (12.5 g, 57 mmol). Yield, 11.9 g (61 %); mp 235–236 ºC; 1H NMR (DMSO-
d6)  3.19 (2H, m, CH2), 3.77 (6H, s, 2×MeO), 4.56 (2H, m, CH2), 5.04 (1H, m, CH), 
6.99–7.04 (4H, m, 4×ArH), 7.17–7.23 (3H, m, 3×ArH), 12.88 (1H, brs, exchangeable, 
COOH). Anal. Calcd. for (C19H19NO5): C, 66.85; H, 5.61; N, 4.10. Found: C, 66.65; 
H, 5.66; N, 3.86. 
 
2-(3, 4, 5-Trimethoxybenzoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
(79j). Compound 79j was prepared from 78 (7.0 g, 32.7 mmol) and 3,4,5-
trimethoxybenzoyl chloride (9.3 g, 39.9 mmol). Yield, 12.0 g (98 %); mp 186–189 ºC; 
1H NMR (DMSO-d6)   3.19 (2H, m, CH2), 3.70 (3H, s, MeO), 3.80 (6H, s, 2×MeO), 
4.59 (2H, m, CH2), 5.02 (1H, m, CH), 6.70 (2H, s, 2×ArH), 7.13–7.28 (4H, m, 
4×ArH), 12.72 (1H, brs, exchangeable, COOH). Anal. Calcd. for (C20H21NO6): C, 
64.68; H, 5.70; N, 3.77. Found: C, 64.44; H, 5.50; N, 3.44.  
 
3-Methyl-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic acid dimethyl 
ester (80a). Dimethyl acetylenedicarboxylate (6.39 g, 45.0 mmol) was added into a 
mixture of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (78, 10 g, 46.8 mmol) in 
acetic anhydride (70 mL) and the reaction mixture was heated at 70 °C with stirring 
for 1.5 h. The reaction mixture was evaporated to dryness in vacuo. The residue was 
recrystallized from MeOH to give 80a, 11.0 g (74 %); mp 152–154 °C (lit.101 mp 
140–142 °C). 1H NMR(DMSO-d6)  2.40 (3H, s, Me), 3.70 (3H, s, COOMe), 3.72 
(3H, s, COOMe), 4.18 (2H, s, CH2), 5.06 (2H, s, CH2), 7.21–7.32 (2H, m, 2×ArH), 
7.35–7.39 (2H, m, 2×ArH).  
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3-Ethyl-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic acid dimethyl 
ester (80b). A mixture of dimethyl acetylenedicarboxylate (DMAD) (6.39 g, 45.0 
mmol) and 79b (7.0 g, 30.0 mmol) in acetic anhydride (50 mL) was heated at 65 °C 
with stirring for 1.5 h. The reaction mixture was evaporated to dryness in vacuo and 
the residue was recrystallized from MeOH to give 80b, 8.77 g (93 %); mp 88–89 ºC. 
1H NMR(DMSO-d6)  1.15 (3H, t, J = 7.6 Hz, Me), 2.85 (2H, q, J = 7.6 Hz, CH2), 
3.71 (6H, s, 2×COOMe), 4.19 (2H, s, CH2), 5.12 (2H, s, CH2), 7.29–7.33 (2H, m, 
2×ArH), 7.38–7.43 (2H, m, 2×ArH). Anal. Calcd. for (C18H19NO4): C, 68.99; H, 6.11; 
N, 4.47. Found: C, 68.96; H, 6.05; N, 4.38. 
 
By following the same synthetic procedure as that for 80b, the following compounds 
were synthesized:  
 
3-Phenyl-5, 10-dihydropyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic acid dimethyl 
ester (80c).  Compound 80c was prepared from DMAD (6.0 g, 41.0 mmol) and 79c 
(8.0 g, 28.4 mmol). Yield, 7.0 g (68 %); mp 137–138 ºC. 1H NMR (DMSO-d6)  3.58 
(3H, s, COOMe), 3.76 (3H, s, COOMe), 4.33 (2H, s, CH2), 4.98 (2H, s, CH2), 7.21–
7.32 (3H, m, 3×ArH), 7.41–7.53 (6H, m, 6×ArH). Anal. Calcd. for (C22H19NO4): C, 
73.12; H, 5.30; N, 3.88. Found: C, 72.91; H, 5.30; N, 3.53. 
 
3-(4-Fluorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic acid 
dimethyl ester (80d).  Compound 80d was prepared from DMAD (10.7 g, 65.0 
mmol) and 79d (15.0 g, 50.1 mmol). Yield, 11.1 g (58 %); mp 149–150 ºC. 1H 
NMR(DMSO-d6)  3.58 (3H, s, COOMe), 3.76 (3H, s, COOMe), 4.32 (2H, s, CH2), 
4.96 (2H, s, CH2), 7.23–7.30 (1H, m, ArH), 7.32–7.36 (4H, m, 4×ArH), 7.40–7.42 
(1H, m, ArH), 7.49–7.52 (2H, m, 2×ArH). Anal. Calcld. For (C22H18FNO4): C, 69.65; 
H, 4.78; N, 3.69. Found: C, 69.54; H, 4.82; N, 3.78. 
 
3-(4-Chlorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic acid 
dimethyl ester (80e).  Compound 80e was prepared from DMAD (6.8 g, 47.0 mmol) 
and 79e (10.0 g, 31.6 mmol). Yield, 8.0 g (64 %); mp 164−166 °C. 1H NMR(DMSO-
d6)  3.60 (3H, s, COOMe), 3.76 (3H, s, COOMe), 4.32 (2H, s, CH2), 4.98 (2H, s, 
CH2), 7.20–7.26 (1H, m, ArH), 7.27–7.33 (2H, m, 2×ArH), 7.39–7.43 (1H, m, ArH), 
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7.48 (2H, d, J = 8.5 Hz, 2×ArH), 7.57 (2H, d, J = 8.5 Hz, 2×ArH). Anal. Calcd. for 
(C22H18ClNO4): C, 66.75; H, 4.58; N, 3.54. Found: C, 66.52; H, 4.85; N, 3.66. 
 
3-(3,4-Difluorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic 
acid dimethyl ester (80f).  Compound 80f was prepared from DMAD (6.71 g, 47.0 
mmol) and 79f (10.0 g, 31.5 mmol). Yield, 8.4 g (67 %); mp 142–144 °C. 1H 
NMR(DMSO-d6)  3.61 (3H, s, COOMe), 3.76 (3H, s, COOMe), 4.31 (2H, s, CH2), 
5.00 (2H, s, CH2), 7.22–7.42 (5H, m, 5×ArH), 7.54–7.61 (2H, m, 2×ArH). Anal. 
Calcd. for (C22H17F2NO4): C, 66.50; H, 4.31; N, 3.52. Found: C, 66.15; H, 4.44; N, 
3.36. 
 
3-(3,4-Dichlorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic 
acid dimethyl ester (80g).  Compound 80e was prepared from DMAD (8.5 g, 60.0 
mmol) and 79g (14.0 g, 40.0 mmol). Yield, 11.0 g (63 %); mp 169−170 °C. 1H NMR 
(DMSO-d6)  3.61 (3H, s, COOMe), 3.77 (3H, s, COOMe), 4.31 (2H, s, CH2), 5.02 
(2H, s, CH2), 7.22–7.33 (3H, m, 3×ArH), 7.40–7.47 (2H, m, 2×ArH), 7.76–7.78 (2H, 
m, 2×ArH). Anal. Calcd. for (C22H17Cl2NO4): C, 61.41; H, 3.98; N, 3.26. Found: C, 
61.33; H, 3.95; N, 2.89. 
 
3-(4-Methoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-dicarboxylic 
acid dimethyl ester (80h).  Compound 80h was prepared from DMAD (7.5 g, 53.0 
mmol) and 79h (10.0 g, 35.1 mmol). Yield, 8.4 g (66 %); mp 155–158 °C. 1H 
NMR(DMSO-d6)  3.58 (3H, s, COOMe), 3.75 (3H, s, COOMe), 3.82 (3H, s, MeO), 
4.31 (2H, s, CH2), 4.95 (2H, s, CH2), 7.05–7.07 (2H, m, 2×ArH), 7.21–7.24 (1H, m, 
ArH), 7.28–7.31 (2H, m, 2×ArH), 7.37–7.42 (3H, m, 3×ArH). Anal. Calcd. for 
(C23H21NO5): C, 70.58; H, 5.41; N, 3.58. Found: C, 70.25; H, 5.44; N, 3.49. 
 
3-(3,4-Dimethoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
dicarboxylic acid dimethyl ester (80i).  Compound 80i was prepared from DMAD 
(5.6 g, 39.0 mmol) and 79i (9.0 g, 26.4 mmol). Yield, 9.0 g (81 %); mp 202–203 oC. 
1H NMR(DMSO-d6)  3.60 (3H, s, COOMe), 3.66 (3H, s, MeO), 3.78 (3H, s, 
COOMe), 3.82 (3H, s, MeO), 4.32 (2H, s, CH2), 5.00 (2H, s, CH2), 6.99 (1H, dd, J = 
2.0 and 8.0 Hz, ArH), 7.02 (1H, d, J = 2.0 Hz, ArH), 7.07 (1H, d, J = 8.0 Hz, ArH), 
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7.22–7.25 (1H, m, ArH), 7.25–7.32 (2H, m, 2×ArH), 7.40–7.42 (1H, m, ArH). Anal. 
Calcd. for (C24H23NO6): C, 68.40; H, 5.50; N, 3.32. Found: C, 68.02; H, 5.53; N, 2.94. 
 
3-(3,4,5-Trimethoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
dicarboxylic acid dimethyl ester (80j).  Compound 80j was prepared from DMAD 
(5.7 g, 40.0 mmol) and 79j (10.0 g, 26.9 mmol). Yield, 6.2 g (51 %); mp 165–166 °C. 
1H NMR(DMSO-d6)  3.63 (3H, s, COOMe), 3.74 (6H, s, COOMe and MeO), 3.80 
(6H, s, 2×MeO), 4.32 (2H, s, CH2), 5.00 (2H, s, CH2), 6.75 (2H, s, 2×ArH), 7.22–7.26 
(1H, m, ArH), 7.28-7.32 (1H, m, ArH), 7.35–7.37 (1H, m, ArH), 7.40–7.42 (1H, m, 
ArH). Anal. Calcd. for (C25H25NO7): C, 66.51; H, 5.58; N, 3.10. Found: C, 66.25; H, 
5.59; N, 3.01. 
 
[3-Methyl-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]dimethanol (81a). A 
solution of 80a (8.0 g, 26.7 mmol) in anhydrous dichloromethane (20 mL) was added 
dropwise in to a stirred suspension of LiAlH4 (2.5 g, 66.0 mmol) in anhydrous diethyl 
ether (50 mL) at 0 to -5 oC. The reaction mixture was further stirred for 15 min after 
the addition was completed. The excess hydride was destroyed by the sequential 
addition of water (2.5 mL), 15% aqueous NaOH (2.5 mL), and water (2.5 mL) at 0 
°C. The mixture was filtered through a pad of Celite, the solid residue was washed 
with dichloromethane. The combined filtrate and washings were evaporated to 
dryness in vacuo. The residue was recrystallized from ether to give 81a, 4.2 g (64.0 
%); mp 99–101 °C. 1H NMR (DMSO-d6)  2.22 (3H, s, Me), 3.96 (2H, s, CH2), 4.33 
(2H, m, CH2), 4.38 (4H, m, CH2 and exchangeable, 2×OH), 4.93 (2H, s, CH2), 7.24–
7.28 (2H, m, 2×ArH), 7.34–7.36 (2H, m, 2×ArH). Anal. Calcd. for (C15H17NO2): C, 
74.05; H, 7.04; N, 5.76. Found: C, 74.24; H, 6.97; N, 5.71. 
 
By following the same synthetic procedure as that for 81a, the following compounds 
were synthesized:  
 
[3-Ethyl-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]dimethanol (81b). 
Compound 81b was prepared from 80b (5.0 g, 15.9 mmol) and LiAlH4 (1.5 g, 39.0 
mmol). Yield, 3.15 g (76 %) as syrup; 1H NMR (DMSO-d6)  1.10 (3H, t, J = 7.6 Hz, 
Me,), 2.66 (2H, q, J = 7.6 Hz, CH2,), 3.95 (2H, s, CH2), 4.33 (3H, m, CH2  and 
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exchangeable, OH), 4.39 (3H, m, CH2 and exchangeable, OH), 4.96 (2H, s, CH2), 
7.23–7.28 (2H, m, 2×ArH), 7.33–7.39 (2H, m, 2×ArH).  
 
[3-Phenyl-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]dimethanol (81c). 
Compound 81c was prepared from 80c (7.0 g, 19.4 mmol) and LiAlH4 (1.8 g, 48.0 
mmol). Yield, 4.7 g (80 %); mp 150–152 o C. 1H NMR (DMSO-d6)  4.06 (2H, s, 
CH2), 4.28 (2H, d, J = 4.8 Hz, CH2,), 4.50 (2H, d, J = 4.8 Hz, CH2,), 4.54 (2H, brs, 
exchangeable OH), 4.98 (2H, s, CH2), 7.18 (1H, t, J = 7.2 Hz, ArH,), 7.26 (2H, t, J = 
7.2 Hz, 2×ArH), 7.36–7.39 (2H, m, 2×ArH), 7.45–7.51 (4H, m, 4×ArH). Anal. Calcd. 
for (C20H19NO2): C, 78.66; H, 6.27; N, 4.59. Found: C, 78.48; H, 6.42; N, 4.41. 
 
[3-(4-Fluorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]dimethanol 
(81d). Compound 81d was prepared from 80d (10.0 g, 26.4 mmol) and LiAlH4 (2.5 g, 
65.0 mmol). Yield, 6.36 g (74 %); mp 135–136 º C. 1H NMR (DMSO-d6)  4.05 (2H, 
s, CH2), 4.26 (2H, d, J = 4.8 Hz, CH2), 4.49 (2H, d, J = 4.8 Hz, CH2,), 4.53 (2H, t, J = 
4.8 Hz, exchangeable, OH,), 4.96 (2H, s, CH2), 7.17–7.21 (1H, m, ArH,), 7.26–7.34 
(4H, m, 4×ArH), 7.38 (1H, m, ArH), 7.48–7.52 (2H, m, 2×ArH). Anal. Calcd. for 
(C20H18FNO2): C, 74.29; H, 5.61; N, 4.33. Found: C, 74.38; H, 5.68; N, 3.98. 
 
[3-(4-Chlorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]dimethanol 
(81e). Compound 81e was prepared from 80e (7.0 g, 17.7 mmol) and LiAlH4 (1.63 g, 
44 mmol). Yield, 3.1 g (52 %); mp 170–172 o C. 1H NMR (DMSO-d6)  4.06 (2H, s, 
CH2), 4.28 (2H, d, J = 4.8 Hz, CH2,), 4.50 (2H, d, J = 4.8 Hz, CH2,), 4.55 (2H, m, 
exchangeable, OH), 4.99 (2H, s, CH2), 7.18–7.20 (1H, m, ArH), 7.21–7.27 (2H, m, 
2×ArH), 7.29 (1H, d, J = 7.6 Hz, ArH,), 7.38 (2H, d, J = 7.2 Hz, 2×ArH,), 7.48 (2H, 
d, J = 7.2 Hz, 2×ArH). Anal. Calcd. for (C20H18ClNO2): C, 70.69; H, 5.34; N, 4.12. 
Found: C, 70.42; H, 5.37; N, 4.05. 
 
[3-(3,4-Difluorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]dimethanol (81f). Compound 81f was prepared from 80f (7.5 g, 18.0 mmol) and 
LiAlH4 (1.73 g, 47 mmol). Yield, 5.3 g (83 %); mp 145–146 °C. 1H NMR (DMSO-d6) 
 4.05 (2H, s, CH2), 4.27 (2H, d, J = 5.2 Hz, CH2z), 4.48 (2H, d, J = 5.2 Hz, CH2,), 
4.53 (1H, t, J = 5.2 Hz, exchangeable, OH), 4.60 (1H, t, J = 5.2 Hz, exchangeable, 
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OH), 5.01 (2H, s, CH2), 7.18–7.33 (4H, m, 4×ArH), 7.37–7.39 (1H, m, ArH), 7.52–
7.54 (2H, m,  2×ArH). Anal. Calcd. for (C20H17F2NO2): C, 70.37; H, 5.02; N, 4.10. 
Found: C, 70.08; H, 5.01; N, 3.76. 
 
[3-(3,4-Dichlorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]dimethanol (81g). Compound 81g was prepared from 80g (9.0 g, 20.9 mmol) 
and LiAlH4 (1.9 g, 52.0 mmol). Yield, 5.7 g (72 %); mp 150–151 o C. 1H NMR 
(DMSO-d6)  4.05 (2H, s, CH2), 4.26 (2H, d, J = 4.8 Hz, CH2,), 4.48 (2H, d, J = 4.8 
Hz, CH2,), 4.53 (1H, t, J = 4.8 Hz, exchangeable OH,), 4.63 (1H, t, J = 4.8 Hz, 
exchangeable, OH,), 5.03 (2H, s, CH2), 7.18–7.21 (1H, m, ArH,), 7.23–7.27 (2H, m, 
2×ArH,), 7.28–7.30 (1H, m,  ArH), 7.38–7.40 (1H, m, ArH), 7.46–7.48 (2H, m, 
2×ArH). Anal. Calcd. for (C20H17Cl2NO2): C, 64.18; H, 4.58; N, 3.74. Found: C, 
63.89; H, 4.40; N, 3.87. 
 
[3-(4-Methoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]dimethanol (81h). Compound 81h was prepared from 80h (7.5 g, 19.0 mmol) 
and LiAlH4 (1.77 g, 47 mmol). Yield, 4.3 g (67 %); mp 174–176 o C. 1H NMR 
(DMSO-d6)  3.82 (3H, s, MeO), 4.04 (2H, s, CH2), 4.26 (2H, s, CH2), 4.48 (4H, m, 
CH2 and exchangeable, OH), 4.93 (2H, s, CH2), 7.04–7.06 (2H, m, 2×ArH), 7.17–
7.21 (1H, m, ArH,), 7.24–7.27 (2H, m, 2×ArH), 7.36–7.39 (3H, m, 3×ArH,). Anal. 
Calcd. for (C21H21NO3): C, 75.20; H, 6.31; N, 4.18. Found: C, 75.36; H, 6.30; N, 4.13.  
 
[3-(3,4-Dimethoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]dimethanol (81i). Compound 81i was prepared from 80i (8.0 g, 18.9 mmol) and 
LiAlH4 (1.75 g, 47 mmol). Yield, 5.34 g (77 %); mp 145–146 o C.  1H NMR (DMSO-
d6)  3.79 (6H, s, 2×MeO), 4.04 (2H, s, CH2), 4.29 (2H, s, CH2), 4.52 (4H, brs, CH2 
and exchangeable, OH), 4.97 (2H, s, CH2), 6.96–6.98 (1H, m, ArH,), 7.05–7.07 (2H, 
m, 2×ArH), 7.19–7.28 (3H, m, 3×ArH), 7.37–7.39 (1H, m, ArH). Anal. Calcd. for 
(C22H23NO4): C, 72.31; H, 6.34; N, 3.83. Found: C, 72.25; H, 6.34; N, 3.95. 
 
[3-(3,4,5-Trimethoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]dimethanol (81j). Compound 81j was prepared from 80j (6.0 g, 13.3 mmol) and 
LiAlH4 (1.2 g, 33.0 mmol). Yield, 3.1 g (58 %); mp 146–147 o C. 1H NMR (DMSO-
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d6)  3.74 (3H, s, MeO), 3.82 (6H, s, 2×MeO), 4.05 (2H, s, CH2), 4.31 (2H, s, CH2), 
4.50 (2H, s, CH2), 4.53 (2H, s, exchangeable, OH), 5.04 (2H, s, CH2), 6.73 (2H, s, 
2×ArH), 7.21–7.27 (2H, m, 2×ArH), 7.33–7.38 (2H, m, 2×ArH). Anal. Calcd. for 
(C23H25NO5): C, 69.86; H, 6.37; N, 3.54. Found: C, 69.71; H, 6.37; N, 3.45. 
 
General procedure for preparing bis(alkylcarbamate) derivatives (82–84). To a 
solution of bis(hydroxymethyl) derivatives (81a–j, 1.0 equivalent) and triethylamine 
(2~3 equivalent) in anhydrous dichloromethane was added alkylisocyanate (5 
equivalent). The reaction mixture was stirred at ambient temperature (for 3–20 h) 
under an argon atmosphere. After the completion of the reaction, the reaction mixture 
was evaporated to dryness in vacuo. The residue was triturated with ether, and solid 
separated was collected by filtration. The desired product was either obtained by 
recrystallization or liquid chromatography.  
 
[3-Methyl-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]bis(methylene) 
bis(methylcarbamate) (82a). Compound 82a was synthesized from 81a (0.80 g, 3.2 
mmol), Et3N (1 mL) and methylisocyanate (1.14 g, 20 mmol). Yield, 0.53 g (44%); 
mp 174−176 °C. 1H NMR (DMSO-d6)  2.23 (3H, s, Me), 2.53 (6H, m, 2×Me), 3.99 
(2H, s, CH2), 4.88 (2H, s, CH2), 4.92 (2H, s, CH2), 4.95 (2H, s, CH2), 6.74 (2H, brs, 
exchangeable, NH), 7.21–7.32 (2H, m, 2ArH), 7.34–7.38 (2H, m, 2ArH). Anal. 
Calcd. for (C19H23N3O4): C, 63.85; H, 6.49; N, 11.76. Found: C, 63.54; H, 6.57; N, 
11.64. 
 
[3-(4-Chlorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene) bis(methylcarbamate) (82e). Compound 82e was synthesized 
from 81e (1.0 g, 3.0 mmol), Et3N (1 mL), and methylisocyanate (0.85 g, 15 mmol). 
Yield, 1.1 g (82 %); mp 194−196 °C. 1H NMR (DMSO-d6)  2.54 (6H, m, 2×Me), 
4.09 (2H, s, CH2), 4.80 (2H, s, CH2), 4.97 (2H, s, CH2), 5.03 (2H, s, CH2), 6.81 (2H, 
brs, exchangeable, NH), 7.17–7.23 (1H, m, ArH), 7.24–7.30 (2H, m, 2ArH), 7.36–
7.40 (1H, m, ArH), 7.45–7.47 (2H, m, 2ArH,), 7.55–7.57 (2H, m, 2ArH,). Anal. 
Cacld. for (C24H24ClN3O4): C, 63.50; H, 5.33; N, 9.26. Found: C, 63.33; H, 5.35; N, 
9.20.  
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[3-(3,4-Difluorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene) bis(methylcarbamate) (82f). Compound 82f was synthesized 
from 81f (1.0 g, 2.9 mmol), Et3N (1 mL ), and methylisocyanate (0.85 g, 15 mmol). 
Yield, 1.0 g (77 %); mp 190−192 °C; 1H NMR (DMSO-d6)  2.54 (6H, m, 2×Me), 
4.09 (2H, s, CH2), 4.81 (2H, s, CH2), 4.99 (2H, s, CH2), 5.03 (2H, s, CH2), 6.83 (2H, 
brs, exchangeable, NH), 7.18–7.23 (1H, m, ArH), 7.25–7.31 (3H, m, 3ArH), 7.36–
7.40 (1H, m, ArH), 7.52–7.61 (2H, m, 2ArH). Anal. Calcd. for (C24H23F2N3O4): C, 
63.29; H, 5.09; N, 9.23. Found: C, 63.00; H, 5.12; N, 9.16.  
 
[3-(4-Methoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene) bis(methylcarbamate) (82h). Compound 82h was synthesized 
from 81h (1.0 g, 2.9 mmol), Et3N (1 mL ), methylisocyanate (1.6 g, 29 mmol). Yield, 
1.2 g (87 %); mp 182−184 °C. 1H NMR (DMSO-d6)  2.53 (6H, m, 2×Me), 3.85 (3H, 
s, MeO), 4.08 (2H, s, CH2), 4.78 (2H, s, CH2), 4.93 (2H, s, CH2), 5.01 (2H, s, CH2), 
6.81 (2H, brs, exchangeable, NH), 7.06–7.08 (2H, m, 2ArH), 7.17–7.23 (1H, m, 
ArH), 7.24–7.30 (2H, m, 2ArH), 7.32–7.40 (3H, m, 3ArH). Anal. Calcd. for 
(C25H27N3O5): C, 66.80; H, 6.05; N, 9.35. Found: C, 66.72; H, 6.15; N, 9.24. 
 
[3-Methyl-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]bis(methylene)bis 
(ethylcarbamate) (83a). Compound 83a was synthesized from 81a (1.0 g, 4.1 mmol), 
Et3N (0.5 mL), and ethylisocyanate(1.1 g, 16 mmol). Yield, 0.83 g (53 %); mp 208–
209 °C; 1H NMR (DMSO-d6)  0.97 (6H, t, J = 8 Hz, 2×Me), 2.25 (3H, s, Me), 2.95 
(4H, q, J = 8 Hz, CH2), 4.00 (2H, s, CH2), 4.89 (2H, s, CH2), 4.93 (2H, s, CH2), 4.96 
(2H, s, CH2), 6.86 (2H, brs, exchangeable, NH,), 7.23–7.29 (2H, m, 2×ArH), 7.34–
7.35 (2H, m, 2×ArH). Anal. Calcd. for (C21H27N3O4): C, 65.44; H, 7.06; N, 10.90. 
Found: C, 65.29; H, 7.14; N, 10.89. 
 
[3-Ethyl-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]bis(methylene)bis 
(ethylcarbamate) (83b). Compound 83b was synthesized from 81b (0.5 g, 1.9 
mmol), Et3N (0.5 mL ), ethylisocyanate (0.55 g, 7.7 mmol). Yield, 0.39 g (50 %); mp 
127–129°C. 1H NMR (DMSO-d6)  0.95 (6H, t, J = 7.2 Hz, 2×Me), 1.10 (3H, t, J = 
7.2 Hz, Me), 2.69 (2H, q, J = 7.2 Hz, CH2), 2.97 (4H, m, CH2), 3.99 (2H, s, CH2), 
4.89 (2H, s, CH2), 4.93 (2H, s, CH2), 4.99 (2H, s, CH2), 6.84 (2H, brs, exchangeable, 
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NH), 7.23–7.29 (2H, m, 2×ArH), 7.34–7.39 (2H, m, 2×ArH). Anal. Calcd. for 
(C22H29N3O4): C, 66.14; H, 7.32; N, 10.52. Found: C, 66.35; H, 7.53; N, 10.74. 
 
[3-Phenyl-5-10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]bis(methylene)bis 
(ethylcarbamate) (83c). Compound 83c was synthesized from 81c (1.0 g, 3.2 mmol), 
Et3N (1.0 mL ), and ethylisocyanate (1.2 g, 16.0 mmol). Yield, 1.17 g (81 %); mp 
170–171 oC;  1H NMR (DMSO-d6)  0.97 (6H, t, J = 7.2 Hz, 2×Me), 2.98 (4H, q, J = 
7.2 Hz, CH2), 4.10 (2H, s, CH2), 4.80 (2H, s, CH2), 4.97 (2H, s, CH2), 5.03 (2H, s, 
CH2), 6.94 (2H, brs, exchangeable, NH), 7.18–7.20 (1H, m, ArH), 7.26–7.29 (2H, m, 
2×ArH), 7.36–7.40 (4H, m, 4×ArH), 7.42–7.44 (2H, m, 2×ArH). Anal. Calcld. For 
(C26H29N3O4): C, 69.78; H, 6.53; N, 9.39. Found: C, 69.64; H, 6.54; N, 9.37. 
 
[3-(4-Fluorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene) bis(ethylcarbamate) (83d). Compound 83d was synthesized 
from 81d (1.0 g, 3.0 mmol), Et3N (1.2 mL), and (1.1 g, 15.0 mmol). Yield, 1.08 g (76 
%); mp 183–184 º C. 1H NMR (DMSO-d6)  0.98 (6H, t, J = 6.8 Hz, 2×Me), 2.97 
(4H, q, J = 6.8 Hz, CH2), 4.09 (2H, s, CH2), 4.79 (2H, s, CH2), 4.95 (2H, s, CH2), 5.02 
(2H, s, CH2), 6.93 (2H, brs, exchangeable, NH), 7.20–7.22 (1H, m, ArH), 7.27–7.41 
(5H, m, 5×ArH), 7.46–7.48 (2H, m, 2×ArH). Anal. Calcd. for (C26H28FN3O4): C, 
67.08; H, 6.06; N, 9.03. Found: C, 67.24; H, 6.02; N, 8.88. 
 
[3-(4-Chlorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene) bis(ethylcarbamate) (83e). Compound 83e was synthesized 
from 81e (1.0 g, 2.9 mmol), Et3N (1.0 mL ), and ethylisocyanate (0.84 g, 18.0 mmol). 
Yield, 0.92 g (64 %); mp 191–192°C. 1H NMR (DMSO-d6)  0.98 (6H, t, J = 7.2 Hz, 
2×Me), 2.97 (4H, q, J = 7.2 Hz, CH2), 4.09 (2H, s, CH2), 4.80 (2H, s, CH2), 4.97 (2H, 
s, CH2), 5.02 (2H, s, CH2), 6.92 (2H, brs, exchangeable, NH,), 7.18–7.22 (1H, m, 
ArH), 7.25–7.27 (2H, m, 2×ArH), 7.28–7.30 (1H, m, ArH), 7.37–7.39 (2H, m, 
2×ArH), 7.44–7.46 (2H, m, 2×ArH). Anal. Calcd. for (C26H28ClN3O4): C, 64.79; H, 
5.86; N, 8.72. Found: C, 64.54; H, 5.84; N, 8.82. 
 
[3-(3,4-Difluorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene)bis (ethyl carbamate) (83f). Compound 83f was synthesized 
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from 81f (1.0 g, 2.9 mmol), Et3N (1 mL), and ethylisocyanate (0.8 g, 11.7 mmol). 
Yield, 1.0 g (70 %); mp 189–190 °C.  1H NMR (DMSO-d6)  0.98 (6H, t, J = 6.8 Hz, 
2×Me), 2.98 (4H, q, J = 6.8 Hz, CH2), 4.09 (2H, s, CH2), 4.81 (2H, s, CH2), 5.00 (2H, 
s, CH2), 5.02 (2H, s, CH2), 6.95 (2H, brs, exchangeable, NH), 7.19–7.21 (1H, m, 
ArH), 7.25–7.39 (4H, m, 4×ArH), 7.53–7.60 (2H, m, 2×ArH). Anal. Calcd. for 
(C26H27F2N3O4): C, 64.59; H, 5.63; N, 8.69. Found: C, 64.50; H, 5.60; N, 8.69. 
 
[3-(3,4-Dichlorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl)bis(methylene]bis (ethylcarbamate) (83g). Compound 83g was synthesized 
from 81g (1.0 g, 2.6 mmol), Et3N (1.0 mL), and ethylisocyanate (0.85 g, 10.7 mmol). 
Yield, 1.15 g (83 %); mp 208–209 °C. 1H NMR (DMSO-d6)  0.98 (6H, t, J = 6.8 Hz, 
2×Me), 2.97 (4H, q, J = 6.8 Hz, CH2,), 4.09 (2H, s, CH2), 4.82 (2H, s, CH2), 5.02 (4H, 
s, 2×CH2), 6.95 (2H, brs, exchangeable, NH,), 7.19–7.22 (1H, m, ArH), 7.26–7.31 
(2H, m, 2×ArH), 7.39–7.45 (2H, m, 2×ArH,), 7.70–7.72 (2H, m, 2×ArH). Anal. 
Calcd. for (C26H27Cl2N3O4): C, 60.47; H, 5.27; N, 8.14. Found: C, 60.34; H, 5.13; N, 
8.10. 
 
[3-(4-Methoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene) bis(ethylcarbamate) (83h). Compound 83h was synthesized 
from 81h (1.0 g, 2.9 mmol), Et3N (1.0 mL), and ethylisocyanate (0.84 g, 11.8 mmol). 
Yield, 0.92 g (65 %); mp 165–166 °C. 1H NMR (DMSO-d6)  0.99 (6H, t, J = 6.8 Hz, 
2×Me), 2.98 (4H, q, J = 6.8 Hz, CH2), 3.83 (3H, s, MeO), 4.09 (2H, s, CH2), 4.78 
(2H, s, CH2), 4.94 (2H, s, CH2), 5.02 (2H, s, CH2), 6.92 (2H, brs, exchangeable, NH), 
7.05–7.08 (2H, m, 2×ArH), 7.19–7.22 (1H, m, ArH), 7.27–7.29 (2H, m, 2×ArH), 
7.35–7.39 (3H, m, 3×ArH). Anal. Calcd. for (C27H31N3O5): C, 67.91; H, 6.54; N, 
8.80. Found: C, 67.73; H, 6.86; N, 8.57. 
 
[3-(3,4-Dimethoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene) bis(ethylcarbamate) (83i). Compound 83i was synthesized from 
81i (1.0 g, 2.7 mmol), Et3N (1 mL), and ethylisocyanate (0.77 g, 10.9 mmol). Yield, 
0.96 g (69 %); mp 124–125 ºC. 1H NMR (DMSO-d6)  0.98 (6H, t, J = 6.8 Hz, 
2×Me), 2.98 (4H, q, J = 6.8 Hz, CH2), 3.77 (3H, s, MeO), 3.82 (3H, s, MeO), 4.08 
(2H, s, CH2), 4.79 (2H, s, CH2), 4.98 (2H, s, CH2), 5.02 (2H, s, CH2), 6.93 (2H, brs, 
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exchangeable NH), 6.96–6.98 (2H, m, 2×ArH), 7.07–7.09 (1H, m, ArH), 7.18–7.22 
(1H, m, ArH), 7.25–7.28 (2H, m, 2×ArH), 7.30–7.37 (1H, m, ArH). Anal. Calcd. for 
(C28H33N3O6): C, 66.26; H, 6.55; N, 8.28. Found: C, 66.34; H, 6.45; N, 8.11. 
 
[3-(3,4,5-Trimethoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]bis 
(methylene)bis(ethylcarbamate) (83j). Compound 83j was synthesized from 81j 
(0.79 g, 2.0 mmol), Et3N (0.8 mL), and ethylisocyanate (0.57 g, 8.0 mmol). Yield, 
0.94 g (99 %); mp 170–171 ºC. 1H NMR (DMSO-d6)  0.97 (6H, t, J = 6.8 Hz, 
2×Me), 2.98 (4H, q, J = 6.8 Hz, CH2), 3.73 (3H, s, MeO), 3.80 (6H, s, 2×MeO), 4.09 
(2H, s, CH2), 4.81 (2H, s, CH2), 5.02 (2H, s, CH2), 5.05 (2H, s, CH2), 6.70 (2H, s, 
2×ArH), 6.95 (2H, brs, exchangeable, NH), 7.19–7.21 (1H, m, ArH), 7.23–7.26 (1H, 
m, ArH), 7.27–7.29 (1H, m, ArH), 7.33–7.35 (1H, m, ArH). Anal. Calcd. for 
(C29H35N3O7): C, 64.79; H, 6.56; N, 7.82. Found: C, 64.68; H, 6.42; N, 7.97. 
 
[3-Methyl-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]bis(methylene)bis(iso-
propylcarbamate) (84a). Compound 84a was synthesized from 81a (0.5 g, 2.0 
mmol), Et3N (0.4 mL ), and isopropylisocyanate (0.69 g, 8.0 mmol). Yield, 0.55 g (65 
%); mp 215–218 °C. 1H NMR (DMSO-d6)  0.99 (12H, d, J = 6.4 Hz, 4×Me), 2.25 
(3H, s, Me), 3.54 (2H, m, CH), 3.99 (2H, s, CH2), 4.89 (2H, s, CH2), 4.93 (2H, s, 
CH2), 4.96 (2H, s, CH2), 6.78 (2H, brs, exchangeable, NH), 7.25–7.29 (2H, m, 
2×ArH), 7.34–7.35 (2H, m, 2×ArH). Anal. Calcd. for (C23H31N3O4): C, 66.81; H, 
7.56; N, 10.16. Found: C, 66.69; H, 7.66; N, 10.10. 
 
[3-Ethyl-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]bis(methylene)bis(iso-
propylcarbamate) (84b). Compound 84b was synthesized from 81b (0.26 g, 1.0 
mmol), Et3N (0.4 mL ), and isopropylisocyanate (0.34 g, 4.0 mmol). Yield, 0.25 g (58 
%); mp 155–158 °C. 1H NMR (DMSO-d6)  1.00 (12H, d, J = 6.4 Hz, 4×Me), 1.10 
(3H, t, J = 7.6 Hz, Me,), 2.69 (2H, q, J = 7.6 Hz, CH2,), 3.55 (2H, m, CH), 3.99 (2H, 
s, CH2), 4.89 (2H, s, CH2), 4.93 (2H, s, CH2), 4.99 (2H, s, CH2), 6.79 (2H, brs, 
exchangeable, NH), 7.25–7.29 (2H, m, 2×ArH), 7.33–7.39 (2H, m, 2×ArH). Anal. 
Calcd. for (C24H33N3O4): C, 67.42; H, 7.78; N, 9.83. Found: C, 67.11; H, 7.55; N, 
9.71. 
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[3-Phenyl-5-10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]bis(methylene)bis(iso-
propylcarbamate) (84c). Compound 84c was synthesized from 81c (0.5 g, 1.6 
mmol), Et3N (0.5 mL ), and isopropylisocyanate (0.54 g, 6.4 mmol). Yield, 0.52 g (74 
%); mp 175–176 oC.  1H NMR (DMSO-d6)  0.99 (12H, d, J = 6.8 Hz, 4×Me), 3.62 
(2H, m, CH), 4.10 (2H, s, CH2), 4.80 (2H, s, CH2), 4.98 (2H, s, CH2), 5.03 (2H, s, 
CH2), 6.86 (2H, brs, exchangeable, NH), 7.18–7.22 (1H, m, ArH), 7.26–7.28 (2H, m, 
2×ArH), 7.38–7.42 (4H, m, 4×ArH), 7.49–7.51 (2H, m, 2×ArH). Anal. Calcd. for 
(C28H33N3O4): C, 70.71; H, 6.99; N, 8.84. Found: C, 70.59; H, 6.92; N, 8.67. 
 
[3-(4-Fluorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene)bis(iso-propylcarbamate) (84d). Compound 84d was 
synthesized from 81d (0.5 g, 1.5 mmol), Et3N (0.5 mL), and isopropylisocyanate 
(0.51 g, 6.0 mmol). Yield, 0.62 g (81 %); mp 190–191 °C. 1H NMR (DMSO-d6)  
0.99 (12H, d, J = 6.4 Hz, 4×Me), 3.60 (2H, m, CH), 4.09 (2H, s, CH2), 4.79 (2H, s, 
CH2), 4.95 (2H, s, CH2), 5.02 (2H, s, CH2), 6.86 (2H, brs, exchangeable, NH), 7.18–
7.22 (1H, m, ArH), 7.26–7.29 (5H, m, 5×ArH), 7.31–7.33 (2H, m, 2×ArH). Anal. 
Calcd. for (C28H32FN3O4): C, 68.14; H, 6.53; N, 8.51. Found: C, 68.31; H, 6.40; N, 
8.60. 
 
[3-(4-Chlorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene)bis(iso-propylcarbamate) (84e). Compound 84e was 
synthesized from 81e (0.45 g, 1.3 mmol), Et3N (0.5 mL ), and isopropylisocyanate 
(0.42 g, 5.0 mmol). Yield, 0.43 g (64 %); mp 191–192°C. 1H NMR (DMSO-d6)  
1.01 (12H, d, J = 6.4 Hz, 4×Me), 3.57 (2H, m, CH), 4.09 (2H, s, CH2), 4.80 (2H, s, 
CH2), 4.97 (2H, s, CH2), 5.02 (2H, s, CH2), 6.86 (2H, brs, exchangeable, NH), 7.18–
7.22 (1H, m, ArH), 7.25–7.30 (2H, m,  2×ArH), 7.37–7.39 (1H, m, ArH), 7.46 (2H, d, 
J = 8.0 Hz, 2×ArH), 7.55 (2H, d, J = 8.0 Hz, 2×ArH). Anal. Calcd. for 
(C28H32ClN3O4): C, 65.94; H, 6.32; N, 8.24. Found: C, 65.76; H, 6.17; N, 8.35. 
 
[3-(3,4-Difluorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene)bis(iso-propylcarbamate) (84f). Compound 84f was synthesized 
from 81f (0.5 g, 1.4 mmol), Et3N (0.5 mL ), and isopropylisocyanate (0.49 g, 5.8 
mmol). Yield, 0.62 g (83 %); mp 176–178 °C. 1H NMR (DMSO-d6)  1.02 (12H, d, J 
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= 6.4 Hz, 4×Me), 3.58 (2H, m, CH), 4.09 (2H, s, CH2), 4.81 (2H, s, CH2), 5.00 (2H, s, 
CH2), 5.02 (2H, s, CH2), 6.87 (2H, brs, exchangeable, NH), 7.19–7.21 (1H, m, ArH), 
7.26–7.30 (3H, m, 3×ArH), 7.37–7.39 (1H, m, ArH), 7.51–7.59 (2H, m, 2×ArH). 
Anal. Calcld. for (C28H31F2N3O4): C, 65.74; H, 6.11; N, 8.21. Found: C, 65.51; H, 
6.05; N, 8.38. 
 
[3-(3,4-Dichlorophenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene)bis(iso-propylcarbamate) (84g). Compound 84g was 
synthesized from 81g (0.5 g, 1.3 mmol), Et3N (0.5 mL), and isopropylisocyanate 
(0.45 g, 5.3 mmol). Yield, 0.6 g (82 %); mp 192–193°C. 1H NMR (DMSO-d6)  1.01 
(12H, d, J = 6.4 Hz, 4×Me), 3.57 (2H, m, CH), 4.09 (2H, s, CH2), 4.81 (2H, s, CH2), 
5.02 (4H, s, 2×CH2), 6.87 (2H, brs, exchangeable, NH), 7.19–7.21 (1H, m, ArH), 
7.25–7.27 (2H, m,  2×ArH), 7.30–7.37 (1H, m, ArH), 7.43–7.45 (1H, m, ArH), 7.69 
(1H, s, ArH) 7.73–7.75 (1H, m, ArH). Anal. Calcd. for (C28H31N3O4Cl2): C, 61.77; H, 
5.74; N, 7.72. Found: C, 61.84; H, 5.67; N, 7.56. 
 
[3-(4-Methoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene)bis(iso-propylcarbamate) (84h). Compound 84h was 
synthesized from 81h (0.5 g, 1.4 mmol), Et3N (0.5 mL), and isopropylisocyanate (0.5 
g, 5.9 mmol). Yield, 0.49 g (65 %); mp 199–200 °C. 1H NMR (DMSO-d6)  1.00 
(12H, d, J = 6.0 Hz, 4×Me), 3.57 (2H, m, CH), 3.82 (3H, s, MeO), 4.07 (2H, s, CH2), 
4.77 (2H, s, CH2), 4.92 (2H, s, CH2), 5.01 (2H, s, CH2), 6.85 (2H, brs, exchangeable, 
NH), 7.04–7.06 (2H, m, 2×ArH), 7.17–7.21 (1H, m, ArH), 7.25–7.28 (2H, m, 
2×ArH), 7.34–7.36 (3H, m, 3×ArH). Anal. Calcd. for (C29H35N3O5): C, 68.89; H, 
6.98; N, 8.31. Found: C, 68.93; H, 6.96; N, 8.14. 
 
[3-(3,4-Dimethoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-
diyl]bis(methylene) bis(iso-propylcarbamate) (84i). Compound 84i was 
synthesized from 81i (0.37 g, 1.0 mmol), Et3N (0.4 mL), and isopropylisocyanate 
(0.34 g, 4 mmol). Yield, 0.30 g (56 %); mp 188–189 ºC. 1H NMR (DMSO-d6)  1.01 
(12H, d, J = 6.0 Hz, 4×Me), 3.57 (2H, m, CH), 3.77 (3H, s, MeO), 3.82 (3H, s, MeO), 
4.08 (2H, s, CH2), 4.78 (2H, s, CH2), 4.98 (2H, s, CH2), 5.01 (2H, s, CH2), 6.84 (2H, 
brs, exchangeable, NH), 6.95–6.97 (2H, m, 2×ArH), 7.06–7.08 (1H, m, ArH), 7.18–
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7.21 (1H, m, ArH), 7.25–7.29 (2H, m, 2×ArH), 7.30–7.37 (1H, m, ArH). Anal. Calcd. 
for (C30H37N3O6): C, 67.27; H, 6.96; N, 7.84. Found: C, 67.27; H, 7.06; N, 7.62. 
 
[3-(3,4,5-Trimethoxyphenyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline-1,2-diyl]bis 
(methylene)bis(iso-propylcarbamate) (84j). Compound 84j was synthesized from 
81j (0.39 g, 1.0 mmol), Et3N (0.4 mL), and isopropylisocyanate (0.34 g, 4 mmol).  
Yield, 0.32 g (57 %); mp 189–190 ºC. 1H NMR (DMSO-d6)  1.01 (12H, d, J = 6.4 
Hz, 4×Me), 3.57 (2H, m, CH), 3.73 (3H, s, MeO), 3.80 (6H, s, 2×MeO), 4.08 (2H, s, 
CH2), 4.79 (2H, s, CH2), 5.01 (2H, s, CH2), 5.05 (2H, s, CH2), 6.69 (2H, s, 2×ArH), 
6.87 (2H, brs, exchangeable, NH), 7.19–7.29 (2H, m, 2×ArH), 7.33–7.39 (2H, m, 
2×ArH). Anal. Calcld. For (C31H39N3O7): C, 65.82; H, 6.95; N, 7.43. Found: C, 65.68; 
H, 6.74; N, 7.11. 
 
2.3 Conclusion 
 
In the present chapter, new chemical entities were prepared to obtain a library 
of DNA bifunctional alkylating agents. A series of linear bis(hydroxylmethyl)-5,10-
dihydropyrrolo[1,2-b]isoquinoline derivatives and their bis(alkylcarbamate) 
derivatives were synthesized. All newly synthesized compounds were tested against 
various human tumor cell lines In vitro and In vivo. Antitumor activities and outcome 
of these compounds are shown in Chapter 3. 
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2.4 Representative Spectra 
2.4.1 1H NMR Spectrum for compound 80a.  
 
 
 
2.4.2 1H NMR Spectrum for compound 81a. 
 
 
N
Me
COOMe
COOMe
Chapter 2                                                                    Synthesis & characterization of… 
       
 
 
50
2.4.3 1H NMR Spectrum for compound 83a.  
 
 
 
2.4.4 1H NMR Spectrum for compound 84a. 
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2.4.5 1H NMR Spectrum for compound 79d. 
 
 
 
2.4.6 1H NMR Spectrum for compound 80d. 
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2.4.7 1H NMR Spectrum for compound 81d. 
 
 
 
D2O exchange 1H NMR Spectrum for compound 81d. 
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2.4.8 1H NMR Spectrum for compound 83d. 
 
 
 
D2O exchange 1H NMR Spectrum for compound 83d. 
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2.4.9 1H NMR Spectrum for compound 84d. 
 
 
 
2.4.10 1H NMR Spectrum for compound 79g.  
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2.4.11 1H NMR Spectrum for compound 80g.  
 
 
 
2.4.12 1H NMR Spectrum for compound 81g. 
 
 
N
COOMe
COOMe
Cl
Cl
N
CH2OH
CH2OH
Cl
Cl
Chapter 2                                                                    Synthesis & characterization of… 
       
 
 
56
D2O exchange 1H NMR Spectrum for compound 81g. 
 
 
 
2.4.13 1H NMR Spectrum for compound 83g. 
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D2O exchange 1H NMR Spectrum for compound 83g. 
 
 
 
2.4.14 1H NMR Spectrum for compound 84g. 
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D2O exchange 1H NMR Spectrum for compound 84g. 
 
 
 
2.4.15 1H NMR Spectrum for compound 79j.  
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2.4.16 1H NMR Spectrum for compound 80j.  
 
 
 
2.4.17 1H NMR Spectrum for compound 81j. 
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D2O exchange 1H NMR Spectrum for compound 81j. 
 
 
 
2.4.18 1H NMR Spectrum for compound 83j. 
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D2O exchange 1H NMR Spectrum for compound 83j. 
 
 
 
2.4.18 1H NMR Spectrum for compound 84j. 
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2.5 High Performance Liquid Chromatography Analysis (HPLC) 
 
The prime and specific objective of the work is to develop simple and Rapid 
Liquid Chromatographic method of newly synthesized compounds 
bis(hydroxymethyl)-5,10-dihydropyrrolo[1,2-b]isoquinolin-1-yl derivatives (81) and 
their bis(alkylcarbamate) derivatives (82-84) for the Purity Determination by High-
performance liquid chromatographic method. 
 
2.6 HPLC Experimental 
 
Instrument 
Liquid chromatography was performed using Hitachi D-2000 Elite instrument 
with Mightysil RP-18 GP 250-4.6 (5µm) column.  
 
Reagents 
Acetonitrile (HPLC grade) 
Tetrahydrofuran (HPLC grade) 
Water (Milli-Q) 
 
Blank 
Diluent was used as blank. 
 
Sample Preparation 
Weigh accurately 10 mg of different new synthesized compounds into 100 ml 
volumetric flask. Add 60 ml of diluent into the flask and sonicate for 30 minutes with 
normal hand-shaking. Cool the flask at room temperature and dilute it to volume with 
diluent. Filter 10 ml of this solution through 0.45 μm nylon syringe filter. The 
concentration obtained is 100 µg/ml. 
 
All samples were prepared as per above mentioned sample preparation method. 
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2.7 Chromatograms 
 
Chromatographic condition 
Sample Code : 81a (BO-1107) 
Mobile phase : MeCN : THF (50 : 50 v/v) 
Column : Mightysil RP-18 GP 250-4.6 (5µm) 
Column Temperature: 27 oC 
Flow rate : 1.0 mL/min 
Detection : 254 nm 
Injection volume : 10 μL 
Diluent : Mobile phase 
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Chromatographic condition 
Sample Code : 81f (BO-1112) 
Mobile phase : MeCN : THF (50 : 50 v/v) 
Column : Mightysil RP-18 GP 250-4.6 (5µm) 
Column Temperature: 27 oC 
Flow rate : 1.0 mL/min 
Detection : 254 nm 
Injection volume : 10 μL 
Diluent : Mobile phase 
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Chromatographic condition 
Sample Code : 82f (BO-1113) 
Mobile phase : MeCN : THF (50 : 50 v/v) 
Column : Mightysil RP-18 GP 250-4.6 (5µm) 
Column Temperature: 27 oC 
Flow rate : 1.0 mL/min 
Detection : 254 nm 
Injection volume : 10 μL 
Diluent : Mobile phase 
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Chromatographic condition 
Sample Code : 83h (BO-1516) 
Mobile phase : MeCN : THF (50 : 50 v/v) 
Column : Mightysil RP-18 GP 250-4.6 (5µm) 
Column Temperature: 27 oC 
Flow rate : 1.0 mL/min 
Detection : 254 nm 
Injection volume : 10 μL 
Diluent : Mobile phase 
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Chromatographic condition 
Sample Code : 84c (BO-1504) 
Mobile phase : MeCN : THF (50 : 50 v/v) 
Column : Mightysil RP-18 GP 250-4.6 (5µm) 
Column Temperature: 27 oC 
Flow rate : 1.0 mL/min 
Detection : 254 nm 
Injection volume : 10 μL 
Diluent : Mobile phase 
 
 
N
CH2OCONH-i-C3H7
CH2OCONH-i-C3H7
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Table 2.3  Elemental analysis of compounds 79b–j and 80a–j. 
 
 
 
Compd. MF MW 
CHN Calculated (%) CHN Found (%) 
C H N C H N 
79b C13H15NO3 233.26 66.94 6.48 6.00 66.64 6.48 5.89 
79ca C17H15NO3 281.11 72.58 5.37 4.98 ND ND ND 
79d C17H14FNO3 299.30 68.22 4.71 4.68 68.08 4.57 4.42 
79e C17H14ClNO3 315.75 64.67 4.47 4.44 64.52 4.56 4.33 
79f C17H13F2NO3 317.29 64.35 4.13 4.41 64.21 4.26 4.56 
79g C17H13Cl2NO3 350.20 58.31 3.74 4.00 58.19 4.04 3.87 
79h C18H17NO4 311.33 69.44 5.50 4.50 69.12 5.62 4.27 
79i C19H19NO5 341.13 66.85 5.61 4.10 66.65 5.66 3.86 
79j C20H21NO6 371.38 64.68 5.70 3.77 64.44 5.50 3.44 
80aa C17H17NO4 299.12 68.21 5.72 4.68 ND ND ND 
80b C18H19NO4 313.13 68.99 6.11 4.47 68.96 6.05 4.38 
80c C22H19NO4 361.39 73.12 5.30 3.88 72.91 5.30 3.53 
80d C22H18FNO4 379.38 69.65 4.78 3.69 69.54 4.82 3.78 
80e C22H18ClNO4 395.84 66.75 4.58 3.54 66.52 4.85 3.66 
80f C22H17F2NO4 397.37 66.50 4.31 3.52 66.15 4.44 3.36 
80g C22H17Cl2NO4 430.28 61.41 3.98 3.26 61.33 3.95 2.89 
80h C23H21NO5 391.42 70.58 5.41 3.58 70.25 5.44 3.49 
80i C24H23NO6 421.15 68.40 5.50 3.32 68.02 5.53 2.94 
80j C25H25NO7 451.16 66.51 5.58 3.10 66.25 5.59 3.01 
aknown compound 
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Table 2.4 Elemental analysis of compounds 81a–j, 82, 83a–j, and 84a–j. 
 
 
 
Compd. MF MW 
CHN Calculated (%) CHN Found (%) 
C H N C H N 
81a C15H17NO2 243.30 74.05 7.04 5.76 74.24 6.97 5.71 
81ba C16H19NO2 257.33 74.68 7.44 5.44 ND ND ND 
81c C20H19NO2 305.37 78.66 6.27 4.59 78.48 6.42 4.41 
81d C20H18FNO2 323.36 74.29 5.61 4.33 74.38 5.68 3.98 
81e C20H18ClNO2 339.82 70.69 5.34 4.12 70.42 5.37 4.05 
81f C20H17F2NO2 341.35 70.37 5.02 4.10 70.08 5.01 3.76 
81g C20H17Cl2NO2 374.26 64.18 4.58 3.74 63.89 4.40 3.87 
81h C21H21NO3 335.40 75.20 6.31 4.18 75.36 6.30 4.13 
81i C22H23NO4 365.16 72.31 6.34 3.83 72.25 6.34 3.95 
81j C23H25NO5 395.17 69.86 6.37 3.54 69.71 6.37 3.45 
82a C19H23N3O4 357.40 63.85 6.49 11.76 63.54 6.57 11.64
82e C24H24ClN3O4 453.93 63.50 5.33 9.26 63.33 5.35 9.20 
82f C24H23F2N3O4 455.47 63.29 5.09 9.23 63.00 5.12 9.16 
82h C25H27N3O5 449.51 66.80 6.05 9.35 66.72 6.15 9.24 
83a C21H27N3O4 385.46 65.44 7.06 10.90 65.29 7.14 10.89
83b C22H29N3O4 399.48 66.14 7.32 10.52 66.35 7.53 10.74
83c C26H29N3O4 447.53 69.78 6.53 9.39 69.64 6.54 9.37 
83d C26H28FN3O4 465.52 67.08 6.06 9.03 67.24 6.02 8.88 
83e C26H28ClN3O4 481.97 64.79 5.86 8.72 64.54 5.84 8.82 
83f C26H27F2N3O4 483.51 64.59 5.63 8.69 64.50 5.60 8.69 
83g C26H27Cl2N3O4 516.42 60.47 5.27 8.14 60.34 5.13 8.10 
83h C27H31N3O5 477.55 67.91 6.54 8.80 67.73 6.86 8.57 
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83i C28H33N3O6 507.58 66.26 6.55 8.28 66.34 6.45 8.11 
83j C29H35N3O7 537.60 64.79 6.56 7.82 64.68 6.42 7.97 
84a C23H31N3O4 413.51 66.81 7.56 10.16 66.69 7.66 10.10
84b C24H33N3O4 427.54 67.42 7.78 9.83 67.11 7.55 9.71 
84c C28H33N3O4 475.58 70.71 6.99 8.84 70.59 6.92 8.67 
84d C28H32FN3O4 493.57 68.14 6.53 8.51 68.31 6.40 8.60 
84e C28H32ClN3O4 510.02 65.94 6.32 8.24 65.76 6.17 8.35 
84f C28H31F2N3O4 511.56 65.74 6.11 8.21 65.51 6.05 8.38 
84g C28H31Cl2N3O4 544.47 61.77 5.74 7.72 61.84 5.67 7.56 
84h C29H35N3O5 505.61 68.89 6.98 8.31 68.93 6.96 8.14 
84i C30H37N3O6 535.63 67.27 6.96 7.84 67.27 7.06 7.62 
84j C31H39N3O7 565.66 65.82 6.95 7.43 65.68 6.74 7.11 
anot determine 
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Section A 
 
Chapter 3. Antitumor Activity of 
bis(hydroxymethyl)-5,10-
dihydropyrrolo[1,2-b]isoquinolin-
1-yl derivatives and their 
bis(alkylcarbamate) derivatives 
Chapter 3                                                                                   Antitumor Activity of… 
       
 
 
72
3.0 Experimental Protocols  
3.0.1  Cytotoxicity Assays  
 
  The effects of the newly synthesized compounds on cell growth were 
determined in T-cell acute lymphocytic leukemia CCRF-CEM) and their resistant 
subcell lines (CCRF-CEM/Taxol and CCRF-CEM/VBL) by the XTT assay103 and 
human solid tumor cells (i.e. breast carcinoma MX-1 and colon carcinoma HCT-116) 
the SRB assay104 in a 72 h incubation using a microplate spectrophotometer as 
described previously.105 After the addition of phenazine methosulfate-XTT solution at 
37 oC for 6 h, absorbance at 450 and 630 nm was detected on a microplate reader (EL 
340; Bio-Tek Instruments Inc., Winooski, VT). The cytotoxicity of the newly 
synthesized compounds against non-small cell lung cancer H1299, human prostate 
cancer PC3, oral carcinoma OECM1 and human glioma U87 were determined by the 
Alamar blue assay106 in a 72 h incubation using a microplate spectrophotometer as 
described previously. After the addition of Alamar blue solution, it was incubated at 
37 oC for 6 h. Absorbance at 570 and 600 nm was detected on a microplate reader. 
IC50 values were determined from dose-effect relationship at six or seven 
concentrations of each drug by using the CompuSyn software by Chou and Martin107 
based on the median-effect principle and plot.108,109 Ranges given for taxol and 
vinblastine were mean ± SE (n = 4). 
 
3.0.2  In vivo studies  
   
Athymic nude mice bearing the nu/nu gene were used for human breast tumor 
MX-1 and human ovarian adenocarcinoma SK-OV-3 xenograft. Outbred Swiss-
background mice were obtained from the National Cancer Institute (Frederick, MD). 
Male mice 8 weeks old or older weighing about 22 g were used for the experiments. 
Drug was administrated via the tail vein by i.v. injection.105 Tumor volumes were 
assessed by measuring length × width × height (or width) by using caliper.  Vehicle 
used was DMSO (50 L) and Tween 80 (40 L) in saline (160 L). The maximal 
tolerable dose of the tested compound was determined and applied for the in vivo 
antitumor activity assay. All animal studies were conducted in accordance with the 
guidelines of the National Institutes of Health Guide for the Care and Use of Animals 
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and the protocol approved by the Memorial Sloan-Kettering Cancer Center’s 
Institutional Animal Care and Use Committee.  
 
3.0.3  Alkaline agarose gel shift assay  
 
 Formation of DNA cross-linking was analyzed by alkaline agarose gel 
electrophoresis.110 In brief, purified pEGFP-N1 plasmid DNA (1.5 μg) was mixed 
with various concentrations (1–20 µM) of 81a, 83a, 81h and 84h in 40 µL binding 
buffer (3 mM sodium chloride/1mM sodium phosphate, pH 7.4, and 1 mM EDTA). 
The reaction mixture was incubated at 37oC for 2 h. At the end of reaction, the 
plasmid DNA was linearized by digestion with BamHI and followed by precipitation 
with ethanol. The DNA pellets were dissolved and denatured in alkaline buffer (0.5 N 
NaOH–10mM EDTA). An aliquot of 20 µL of DNA solution (1 μg) was mixed with a 
4 µL of 6 X alkaline loading dye and then electrophoretically resolved on a 0.8 % 
alkaline agarose gel with NaOH–EDTA buffer at 4 oC. The electrophoresis was 
carried out at 18 V for 22 h. After staining the gels with an ethidium bromide solution, 
and the DNA was then visualized under UV light. 
 
3.0.4 Flow cytometric analysis 
 
 The effects of 81a on cell cycle distribution were analyzed with a flow 
cytometer as previously described.96 Briefly, human non-small cell lung carcinoma 
H1299 cells were treated with 81a at 1.25, 2.5, and 5 µM for 24 h. The attached cells 
were then trypsinized, washed with phosphate buffer saline (PBS), and fixed with ice-
cold 70% ethanol for 30 min. The cells were stained with 4 µg/ml propidium iodide 
(PI) in PBS containing 1% Triton X-100 and 0.1 mg/ml RNase A. The stained cells 
were then analyzed using the FACS SCAN flow cytometer (Becton Dickinson, San 
Joes, CA, USA). The percentage of the cells in each cell cycle phase was determined 
using the ModFit LT 2.0 software based on the DNA histograms.
Chapter 3                                                                                   Antitumor Activity of… 
       
 
 
74
3.1 In vitro cytotoxicity 
 
Table 3.1 shows the antiproliferative activities of the newly synthesized 
bis(hydroxylmethyl)-5,10-dihydropyrrolo[1,2-b]isoquinoline derivatives (81) and 
their bis(alkylcarbamate) derivatives (82, 83 and 84) against human lymphoblastic 
leukemia (CCRF-CEM) and its drug-resistant sublines resistant to Taxol (CCRF-
CEM/Taxol) and Vinblastine (CCRF-CEM/VBL) cell growth in vitro. It demonstrated 
that the newly synthesized conjugates possess significant cytotoxicity with IC50 in 
submicro molar range. In the series of bis(hydroxymethyl) derivatives, it showed that 
3-alkyl (Me or Et) substituted derivatives are more cytotoxic than the 3-phenyl 
substituted compounds. The order of their potency, for example, is 81a (3-Me) > 81b 
(3-Et) > 81c (3-Ph), indicating that the compounds having a smaller size of substituent 
at C3 have greater cytotoxicity. A similar observation is found in 3-phenyl 
derivatives: the cytotoxicity decreases when the number of the methoxy functions 
increases (81h vs. 81i vs. 81j). Furthermore, the cytotoxicity decreases when the 
number of the halo function increases in the halo substituted 3-phenyl derivatives 
(81d > 81f and 81e > 81g). In this study, one can observe that the C3-methoxyphenyl 
derivatives are somewhat more cytotoxic than the corresponding halophenyl 
compounds. This suggests that the electron properties of the substituent(s) on the 
phenyl ring have very little influence over their potency. 
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Table 3.1 The cytotoxicity of newly synthesized bis(hydroxymethyl)-5,10-
dihydropyrrolo[1,2-b]isoquinolin-1-yl derivatives (81) and their bis(alkylcarbamate) 
derivatives (82 to 84)  against human lymphoblastic leukemia (CCRF-CEM) and its 
drug-resistant sublines (CCRF-CEM/Taxol and CCRF-CEM/VBL)a 
 
 
 
Compd. R1 
Cell Growth inhibition (IC50 µM) 
CCRF-CEM 
CCRF-CEM/ 
Taxolb 
CCRF-CEM/ 
VBLb 
81a Me 0.08±0.02 
0.10±0.001 
[1.22]c 
0.09±0.01 
[1.1] 
81b Et 0.18±0.01 
0.21±0.003 
[1.15] 
0.19±0.02 
[1.03] 
81c C6H5 0.51±0.01 
0.50±0.04 
[0.99] 
0.29±0.02 
[0.56] 
81d 4’-F-C6H4 0.51±0.01 
0.88±0.03 
[1.72] 
0.49±0.002 
[0.95] 
81e 4’-Cl-C6H4 0.60±0.002 
0.77±0.17 
[1.28] 
0.72±0.18 
[1.2] 
81f 3’,4’-Di-F-C6H3 1.14±0.22 
1.26±0.26 
[1.11] 
0.95±0.21 
[0.84] 
81g 3’,4’-Di-Cl-C6H3 8.44±0.06 
4.82±0.01 
[0.57] 
6.42±0.05 
[0.76] 
81h 4’-MeO-C6H4 0.23±0.03 
0.25±0.001 
[1.02] 
0.11±0.001 
[0.48] 
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81i 3’,4’-Di- MeO-C6H3 1.10±0.04 
0.76±0.02 
[0.69] 
0.62±0.01 
[0.56] 
81j 
3’,4’,5’-Tri- MeO -
C6H2 
1.97±0.46 
2.88±0.05 
[1.45] 
2.78±0.09 
[1.40] 
82a Me 0.13±0.01 
0.11±0.002 
[0.86] 
0.08±0.001 
[0.59] 
82e 4’-Cl-C6H4 0.19±0.01 
0.22±0.004 
[1.18] 
0.16±0.05 
[0.87] 
82f 3’,4’-Di-F-C6H3 0.49±0.09 
0.45±0.20 
[0.91] 
0.47±0.05 
[0.97] 
82h 4’- MeO-C6H4 0.18±0.03 
0.13±0.03 
[0.72] 
0.09±0.02 
[0.49] 
83a Me 0.24±0.002 
0.11±0.001 
[0.48] 
0.12±0.003 
[0.51] 
83b Et 0.44±0.01 
0.21±0.01 
[0.48] 
0.24±0.01 
[0.53] 
83c C6H5 0.26±0.01 
0.26±0.03 
[1.01] 
0.23±0.001 
[0.90] 
83d 4’-F-C6H4 0.31±0.01 
0.43±0.05 
[1.39] 
0.57±0.01 
[1.85] 
83e 4’-Cl-C6H4 0.59±0.01 
0.35±0.01 
[0.59] 
0.57±0.06 
[0.97] 
83f 3’,4’-Di-F-C6H3 2.08±0.02 
1.25±0.02 
[0.60] 
0.67±0.003 
[0.32] 
83g 3’,4’-Di-Cl-C6H3 2.37±0.02 
0.90±0.002 
[0.38] 
1.19±0.04 
[0.50] 
83h 4’- MeO-C6H4 0.37±0.02 
0.22±0.003 
[0.58] 
0.35±0.01 
[0.93] 
83i 3’,4’-Di- MeO-C6H3 1.07±0.001 
0.81±0.01 
[0.75] 
0.65±0.02 
[0.60] 
83j 
3’,4’,5’-Tri- MeO-
C6H2 
1.41±0.02 
2.14±0.08 
[1.52] 
3.13±0.03 
[2.23] 
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84a Me 0.27±0.004 
0.23±0.002 
[0.84] 
0.14±0.003 
[0.50] 
84b Et 0.57±0.01 
0.32±0.01 
[0.56] 
0.18±0.0002 
[1.42] 
84c C6H5 0.45±0.01 
0.23±0.02 
[0.50] 
0.25±0.01 
[0.55] 
84d 4’-F-C6H4 0.76±0.03 
0.23±0.01 
[0.30] 
0.23±0.001 
[0.31] 
84e 4’-Cl-C6H4 0.54±0.003 
0.63±0.01 
[1.16] 
0.57±0.04 
[1.06] 
84f 3’,4’-Di-F-C6H3 1.33±0.01 
0.78±0.003 
[0.58] 
0.61±0.05 
[0.46] 
84g 3’,4’-Di-Cl-C6H3 3.55±0.02 
2.47±0.07 
[0.69] 
1.35±0.04 
[0.38] 
84h 4’- MeO-C6H4 0.34±0.002 
0.19±0.002 
[0.56] 
0.16±0.001 
[0.47] 
84i 3’,4’-Di- MeO-C6H3 1.29±0.10 
0.60±0.02 
[0.46] 
0.77±0.05 
[0.59] 
84j 
3’,4’,5’-Tri- MeO-
C6H2 
0.89±0.01 
1.20±0.01 
[1.35] 
1.42±0.05 
[1.59] 
Taxol  0.003 ±0.0003
0.43±0.05 
[330] 
1.27 ± 0.05 
[980] 
Vinblas
tine 
 0.0007±0.001 
0.08±0.01 
[106.2] 
0.50±0.12 
[679.5] 
 
a Cell growth inhibition was measured by the XTT assay103 for leukemic cells after 72-h 
incubation using a microplate spectrophotometer as described previously.105 Similar in vitro 
results were obtained by using the Cell Counting Kit-8 for the CCK-8 assays as described by 
technical manual of Dojindo Molecular Technologies, Inc. (Gaithersburg, MD; Website: 
www.dojindo.com). IC50 values were determined from dose-effect relationship at six or seven 
concentrations of each drug by using the CompuSyn software by Chou and Martin104 based on 
the median-effect principle and plot using the serial deletion analysis.108,109 Ranges given for 
taxol and vinblastine were mean ± SE (n = 4). 
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bCCRF-CEM/Taxol and CCRF-CEM/VBL are subcell lines of CCRF-CEM cells that are 
330-fold resistant to Taxol, and 680-fold resistant to vinblastine, respectively, when 
comparing with the IC50 of the parent cell line. 
c Numbers in the brackets are fold of cross-resistant determined by comparison with the 
corresponding IC50 of the parent cell line. 
 
In the series of bis(alkylcarbamates) derivatives, the alkylcarbamate moiety 
may serve as a better leaving group than that of the OH group. Thus, the 
bis(alkylcarbamates) derivatives may easily generate nucleophilic cations on both 
methylene functions that allow the cations to become more favorable targets of DNA. 
In the series of 3-phenyl substituted derivatives, the bis(alkylcarbamates) are 
generally more potent than their corresponding bis(hydroxymethyl) derivatives, 
except for compound bis(ethylcarbamate) 83i, which is as potent as the corresponding 
bis(hydroxymethyl) 81i and more cytotoxic than bis(iso-propylcarbamates) 84i. 
However, in the series of C3-alkyl derivatives, the bis(hydroxymethyl) derivatives 
(81a and 81b) are more potent than their corresponding bis(alkylcarbamates) (82a, 
83a, and 84a; 83b and 84b, respectively).  
 
Our previous research on the SAR studies of 1,2-
bis(hydroxylmethyl)cyclopenta[a]indenes and their counterparts 1,2-
bis(methylcarbamate) derivatives (72–75, Figure 14) demonstrated that the size and 
the electron property of the substituents at the C3 position affected the cytotoxicity of 
these agents.96 However, we found that the cytotoxicity of pyrrolo[1,2-b]isoquinolines 
is mainly affected by the size of the substituents at the C3 position rather than the 
electron property in the current studies. In comparison with the potency of both these 
series, the bis(hydroxymethyl) derivatives of pyrrolo[1,2-b]isoquinoline are more 
cytotoxic than the corresponding cyclopenta[a]indenes. In contrast, the 
bis(alkylcarbamate) derivatives of cyclopenta[a]indenes are more potent than the 
corresponding pyrrolo[1,2-b]isoquinolines.  
 
Our previous report demonstrated that cyclopenta[a]indenes have no multi-
drug resistance toward antitumor agents such as Taxol and Vinblastine. To realize 
whether the newly synthesized pyrrolo[1,2-b]isoquinoline derivatives also have no 
cross-resistance to these two agents, we evaluated their cytotoxicity against CCRF-
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CEM/Taxol and CCRF-CEM/VBL, which are subcell lines of CCRF-CEM cells that 
are 330-fold resistant to Taxol, and 680-fold resistant to Vinblastine, respectively. As 
shown in Table 3.1, the newly synthesized pyrrolo[1,2-b]isoquinolines have no cross-
resistance to either Taxol or Vinblastine. This suggests that all derivatives are neither 
a good substrate of membrane multidrug resistance transporters (i.e., p-glycoprotein) 
nor mutated tubulin.  
 
The antiproliferative activity of the selected pyrrolo[1,2-b]isoquinoline 
derivatives in inhibiting human solid tumors such as breast carcinoma MX-1, colon 
carcinoma HCT-116, non-small cell lung carcinoma H1299, prostate PC3, oral 
carcinoma OECM1 and glioma U87 cell growth in vitro (Table 3.2) were also 
investigated. Of these compounds, C3-Me derivative (81a) was found to have potent 
cytotoxicity in inhibiting MX-1 cell growth in vitro with IC50 values of 0.66 M. 
Compounds 81a, 82e, and 82f exhibited potent inhibitory activity against human 
colon carcinoma HCT-116 with IC50 values of 0.29, 0.04 and 0.36 M, respectively. 
The tested compounds have good to moderate effects against H1299, PC3, OECM1 
and U87 cell growth in vitro. 
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Table 3.2 The cytotoxicity of newly synthesized bis(hydroxymethyl)-5,10-
dihydropyrrolo[1,2-b]isoquinolin-1-yl derivatives (81) and their bis(alkylcarbamate) 
derivatives (82 to 84)  against human solid tumors (breast carcinoma MX-1, colon 
carcinoma HCT-116, lung carcinoma H1299, prostate carcinoma PC3, oral carcinoma 
OECM1 and glioma U87) cell growth in vitro. 
 
Compd. 
Cell Growth inhibition (IC50 µM) 
MX-1a HCT-116a H1299b PC3b OECM1b U87b 
81a 0.66±0.03 0.29±0.01 2.48±1.22 6.07±1.70 6.10±1.11 27.91±3.90 
81d 4.01±0.05 2.46±0.08 8.76±1.15 5.93±1.52 6.99±0.12 23.25±0.26 
81e 3.28±0.01 3.06±0.46 24.73±8.16 9.85±0.79 12.05±0.67 26.68±5.79 
81f 6.99±0.35 3.21±0.21 NDc ND ND ND 
81h 1.99±0.07 1.13±0.07 13.94±0.83 10.93±1.21 6.12±0.21 10.57±0.23 
82a 1.68±0.01 1.17±0.02 ND ND ND ND 
82e 1.18±0.01 0.04±0.002 ND ND ND ND 
82f 2.73±0.05 0.36±0.001 ND ND ND ND 
82h 1.33±0.02 1.07±0.05 ND ND ND ND 
83a 2.27±0.01 0.90±0.03 19.42±0.42 15.45±1.84 11.34±2.07 13.89±4.90 
83d 1.51±0.03 0.79±0.05 3.94±1.13 9.59±1.31 12.52±1.70 28.36±4.86 
83e 1.69±0.06 0.62±0.10 37.25±0.89 10.98±1.14 25.32±0.18 33.59±3.91 
83h 1.27±0.05 0.75±0.004 27.61±1.65 18.54±0.82 10.48±0.13 17.06±1.78 
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84a 1.28±0.01 1.38±0.02 9.77±3.75 16.87±7.42 11.80±2.58 26.61±4.21 
84d 1.17±0.19 0.63±0.001 8.13±1.34 12.29±1.34 11.05±2.61 36.87±5.98 
84e 1.70±0.09 0.69±0.01 25.15±4.05 9.97±1.32 26.10±7.86 22.72±2.03 
84h 0.98±0.03 0.97±0.04 13.16±1.94 6.79±1.01 8.83±0.74 21.04±0.67 
Taxol 
0.035±0.0
0514 
0.0013±0.0
005 
ND ND ND ND 
Vinblas
tine 
0.0029±0.
0002 
0.0018±0.0
004 
ND ND ND ND 
Cisplati
n 
ND ND 4.95±0.60 26.65±4.19 ND ND 
 
aCell growth inhibition was measured by the SRB assay104 for solid tumor cells after 72-h 
incubation using a microplate spectrophotometer as described previously.105 
 
bCell growth inhibition was determined by the Alamar blue assay106 in a 72 h incubation using 
a microplate spectrophotometer as described previously. 
 
cNot determined. 
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3.2 In vivo antitumor activity 
 
To investigate the antitumor activity of pyrrolo[1,2-b]isoquinoline derivatives 
in animal models, we selected compound 81a for evaluating its therapeutic efficacy in 
animal models since this agent has the most potent cytotoxicity among all of the 
compounds tested and exhibits a broad spectrum of antitumor activity in inhibiting 
both CCRF/CEM and other solid tumors in vitro. Nude mice implanted with human 
breast carcinoma MX-1 xenograft were given 30 mg/kg, every two days for two times 
(Q2D2), intravenous injection (i.v. injection) on day 8 and 10 (Figure 16). 
Remarkably, it shows that complete tumor remission against human breast carcinoma 
MX-1 in nude mice was achieved (Figure 16A). This concentration was established 
from tolerability studies. Under this dosage, one can see that nude mice’s body 
weights recovered after cessation of the treatment, indicating the low toxicity of the 
compound to the host (Figure 16B). In another experiment, we found that 81a was 
able to effectively suppress human ovarian tumor SK-OV-3 implanted in nude mice 
on day 22 at the dose of 20 mg/kg, every day for four times (QD4), i.v. injection 
(Figure 17AB). The results of MX-1 and SK-OV-3 xenografts studies show the 
potential utility of compound 81a in inhibiting the growth of both tumors. 
Chapter 3                                                                                   Antitumor Activity of… 
       
 
 
83
 
 
 
 
Figure 16 Therapeutic effects of 81a in nude mice bearing MX-1 human mammary 
xenograft (i.v. inj., n = 4). A: average tumor size changes. B: average body weight 
changes. 
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Figure 17 Therapeutic effects of 81a in nude mice bearing ovarian adenocarcinoma 
SK-OV-3 xenograft (i.v. inj, n=4). A: average tumor size changes. B: average body 
weight changes. 
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3.3 DNA cross-linking study 
 
To realize whether the newly synthesized compounds are capable of cross-
linking with DNA double strands, pEGFP-N1 plasmid DNA was treated with 
bis(hydroxymethyl) derivatives (81a and 81h) and their corresponding 
bis(alkylcarbamate) derivatives (83a and 84h, respectively) at various concentrations 
as indicated (1, 10, and 20 µM) using alkaline agarose gel shifting assay (Figure 
18).110 Melphalan (1, 5, and 10 µM) was used as the positive control.  As revealed in 
Figure 18, one can see that all of the tested compounds were able to induce DNA 
interstrand cross-linking, suggesting that DNA cross-linking may be the main 
mechanism of action for these agents. 
 
 
 
 
 
 
 
Figure 18 Representative DNA cross-linking gel shift assay for bis(hydroxymethyl) 
derivatives (81a and 81h) and their corresponding bis(alkylcarbamate) derivatives 
(83a and 84h, respectively) at various concentrations as indicated. Control lane shows 
single-stranded DNA (SS), while CL shown in all tested lanes is DNA double-
stranded cross-linking. Melphalan (1, 5, and 10 µM) was used as a positive control. 
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3.4 Cell cycle inhibition 
 
It is well known that DNA interacting agents can alter the cell cycle 
progression by arresting the cell cycle at the G2/M phase.111 Previously, we have 
demonstrated that 3a-aza-cyclopenta[a]indene derivatives were able to induce G2/M 
arrest.96 We therefore studied the inhibitory effect of 81a on cell cycle distribution 
(Table 3.3). The human non small lung carcinoma H1299 cells were treated with 81a 
at the concentrations of 1.25, 2.5, and 5 µM for 24 h. The cells were harvested, 
stained with propidium iodide (PI) and analyzed with a flow cytometer. It clearly 
shows that 81a remarkably accumulated the cells at G2/M phase. Furthermore, 
increased sub-G1 populations were noticed in cells treated with 81a at each 
concentration. 
 
Table 3.3 Effects of compound 81a on cell cycle progress in human non-small 
cell lung adenocarcinoma H1299. 
 
Concentr
ation 
(µM) 
0 1.25 2.5 5 
 
   
sub G1 14.1±0.7 21.6±4.2 26.6±0.7 26.5±3.0 
G1 42.9±0.8 5.6±0.6 7.7±0.7 0.5±0.3 
S 22.5±0.3 32.7±5.9 18.3±8.4 24.7±4.6 
G2/M 20.5±0.9 40.1±6.5 47.3±2.1 48.4±2.2 
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3.5 Conclusion 
 
Both bis(hydroxymethyl)pyrrolo[1,2-b]isoquinoline and their 
bis(alkylcarbamate) derivatives show potent antitumor activity in inhibiting various 
human tumor xenografts in vitro. Among these analogues, we discovered compound 
81a, which was selected for antitumor studies in animal models, exhibits potent 
therapeutic efficacy against human breast MX-1 xenograft in nude mice, as complete 
tumor remission was observed. This agent is also able to significantly suppress human 
ovarian tumors implanted in nude mice. The results reported herein warrant further 
investigation to optimize the schedule and dosage to get greater suppression of other 
human tumor growth in animal models. Additional, the evaluation of the antitumor 
activity of 81a in combination with DNA repair inhibitor (e.g. ATO) is currently 
undergoing in our laboratory. 
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Chapter 4. Introduction of 
Pyrano[3,2-c]Quinolone 
Derivatives  
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4.0 Introduction 
4-hydroxy-2-quinolone is an important compound, because this moiety is exits 
in natural products exhibit variety of interesting pharmacological properties.1 While 
pyranofused heterocycles are biologically important as antibacterial2, antihistamines3, 
antimicrobials4, enzyme substrates5 and alkaloids6. Pyranoquinolinones show good 
pharmacological activities1,7 such as, antibacterial, antimicrobial, anti-HIV and 
antiviral and antitumor. The derivatives of fused 2-quinolones are useful as 
cardiovascular agents7. Quinolone alkaloids are also known to possess antimicrobial 
activity and marked cytotoxicity against animal and plant tumors.8 A novel class of 4-
hydroxyquinolin-2(1H)-ones has recently been described9 as selective glycinesite 
NMDA antagonists with potent in vivo activity after oral administration. However, 
depending on their structural types, quinolone derivatives exhibit different activities.10 
Furo[2,3-c]quinolin-4(5H)-one and 2H-pyrano[3,2-c]quinolin-5(6H)-one derivatives 
are abundantly distributed in nature.11 
 
4.1 Quinolone alkaloids 
1-Methyl tetradecylquinolin-4(1H)-one (1), was isolated from the fruits of 
Evodia rutaecarpa together with evocarpine (2) and related alkadienes (3) and (4). 12 
 
These are the first quinolone alkaloids have been tested as DGAT inhibitors; 
the moderate activity of purified compounds (IC50 69.5, 23.8, 20.1 and 13.5 µM, 
respectively) indicates possible utility in the design of hypolipidaemic and antiobesity 
agents. Evocarpine and the positional isomer (5) show strong antibacterial activity 
against Helicobacter pylori both in vitro and in vivo by inhibiting respiration, the 
results reinforcing previous indications of this class of alkaloids as novel therapeutical 
agents for the treatment of ulcers.13 Another Evodia alkaloid, 1-methyl-2-
undecylquinolin-4(1H)-one (6), has proved to be an irreversible and selective 
inhibitor of type B monoamine oxidase, suggesting potential value in the treatment of 
neurological disorders such as Parkinson’s and Alzheimer’s diseases.14  
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The herb rue (Ruta graveolens) is known for its medicinal properties: New 
alkaloids for ex., graveoline (7) was found to be cytotoxic towards the HeLa cancer 
cell line (ED50 3.35 µg ml-1), and its isomer graveolinine (8) was an effective inhibitor 
of platelet aggregation induced by arachidonic acid and collagen at low concentration 
(5 µg ml-1).15 
It is well known that simple quinoline alkaloids from Galipea and related 
rutaceous genera show substantial trypanocidal, antileishmanial and antimalarial 
activity. Some of these findings have now been reviewed by Fournet and Munoz.16  
The unique structural feature in helietidine (9), a new alkaloid was isolated 
from the Brazilian medicinal plant Helietta longifoliata17, the pyrano[3,2-g]quinoline 
ring system, hitherto unprecedented among the hemiterpenoid quinoline alkaloids; 
indeed, even 6-prenylquinolines, likely precursors for this tricyclic ring system, were 
unknown as natural products. The structure was presented as a quinolin-2-ol, but the 
quinolin-2-one tautomer is undoubtedly more plausible. 
 
N
O
Me
7, Graveoline
Figure 2
O
O
N
O
OMe
O
O
8, Graveolinine
N OH
MeMe
O
Me
Me
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A cytotoxic fraction from the stem bark extract of Stauranthus perforatus, was 
analyzed by the comparatively rare technique of HPLC–NMR, HPLC–MS 
measurements, showed the new compounds to be analogues of veprisine (10) (7,8-
dimethoxy-N-methyl.indersine), which had been found in this species previously and 
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was again detected in this study. One of the new alkaloids was (11), 7,8-
methylenedioxy equivalent of veprisine, which is known as stauranthine. The 
remaining alkaloids were oxidized analogues of both veprisine and stauranthine, and 
included the trans-3, 4-dihydroxy-3,4-dihydro derivatives (12) and (13), the 3,6-
dihydroxy-3,6-dihydro derivatives (14) and (15), and the 6-hydroxy-3-keto analogues 
(16) and (17). The 3,4-dihydroxypyran component in (12) and (13) has previously 
been found in other rutaceous quinoline and acridone alkaloids, but the involvement 
of the hemiterpenoid moiety in the remaining alkaloids in hemiketal formation with a 
quinolin-4-one is unprecedented. Trans-3,4-dihydroxy-3,4-dihydroveprisine (13) is 
identical to the alkaloid araliopsinine, reported from Araliopsis tabouensis by Ngadjui 
et al. in 1988.18 Interestingly, the alkaloids of the stauranthine series were all more 
stable than those of the veprisine series, perhaps reflecting the greater tendency 
towards oxidation of the vicinal dimethoxy grouping as compared with the 
methylenedioxy substituent. A pyrano[3,2-c]quinolone alkaloid ravesoline (18) was 
isolated from the leaves of Ravenia spectabilis.19 
 
 
Pyranoquinoline alkaloids simulenoline (19, R=OH) 20, 21 and huajiaosimuline 
(20)22 were isolated from root barks of Zanthoxylum simulans, a shrub found in 
Taiwan and mainland China. While simulenoline (19, R=OH) was the most recently 
isolated of the two alkaloids, a third pyranoquinoline alkaloid zanthodioline (21) from 
the same species was recently disclosed in the literature.20 These novel monoterpenoid 
pyranoquinolines are potent inhibitors of platelet aggregation. For example, at a 
concentration of 100 µg/mL, simulenoline (19, R=OH) demonstrates a nearly 
complete suppression of platelet aggregation induced in vitro by collagen, arachidonic 
acid, and PAF in general.20 While simulenoline (19, R=OH) and zanthodioline (21) 
are not cytotoxic, huajiaosimuline (20) is toxic toward several human cultured cell 
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lines, especially the estrogen receptor-positive breast cancer cells, ZR-75-127. 
Structurally, these alkaloids contain three fused six-membered rings with a unique 
terpenoid side chain at C-2. The BC-ring is essentially the quinolone nucleus, and the 
A-ring is a 2H-pyran.  
 
 
 
4.2 Pharmacological Profile 
4.2.1 Antibiotic activity profile of Quinolone derivatives 
The whole quinolone anti-infective agents are synthetic origin and not 
modeled knowingly after any natural antibiotic. Several ring systems are or have been 
involved (Figure 5). Those of greatest prominences and their numbering systems are 
illustrated in figure below.23 
 
 
 
The first antimicrobial quinolone was discovered called nalidixic acid 
demonstrated Gram negative antibacterial activity, remains in the market today, so-
called first generation quinolones. Despite its convenient oral activity, bactericidal 
action, and ease of synthesis, its limited antimicrobial spectrum (primarily activity 
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against Escherichia coli) and poor pharmacokinetic characteristics limit. It is used 
primarily in treatment of sensitive community acquired urinary tract infections. 
  
Norfloxacin, the first of the second-generation family of quinolones.24 This 
agent had dramatically enhanced and broader spectrum anti Gram-negative activity 
and possessed significant anti Gram-positive activity as well. The potency of 
norfloxacin was in the same range as that of many fermentationderived antibiotics, its 
comparative structural simplicity and synthetic accessibility lead to a very significant 
effort to find even more improved analogues. Norfloxacin and its N-methyl analogue 
pefloxacin ultimately failed to find major use outside of the genitourinary tract 
because of poor active blood levels and limited potency against Gram-positives. 
 
Shortly thereafter, ciprofloxacin25-27 and ofloxacin, 27, 28 as well as its optically 
active form levofloxacin29, were introduced. The second-generation agents have 
significant broad-spectrum antimicrobial activity including important Gram-positive 
pathogens. This is coupled with gratifying safety and pharmacokinetic characteristics. 
 
A wide variety of clinical indications have been approved for quinolones 
including many infections commonly encountered in community practice including 
upper and lower respiratory, gastrointestinal and gynecologic infections, sexually 
transmitted diseases, prostatitis, and some skin, bone, and soft tissue infections.30 
 
Recently the fluoroquinolone family members were introduced belong to the 
third generation. It includes gatifloxacin31 and moxifloxacin32 which possessed further 
enhanced activity against Gram-positive infections, and anti-anaerobic coverage. 
Although at present only trovafloxacin33 is approved for this indication. Among the 
agents, in preclinical study, still clinifloxacin34 is the most promising anti-anaerobic 
agent. When first introduced, there was no idea of the molecular mode of action of 
these agents. 
 
In a later study of 15 quinolones, they were divided into three groups on the 
basis of their relative ability to inhibit S. aureus strains with a resistance mutant 
toward one or the other enzyme. With group 1 (norfloxacin, enoxacin, fleroxacin, 
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ciprofloxacin, lomefloxacin, trovafloxacin, grepafloxacin, ofloxacin, and 
levofloxacin) topoisomerase IV were the more sensitive target. With group 2 
(sparfloxacin and nadifloxacin) DNA gyrase was the more sensitive target. With 
group 3 (gatifloxacin, pazufloxacin, moxifloxacin, and clinafloxcin) were 
equivalently sensitive. The later were termed the dual targeting quinolones.35 
 
 
4.2.2 Anticancer activity 
 
Ih-Sheng Chen, et al.22b have isolated pyranoquinolone alkaloids 
zanthosimuline (44) and huajiaosimuline (45) from the root bark of Zanboxylum 
simulans, exhibited cytotoxic activity. In addition, compound (45) showed significant 
antiplatelet aggregation activity and induced terminal differentiation with cultured 
HL-60 cells. 
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Compound (44) demonstrated a general cytotoxic response when evaluated 
with a variety of cultured human cancer cell lines and cultured P-388 cells.36 
Multidrug-resistant KB-VI cells demonstrated a sensitivity that was approximately 
equivalent to the observed with cultured KB cells. In the presence of vinblastine, 
activity was enhanced about 3-fold with KB-VI cells, suggesting reversal of the drug 
resistance of the phenotype.37 Conversely, oxidation of the side-chain produced a 
more selective profile of cytotoxic activity, as exhibited by compound (45). From 
particular note, the human tumor cell lines were tested, greatest activity was observed 
with the estrogen receptor-positive breast cancer cells, ZR-75-1, and even more 
pronounced reversal of resistance to vinblastine was demonstrated with KB-VI cells. 
In addition, prompted by the structural similarity of the compound (44) and (45) side-
chains and vitamin D metabolites, studies were performed with cultured HL-60 cells. 
 
 
 
Olivia Jansen, et al.38a during their systematic chemotaxonomic study of 
Uzbek Haplophyllum A. Juss. plants selected on ethnopharmacological data, have 
screened 14 alkaloids for their cytotoxic properties. In first selection for interesting 
compounds, each alkaloid was tested against two human cancer cell lines (HeLa and 
HCT-116), using WST-1 reagent. 
 
Of the 14 alkaloids, 5 were cytotoxic when tested against the HeLa line with 
an IC50 <100 µM. These five compounds consisted of three furoquinolines: 
skimmianine (46), γ-fagarine (47), and haplopine (48) and two pyranoquinolones: 
flindersine (49a) and haplamine (49b). Only haplamine was active against the HCT-
116 line. 
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The cytotoxic properties of these five alkaloids were further investigated 
against five additional human cancer cell lines. Of these five pre-selected alkaloids, 
only haplamine showed significant cytotoxic activity against all the tested cell lines. 
Finally, this pyranoquinolone alkaloid was tested against 14 different cancer cell lines 
and against normal skin fibroblasts. 
 
 
 
Meark Serono has worked extensively on KSP inhibitor, tetrahydroquinoline 
core derivatives which led into clinical trials.38b The most extensive of this is based on 
the hexahydropyranoquinoline (50a, HHPQ) scaffold, including compound (50b).38c 
Following a high-throughput screen, derivatives from this series were identified as 
potent, selective inhibitors of KSP and inhibition of cellular proliferation in a variety 
of tumor cell lines (Colo205, HCT116 and SW707).38d 
 
 
 
4.2.3 Anti-HIV activity 
 
Antiviral nucleoside agents such as AZT, ddC, ddl, d4 T and 3TC being 
Reverse Transcriptase (R.T.) inhibitors are approved for clinical use. Although these 
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nucleoside based drugs can extend the life of the patient, they are associated with 
several side effects and not capable of curing the disease. The urge for the promising 
RT inhibitors to cure AIDS, resulted in the identification of a group of coumarin 
derivatives isolated from genus Calophyllum as HIV-1 specific non-nucleoside 
inhibitors, among which Calanolide A represented by (51, X=O) is the most potent 
and is currently undergoing clinical trials (phase III).39 
 
Calanolides, a ‘dipyrano-coumarin‘ class of compounds are active not only 
against the AZT-resistant strain of HIV-1, but also against virus strains resistant to 
some other non-nucleoside inhibitors such as TIBO pyridinone, and nevirapine. 
Calanolides are in the advance stage of biological evaluation as anti-HIV agents in 
clinical trials (phase III). The main drawbacks of this class of compounds are (a) poor 
solubility of this class of compounds in the physiological medium and (b) lesser 
stability of the coumarin ring system in biological environment. It, thus, would be 
desirable to prepare the New Chemical Entities (NCEs) having calanolide skeleton 
but with better therapeutic index. In addition, the NCEs are desirable to overcome the 
problems associated with calanolides such as stability and solubility in the 
physiological medium. 
 
Quinolinones are shown to be part structures of several bio-active compounds 
with profound bio-efficacy. Unlike the lactone bond in coumarins, the lactam bond in 
quinolinones is highly stable. 
M. K. Gurjar, et al.40 have patented a novel ‘dipyrano-quinolinone‘ class of 
compounds related to calanolide structural frame work as NCEs and envisaged to 
circumvent the problems associated with calanolides and has improved therapeutic 
indices. 
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The invention deals with the synthesis of novel and new ‘dipyrano-
quinolinone‘class of compounds, where the major differences in the structural 
arrangement are the replacement of coumarin ring oxygen (at position 1) of calanolide 
structure with nitrogen (at position 1). New ‘quinolinone‘ ring system was represented 
by (52). These quinolinone analogues of calanolides are NCEs and envisaged as 
potential candidate molecules as anti-HIV agents. The rationale for the synthesis of 
these ‘dipyrano-quinolinones‘ reported in this specification are as follows: (1) 
Replacement of oxygen (at position 1) of natural products, calanolides, with nitrogen 
leads to dipyranoquinolinones as anti-HIV agents with better therapeutic index. (2) 
The inherent problems associated with naturally occurring calanolides such as 
metabolic stability and solubility in physiological medium can be circumvented with 
the new dipyrano-quinolinone derivatives that are reported in this patent. (3) The 
derivatisation of water-soluble derivatives of these new chemical entities represented 
in this patent are easily possible. (4) The metabolic stability is expected to enhance 
due to the presence of nitrogen atom in the skeleton of dipyrano-quinolinones 
derivative presented in this patent. (5) The structure activity relationship coupled with 
positive activity against calanolide resistant strain of HIV virus can be explored due to 
the presence of nitrogen atom in the dipyrano-quinolinone system. 
 
The dipyrano-quinolone of the present invention screened for anti-HIV 
activity (reverse transcriptase inhibition), have shown potential therapeutic values as 
“Candidate Molecules”. The above compound (51, X=NH) was reported in this 
invention shown equal potency of activity against HIV infected cell lines that 
observed for calanolide in the in vitro preliminary screening studies. The IC50, EC50 
and TI values of both calanolides and the ‘new dipyrano-quinolinone chemical 
entities (51, X =NH) were described in the present invention have equal and more 
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protecting capacity against the HIV infection. The NCE has prepared in this 
invention, shown a mean therapeutic index value of 12 and indicative of superior 
activity for the new compound compared to the natural one. 
 
4.2.4 Calcium Channel Blockers 
 
Karnail Atwal41 have reported novel pyranyl quinolines (53) having calcium 
channel blocking activity. It was suggested that compounds (53) and their 
pharmaceutically acceptable salts were cardiovascular agents. They act as calcium 
entry blocking vasodilators and are useful as antihypertensive agents. Thus, by the 
administration of a composition containing one (or a combination) of the compounds 
of this invention, the blood pressure of a hypertensive mammalian (e.g., human) host 
is reduced. A single dose, or two to four divided daily doses, provided on a basis of 
about 0.1 to 100 milligrams per kilogram of body weight per day, preferably from 
about 1 to about 50 milligrams per kilogram per day, is appropriate to reduce blood 
pressure. 
 
Figure 11
N O
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R = H, heloalkyl, alkyl C (1-10), alkenyl C (1-10), aryl,
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As a result of the calcium entry blocking activity of the compounds (53), and 
the pharmaceutically acceptable salts thereof, these compounds, in addition to being 
antihypertensive agents, are especially useful as antiischemic agents, and also useful 
as anti-arrhythmic agents, anti-anginal agents, anti-fibrillatory agents, anti-asthmatic 
agents, as an agent to increase the ratio of HDL-cholesterol to total serum cholesterol 
in the blood and in limiting myocardial infarction. 
 
4.2.5 Antiallergic activity 
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 Repirinast (54, MY-5116; isoarnyl 5,6-dihydro-7,8-dimethyl-4,5-dioxo-4H-
pyrano[3,2-c]quinoline-2-carboxylate) is an anti-allergic effective drug for treatment 
of bronchial asthma in humans. N.Yamada, et al.42 have demonstrated that (55, MY-
1250; 5,6-dihydro-7,8-dimethyl-4,5-dioxo-4H-pyrano[3,2-c]quinoline-2-carboxylic 
acid), a major metabolite of repirinast, inhibits antigen induced histamine release from 
rat peritoneal mast cells. MY-1250 causes a rapid increase in cyclic adenosine 
monophosphate (cAMP) levels in rat peritoneal mast cells MY-1250 inhibited cyclic 
AMP phosphodiesterase activities from rat peritoneal cells and guinea pig lung tissue 
in a concentrat dependent manner with IC50 value of 2 µg/ml and 1.67 µg/ml 
respectively. However MY-1250 showed no effect on adenylate cyclase activity from 
rat peritoneal cells. These results suggested that the inhibitory effect of MY-1250 on 
histamine release might be partly due to the inhibition of cyclic AMP 
phosphodiesterase activity. 
 
 
4.2.6 Antimicrobial activity 
 
 Trkovnik et al.43 have reported ethyl-2,6-dioxo-6,9-dihydro-substituted-
2Hpyrano[3,2-g]quinoline-7-carboxylates (56) and their antimicrobial activity against 
S.aureus, P.aenrgiizosa, Streptococcus pyogens, Streptococcus faecalis, Staphiloc 
epiderms etc. El-Taweel et al.44 have evaluated polysubstituted pyrano[3,2-
c]quinolones (57) for their bactericidal activity against various gram positive and 
gram negative bacterial species. 
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Figure 13
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4.3 Synthetic Approaches 
 
Majumdar K. C. et al.45 have synthesized pyrano[3,2-f]quinolin-2(7H)-ones by 
a thermal [3, 3]-sigmatropic rearrangement with 60-65% yield by heating the 
propargyl ethers in N,N-dimethylaniline.(Scheme-1) 
 
 
Wang X. et al.46 have described one-step synthesis of 2-amino-4-aryl-1,4,5,6- 
tetrahydropyrano[3,2-c]quinolin-5-one derivatives from arylaldehyde, malononitrile 
and 4-hydroxyquinolin-2-one with KF-Al2O3 treatment as a catalyst in refluxing ethyl 
alcohol. Prior to this investigation, the synthesis of pyrano[3,2-h]quinoline derivatives 
was reported47 from arylmethylidene malononitriles and 8-hydroxyquinoline using 
KF-Al2O3 catalyst which was a versatile solid support reagent for many reactions such 
as Knoevenaegel condensation.48 (Scheme-2) 
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Dandia A. et al.49 have prepared fluorine-containing substituted spiro 
derivatives of pyrano[3,2-c]quinoline by microwave irradiation and conventional 
methods with 80-85 % yield. (Scheme 3)  
 
 
 
The condensation of α-ketoesters with phenolic compounds in the presence of 
sulfuric acid yields coumarin derivatives.50 This synthesis is known as Pechmann 
condensation51 and has extensive application to prepare many naturally occuring 
coumarins. Acidic catalysts such as aluminium trichloride, zinc chloride, phosphoryl 
oxychloride, phosphoric acid, polyphosphoric acid, trifluoro acetic acid and 
hydrochloric acid were used. C. Mayer52 and T. Kappe53 have found that ammonium 
acetate can be used as a source of ammonia and that readily reacted with phenolic 
heterocyclic compounds to yield corresponding α-pyrone derivatives. 
α-acetyl-butyrolactone, an interesting cyclic α-ketoesters can be used for the 
synthesis of heterocyles containing a hydroxyethyl side chain.54 R. Toche, et al55 have 
reported the pechmann reaction of 4-hydroxy-2(1H)-quinolones with α-acetyl-
butyrolactone. Moreover this reaction was extended to α-formyl-butyrolactone (used 
as its sodium salt). (Scheme-4) 
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Thus, the condensation of 4-hydroxy-2-quinolones with α-acetyl-
butyrolactone in the presence of ammonium acetate at 120oC gave pyrano[3,2-
c]quinoline-2,5-diones with 70-75% yield, while sodium salt of α-formyl-
butyrolactone 56 (obtained by formylation of butyrolactone) reacted smoothly with 4-
hydroxy-2-quinolones in presence of ammonium acetate to yield 3-hydroxyethyl-2-
pyranone derivatives. 
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2-Quinolones were synthesized by several methods like (i) thermal cyclization 
of aniline with diethyl malonate at 180-200oC57, (ii) condensation of aniline with 
diethylmalonate in the presence of phosphorous oxychloride58, or (iii) condensation of 
anilines with bis-2,4-dichlorophenyl or bis-2,4,6-trichlorophenyl malonate.59 A. 
Knierzinger and O. Wolfbeis60 suggested that the conversion of 2-quinolones into 
their 3-anilino methylene derivatives was effected by heating with an equimolar 
amount of and a 1.5 molar excess of triethoxy methane in glacial acetic acid or DMF. 
2-Aminomethylene-1,3-diketones are synthetic equivalents to the less readily 
available and less stable 2-formaldehyde of 1,3-diketones. Thus when the enamine 
was reacted with equimolar amounts of a nitrile in the presence of strong base in 
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DMF, aniline was replaced by nitrile anion and subsequent acidification affords the 
corresponding pyrones. (Scheme-5) 
 
 
S. Yamaguchi et al.61 have synthesized eight number of 2- and 3-halo-11,12-
dihydro-5H-[1]-benzopyrano[4,3-c]quinolin-5,11-dione by demethyl cyclization of 
corresponding halo-3-(2-methoxyphenyl)-2-oxo-1,2-dihydroquinoline-4-carboxylic 
acids, which were synthesized by Pfitzinger condensation of 5- or 6-halo isatins with 
(2-methoxyphenyl)acetic acid. (Scheme-6) 
 
 
Morinaka and Takahashi have patented62 ester derivatives of pyrano[3,2-
c]quinolin-2-carboxylic acid, synthesized by following route. (Scheme-7) 
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A couple of 2,3,4,6-tetrahydro-2-hydroxy-2-methylpyrano[3,2-c]quinolin-5-
ones were prepared by the reaction of 4-hydroxyquinolin-2(1H)-ones with 1-
(dimethylamino)butan-3-one in the presence of potassium hydroxide and methyl 
iodide.63 Some 6-alkyl-3,4-dihydropyrano[3,2-c]quinolin-5-ones were prepared by the 
reaction of 4-hydroxyquinolin-2(1H)-ones 4 with acetylenic halides and the 
subsequent intramolecular cyclization of the acetylenic ethers.64 (Scheme-8) 
 
 
Jai-Hai Ye et al.65 have reported convenient one pot synthesis of 2,3,4,6-
tetrahydro-2-hydroxypyrano[3,2-c]quinolin-5-one derivatives from 4-
hydroxyquinolin-2(1H)-ones by tandem Knoevenagel condensation. In 1st step 4-
hydroxyquinolin-2(1H)-ones reacted with aliphatic aldehyde–Michael-type 1,4-
addition of the enamine (derived from the aldehyde and diethylamine in situ) with the 
quinone methide (quinomethane). This reaction sequence was achieved in one pot by 
direct thermal reaction of with an aldehyde in the presence of diethylamine as a base 
in refluxing benzene, which afforded the corresponding 2,3,4,6-tetrahydropyrano-
[3,2-c]quinolin-5-one as a main product together with the 3,3’-alkane-1,1-diylbis(4-
hydroxyquinolin-2(1H)-one) as a minor product.(Scheme-9) 
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H. Abd el-Nabi66 suggested that 4-hydroxy-2-quinolone reacted with 
cinnamonitrile derivatives in presence of catalytic amounts of triethylamine to afford 
pyrano[3,2-c]quinolines. The reaction of pyrano[3,2-c]quinolines with reagents such 
as acetic anhydride/pyridine, formamide and formic acid/formamide gave the fused 
heterotetracyclic system of the type of pyrimido[4’,5’:6,5]pyrano[3,2-c]quinoline. 
(Scheme-10) 
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N. Venkatesh Kumar and S. Rajendran67 have described that 4-hydroxy-2-
quinolone being endowed with both nucleophilic and electrophilic properties furnish 
the dimeric quinoline in a base catalyzed self-condensation process. A one step 
synthesis, starting from 4-hydroxy-2-quinolone with ethylacetoacetate and pyridine 
proceeded through the Michael addition, which was followed by cyclization, gave an 
angular isomer 4-methylpyrano[3,2-c]quinolin-2,5[6H]-dione. (Scheme-11) 
 
Scheme 11
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V. Mulwad and M. Lohar68 have synthesized novel spiro-[3H-indole-3,7’-(9’-
amino-8’-cyano-[7’H]-pyrano-[3,2-c]-quinolin)]-2,6’-[1H]-diones by the reaction of 
N-methyl-4-hydroxy-2-quinolone with isatine and malononitrile. (Scheme-12) 
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Igor V. Magedov et al.69 have recently reported a three component reaction of 
pyridone with malononitrile and various aromatic aldehydes in a 1:1:1 ratio proceeds 
smoothly in refluxing ethanol containing a small quantity of triethyl amine. (Scheme 
13) Pyranopyridones were precipitated directly from the refluxing reaction mixtures 
and required no further purification. The pyrano[3,2-c]quinolones analogues were 
found low nanomolar (down to 3 nM) antiproliferative properties in HeLa and MCF-7 
human cancer cell lines. 
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4.4 Work Done at Our Laboratory 
  The reaction of phenols with malonic acid in the presence of an admixture of 
condensing agents zinc chloride and phosphorous oxychloride gave yields of 4-
hydroxy coumarins.70 Moreover the specific condensing action of this admixture have 
also been observed.71 
From the beginning of our ongoing research on studies of 2,4-
dihydroxyquinoline derivatives and their analogues, Dodia72 extended this reaction 
with primary aromatic amines and found that with malonic acid and admixture of the 
condensing agents zinc chloride and phosphorous oxychloride at a suitable 
temperature 60 oC to 100 oC to give fairly good yields of 2,4-dihydroxyquinolines. 
By using 2,4-dihydroxyquinolines as a central intermediate, a good number of 
substituted fused and dimeric analogues have been prepared, which includes 3-
substituted-2,4-dihydroxyquinolines, pyrano[3,2-c]quinolines, pyrimido[5’,4’:5,6] 
pyrano[3,2-c]quinolines and dimeric 2,4-dihydroxy quinoline derivatives were 
screened them for various biological activity. A number of pyrano[3,2-c]quinolones 
analogues had shown potent activity as anti-HIV, antitubercular, antimicrobial and 
antimalarial activity.  
Acharya73, Mishra74, Manvar75 and  Upadhyay76 have extended the analogue 
making with the condensation of N-methylaniline, N-ethylaniline and N-
benzylanilines with diethylmalonates in 1:2 mole proportion to afford pyrano[3,2-
c]quinolones which further reacted with cinnamonitrile derivatives to yield 
pyrano[2’,3’:4,5]pyrano[3,2-c]quinolone derivatives. (Figure 14) 
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4.5 Research Aim 
The quinoline derivatives exhibited wide variety of biological activities and 
evaluated its potential in pharmaceutical areas, such as central nervous system,77 
haematology,78 virology,79 chemotherapy such as stomach cancer, brain tumor, and 
large intestine cancer,80,81 transmissible spongiform encephalopathies,82 and 
proliferative diseases.83 It is well-known that 4H-pyran derivatives have different 
pharmacological activities, e.g., antifungal activity,84 anti-inflammatory activity,85 and 
antimicrobial activity.86 Moreover, it is demonstrated that pyrano[3,2-c]quinoline 
derivatives, which contain both a quinoline ring and pyran moieties, and their 
synthetic analogues are currently research interest because they have a wide range of 
biological activities and have potential of medical and other applications.87,88 
In continuation of our earlier work and results obtained of pharmacological 
properties of quinolines and pyrans we designed several new compounds featuring 
substituted pyran rings fused onto the quinoline moiety with the aim of obtaining 
more potent and active compounds. 
The current work encompasses with dihydropyrido fused system of quinoline 
ring to study the changes in the biological activity. The current work presents direct, 
efficient and operationally convenient approach to the synthesis of some novel 
dihydropyrido fused Pyranoquinolone derivatives. The Knoevanagel condensation 
and Micheal addition reaction between 1-hydroxy-6,7-dihydropyrido[3,2,1-
ij]quinolin-3(5H)-one and ethylcyano-acetate derivatives of aromatic and 
heteroaromatic aldehydes were studied. (Figure 15) 
 
N
O
O NH2
COOC2H5
HN
O
N
O
O NH2
COOC2H5
R
Figure 15 4H ,5H ,6H ,9H-Pyrido[ij]Pyrano[3,2-c]Quinolone derivatives  
 
The chemical synthesis and characterization of 4H,5H,6H,9H-
Pyrido[ij]Pyrano[3,2-c]Quinolone derivatives are described in Chapter 5. 
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5.0 Chemistry 
 
The synthetic route for Ethyl-11-amino-7,8-dihydro-8-oxo-9-(substituted)-
4H,5H,6H,9H-pyrido[ij]pyrano[3,2-c]quinoline-3-carboxylate derivatives are shown 
in Scheme 2. The known 1-hydroxy-6,7-dihydropyrido[3,2,1-ij]quinolin-3(5H)-one 
(67) was synthesized by commercially available 1,2,3,4-tetrahydroquinoline (65) with 
diethyl malonate (66) in diphenyl ether by following the procedure.89 Compound 67 
was treated with various aromatic aldehyded and/or heteroaromatic aldehyded (69a–t, 
RCHO) and ethylcyanoacetate (68) in the presence of weak base (piperidine) to give 
ethyl-11-amino-7,8-dihydro-8-oxo-9-(substituted)-4H,5H,6H,9H-pyrido[ij]pyrano-
[3,2-c]quinoline-3-carboxylate (71a–t). The spiro derivative 74 was prepared with 
good yields from 67 by reacting with isatine (72) and ethylcyanoacetate (68) (Scheme 
3). Table 5.1 show the yields and the physical data of these compounds. 
 
5.1 Reaction Scheme 
5.1.1 Scheme 1 Synthetic routes for 1-hydroxy-6,7-dihydropyrido[3,2,1-
ij]quinolin-3(5H)-one (67). 
 
N
O
OH
NH EtO
EtO
O
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5.1.2 Scheme 2 Synthetic routes for Ethyl-11-amino-7,8-dihydro-8-oxo-9-
(substituted)-4H,5H,6H,9H-pyrido[ij]pyrano[3,2-c]quinoline-3-carboxylate 
derivatives (71a–t). 
 
N
O
OH
CHO
R
CN
COOC2H5
N
O
O NH2
COOC2H5
R
Piperidine
67
68 69a-t
71a-tRT, 45 min
R
COOC2H5
CN
Piperidine
Methanol
80 oC, 2-4 hr
a: R = C6H5,
b: R = 2'-MeO-C6H4,
c: R = 3'-MeO-C6H4,
d: R = 4'-MeO-C6H4,
e: R = 3',4'-Di-MeO-C6H3,
f: R = 2',3',4'-Tri-MeO-C6H2,
g: R = 3',4',5'-Tri-MeO-C6H2,
h: R = 2'-F-C6H4,
i: R = 4'-F-C6H4,
j: R = 2'-Cl-C6H4,
k: R = 4'-Cl-C6H4,
l: R = 2'-Br-C6H4,
m: R = 4'-Br-C6H4,
n: R = 2'-Me-C6H4,
o: R = 3'-Me-C6H4,
p: R = 4'-Me-C6H4,
q: R = 2'-OH-5'-Cl-C6H3,
r: R = 4'-OH-3'-MeO-C6H3,
s: R = 2'-Furanyl,
t: R = 2'-Thiapheneyl
70a-t
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5.1.3 Scheme 3 Synthetic routes for Ethyl-11-amino-7,8-dihydro-8-oxo-9-
{spiro-[3-H-isatine]}-4H,5H,6H,9H-pyrido[ij]pyrano[3,2-c]quinoline-3-carboxylate 
74. 
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Table 5.1 Yields and physical data of the compounds 71a–t and 74. 
N
O
O NH2
COOC2H5
HN
O
74
N
O
O NH2
COOC2H5
R
71a-t  
Compd. Substitute R 
Yield 
% 
MP °C Analysis 
71a C6H5 82 270–271 CHN 
71b 2’-MeO-C6H4 69 248–249 CHN 
71c 3’-MeO-C6H4 68 197–198 CHN 
71d 4’-MeO-C6H4 78 245–246 CHN 
71e 3’,4’- di-MeO-C6H3 65 230–231 CHN 
71f 2’,3’,4’-tri-MeO-C6H2 66 215–216 CHN 
71g 3’,4’,5’-tri-MeO-C6H2 71 229–230 CHN 
71h 2’-F-C6H4 78 228–229 CHN 
71i 4’-F-C6H4 77 222–223 CHN 
71j 2’-Cl-C6H4 75 226–227 CHN 
71k 4’-Cl-C6H4 82 234–235 CHN 
71l 2’-Br-C6H4 74 248–249 CHN 
71m 4’-Br-C6H4 83 241–242 CHN 
71n 2’-Me-C6H4 74 229–230 CHN 
71o 3’-Me-C6H4 71 208–209 CHN 
71p 4’-Me-C6H4 77 222–223 CHN 
71q 2’-OH-5’-Cl-C6H3 65 213–214 CHN 
71r 4’-OH-3’-OMe-C6H3 74 224–225 CHN 
71s 2’-Furanyl 62 190–191 CHN 
71t 2’-Thiapheneyl 64 189–190 CHN 
74 Isatine 61 >290 (d.) CHN 
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5.2 Experimental  
5.2.1 General methods and materials 
 
All commercial chemicals and solvents were reagent grade and used without 
further purification unless otherwise specified. Melting points were determined on a 
Fargo melting point apparatus and are uncorrected. Thin-layer chromatography was 
performed on silica gel G60 F254 (Merck) with short-wavelength UV light for 
visualization. All reported yields are isolated yields after chromatography or 
crystallization. Elemental analyses were done on a Heraeus CHN-O Rapid instrument. 
1H NMR spectra were recorded on a 600 MHz, Brucker AVANCE 600 DRX and 400 
MHz, Brucker Top-Spin spectrometers in the indicated solvent. The chemical shifts 
were reported in ppm () relative to TMS and coupling constants (J) in Hertz (Hz) 
and s, d, t, m, brs, refer to singlet, doublet, triplet, multiplet, broad respectively.  
 
All the synthesized compounds were characterized by using 1H NMR, 13C 
NMR and Elemental analysis. For compounds 71a–t, the characteristic proton signals 
for pyran-H4 (CH) appeared at the range of 4.81–4.88 δ ppm, and for ethyl ester 
(OC2H5) appeared at the range of 1.11–1.14 and 3.96–4.02 δ ppm. The characteristic 
proton for NH2 appeared at the range of 7.70–7.79 δ ppm as singlet and D2O 
exchangeable single. The elemental analysis of the newly synthesized derivatives was 
within ±0.4% range of the calculated C, H, N data. 
 
Synthesis of 1-hydroxy-6,7-dihydropyrido[3,2,1-ij]quinolin-3(5H)-one (67). 
Diethyl malonate (66, 64 g, 400 mmol) was added into a mixture of 1,2,3,4-
tetrahydroquinoline (65, 26.6 g, 200 mmol) in diphenyl ether (200 mL). The reaction 
mixture was heated at 160 °C equipped with a distillation apparatus. At about 160 oC 
liberation of ethanol took place and the temperature was increased slowly to 220 oC, 
where it was kept until no more ethanol was formed. Then the reaction mixture was 
allowed to cool at room temperature. The precipitates were filtered and washed with 
hexane to give 67, 24.9 g (57%); mp >280 °C (lit.89 mp 282–284 °C). 
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Ethyl-11-amino-7,8-dihydro-8-oxo-9-phenyl-4H,5H,6H,9H-pyrido[ij]pyrano[3,2-
c]quinoline-3-carboxylate (71a). A solution of ethylcyanoacetate (68, 1.2 g, 10.1 
mmol), benzaldehyde (5a, 1.2 g, 10.1 mmol) and catalytic amounts of piperidine (1-2 
drops) in methanol 10 mL was stirred at room temperature. After 45 min, 1-hydroxy-
6,7-dihydropyrido[3,2,1-ij]quinolin-3(5H)-one (67, 2 g, 10 mmol) was added and the 
reaction mixture was further stirred and reflux for 3 h. After completion of the 
reaction (monitored by TLC, ethyl acetate:hexane (1:1)), the reaction mixture was 
concentrated under reduced pressure, and 1 mL of water was added. The separated 
solid product was collected by filtration and recrystallized from Ethanol to give 71a, 
3.3 g (82 %); mp 270–271 °C; 1H NMR (DMSO-d6)  1.12 (3H, t, J = 7.2 Hz, Me), 
1.95 (2H, m, CH2), 2.91 (2H, m, Ar-CH2), 3.99 (4H, m, OCH2 & NCH2), 4.87 (1H, s, 
pyran H4), 7.07–7.10 (1H, m, ArH), 7.17–7.28 (5H, m, 5 × ArH), 7.43 (1H, d, J = 7.2 
Hz, ArH), 7.74 (2H, s, exchangeable NH2), 7.91 (1H, d, J = 8 Hz, ArH). 13C NMR 
(DMSO-d6)  14.2, 20.0, 26.8, 35.0, 41.8, 58.8, 77.4, 111.6, 112.6, 120.0, 121.6, 
125.1, 125.9, 127.8, 127.9, 130.4, 135.2, 145.9 150.0, 159.4, 159.6, 167.8. Anal. 
Calcd. for (C24H22N2O4): C, 71.63; H, 5.51; N, 6.96. Found: C, 71.41; H, 5.56; N, 
6.72. 
 
By following the same synthetic procedure as that for 71a, the following compounds 
were synthesized: 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(2-methoxyphenyl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71b). Yield, 69 %; mp 248–249 °C. 1H 
NMR (DMSO-d6)  1.10 (3H, t, J = 6.8 Hz, Me), 1.95 (2H, m, CH2), 2.91 (2H, m, 
Ar–CH2), 3.58 (3H, s, OMe), 3.99 (4H, m, OCH2 & NCH2), 4.91 (1H, s, pyran H4), 
6.78–6.82 (2H, m, 2 × ArH), 7.06–7.10 (1H, m, ArH), 7.23–7.27 (2H, m, 2 × ArH), 
7.41 (1H, d, J = 7.2 Hz, ArH), 7.66 (2H, s, exchangeable NH2), 7.91 (1H, d, J = 7.6 
Hz, ArH). Anal. Calcd. for (C25H24N2O5): C, 69.43; H, 5.59; N, 6.48. Found: C, 
69.21; H, 5.62; N, 6.31. 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(3-methoxyphenyl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71c). Yield, 68 %; mp 197–198 °C. 1H NMR 
(DMSO-d6)  1.14 (3H, t, J = 6.8 Hz, Me), 1.96 (2H, m, CH2), 2.92 (2H, m, Ar–CH2), 
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3.67 (3H, s, OMe), 4.02 (4H, m, OCH2 & NCH2), 4.85 (1H, s, pyran H4), 6.67–6.78 
(3H, m, ArH), 7.10 (1H, t, J = 8 Hz, ArH), 7.25 (1H, t, J = 8 Hz, ArH), 7.43 (1H, d, J 
= 7.6 Hz, ArH), 7.73 (2H, s, NH2), 7.89 (1H, d, J = 7.6 Hz, ArH). Anal. Calcd. for 
(C25H24N2O5): C, 69.43; H, 5.59; N, 6.48. Found: C, 69.52; H, 5.22; N, 6.61. 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(4-methoxyphenyl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71d). Yield, 78 %; mp 245–246 °C. 1H 
NMR (DMSO-d6)  1.14 (3H, t, J = 6.8 Hz, Me), 1.96 (2H, m, CH2), 2.92 (2H, m, Ar-
CH2), 3.66 (3H, s, OMe), 4.02 (4H, m, OCH2 & NCH2), 4.81 (1H, s, pyran H4), 6.75 
(2H, d, J = 7.2 Hz, 2 × ArH), 7.12 (2H, d, J=7.2 Hz, 2 × ArH), 7.24–7.28 (1H, m, 
ArH), 7.43 (1H, d, J = 7.2 Hz, ArH), 7.70 (2H, s, exchangeable NH2), 7.90 (1H, d, J = 
7.6 Hz, ArH). 13C NMR (DMSO-d6)  14.3, 20.1, 26.8, 34.1, 41.8, 54.9, 58.8, 77.7, 
111.9, 112.6, 113.1, 119.9, 121.5, 125.1, 128.8, 130.3, 135.1, 138.1, 149.8, 157.5, 
159.5, 159.6, 167.9. Anal. Calcd. for (C25H24N2O5): C, 69.43; H, 5.59; N, 6.48. 
Found: C, 69.11; H, 5.43; N, 6.57. 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(3,4-dimethoxyphenyl)-4H,5H,6H,9H-
pyrido[ij]pyrano[3,2-c]quinoline-3-carboxylate (71e). Yield, 65 %; mp 230–231 
°C. 1H NMR (DMSO-d6)  1.13 (3H, t, J = 7.2 Hz, Me), 1.94 (2H, m, CH2), 2.92 (2H, 
m, Ar-CH2), 3.58 (3H, s, OMe), 3.65 (3H, s, OMe), 3.98 (4H, m, OCH2 & NCH2), 
4.84 (1H, s, pyran H4), 6.59–6.63 (2H, m, ArH), 6.91–6.95 (1H, m, ArH), 7.25 (1H, t, 
J = 8 Hz, ArH), 7.43 (1H, d, J = 7.2 Hz, ArH), 7.67 (2H, s, exchangeable NH2), 7.90 
(1H, d, J = 8 Hz, ArH). Anal. Calcd. for (C26H26N2O6): C, 67.52; H, 5.67; N, 6.06. 
Found: C, 67.62; H, 5.61; N, 5.84. 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(2,3,4-trimethoxyphenyl)-4H,5H,6H,9H-
pyrido[ij]pyrano[3,2-c]quinoline-3-carboxylate (71f). Yield, 66 %; mp 215–216 
°C. 1H NMR (DMSO-d6)  1.13 (3H, t, J = 7.2 Hz, Me), 1.94 (2H, m, CH2), 2.92 (2H, 
m, Ar-CH2), 3.57 (3H, s, OMe), 3.64 (3H, s, OMe), 3.72 (3H, s, OMe), 3.98 (4H, m, 
OCH2 & NCH2), 4.84 (1H, s, pyran H4), 6.63 (1H, d, J = 7.6 Hz, ArH), 6.91–6.95 
(1H, m, ArH), 7.25 (1H, t, J = 8 Hz, ArH), 7.42 (1H, d, J = 7.2 Hz, ArH), 7.67 (2H, s, 
exchangeable NH2), 7.90 (1H, d, J = 8 Hz, ArH). Anal. Calcd. for (C27H28N2O7): C, 
65.84; H, 5.73; N, 5.69. Found: C, 65.62; H, 5.61; N, 5.84. 
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Ethyl-11-amino-7,8-dihydro-8-oxo-9-(3,4,5-trimethoxyphenyl)-4H,5H,6H,9H-
pyrido[ij]pyrano[3,2-c]quinoline-3-carboxylate (71g). Yield, 71 %; mp 229–230 
°C.  1H NMR (DMSO-d6)  1.17 (3H, t, J = 7.2 Hz, Me), 1.98 (2H, m, CH2), 2.93 
(2H, m, Ar-CH2), 3.59 (3H, s, OMe), 3.66 (6H, s, 2×OMe), 4.01 (4H, m, OCH2 & 
NCH2), 4.86 (1H, s, pyran H4), 6.49 (2H, s, ArH), 7.26 (1H, t, J = 8 Hz, ArH), 7.44 
(1H, d, J = 7.2 Hz, ArH), 7.74 (2H, s, exchangeable NH2), 7.90 (1H, d, J = 8 Hz, 
ArH). 13C NMR (DMSO-d6)  14.2, 19.9, 26.7, 35.0, 41.8, 55.6, 58.7, 59.7, 77.1, 
105.0, 111.4, 112.4, 119.9, 121.4, 125.0, 130.2, 135.1, 135.8, 150.1, 152.1, 159.6, 
167.7.  Anal. Calcd. for (C27H28N2O7): C, 65.84; H, 5.73; N, 5.69. Found: C, 65.54; 
H, 5.81; N, 5.58. 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(2-fluorophenyl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71h). Yield, 78 %; mp 228–229 °C. 1H 
NMR (DMSO-d6)  1.12 (3H, t, J = 6.8 Hz, Me), 1.95 (2H, m, CH2), 2.92 (2H, m, Ar-
CH2), 3.99 (4H, m, OCH2 & NCH2), 4.87 (1H, s, pyran H4), 6.78–6.82 (2H, m, ArH), 
7.08 (1H, t, J = 7.2 Hz, ArH), 7.23–7.27 (2H, m, ArH), 7.43 (1H, d, J = 7.2 Hz, ArH), 
7.68 (2H, s, exchangeable NH2), 7.90 (1H, d, J = 7.6 Hz, ArH). Anal. Calcd. for 
(C24H21N2O4F): C, 68.56; H, 5.03; N, 6.66. Found: C, 68.24; H, 4.88; N, 6.53.  
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(4-fluorophenyl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71i). Yield, 77 %; mp 222–223 °C. 1H NMR 
(DMSO-d6)  1.13 (3H, t, J = 6.8 Hz, Me), 1.95 (2H, m, CH2), 2.92 (2H, m, Ar-CH2), 
3.99 (4H, m, OCH2 & NCH2), 4.87 (1H, s, pyran H4), 6.80–6.84 (2H, m, ArH), 7.16–
7.20 (2H, m, ArH), 7.25–7.27 (1H, m, ArH), 7.43 (1H, d, J = 7.2 Hz, ArH), 7.68 (2H, 
s, exchangeable NH2), 7.90 (1H, d, J = 7.6 Hz, ArH). Anal. Calcd. for (C24H21N2O4F): 
C, 68.56; H, 5.03; N, 6.66. Found: C, 68.34; H, 4.76; N, 6.58.  
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(2-chlorophenyl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71j). Yield, 75 %; mp 226–227 °C. 1H NMR 
(DMSO-d6)  1.14 (3H, t, J = 6.8 Hz, Me), 1.94 (2H, m, CH2), 2.92 (2H, m, Ar-CH2), 
3.99 (4H, m, OCH2 & NCH2), 4.87 (1H, s, pyran H4), 6.82–6.86 (2H, m, ArH), 7.18 
(1H, t, J = 7.2 Hz, ArH), 7.20–7.24 (2H, m, ArH), 7.44 (1H, d, J = 7.2 Hz, ArH), 7.68 
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(2H, s, exchangeable NH2), 7.90 (1H, d, J = 7.6 Hz, ArH). Anal. Calcd. for 
(C24H21N2O4Cl): C, 65.98; H, 4.84; N, 6.41. Found: C, 65.86; H, 4.75; N, 6.28.  
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(4-chlorophenyl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71k). Yield, 82 %; mp 234–236 °C. 1H 
NMR (DMSO-d6)  1.14 (3H, t, J = 6.8 Hz, Me), 1.95 (2H, m, CH2), 2.93 (2H, m, Ar-
CH2), 4.01 (4H, m, OCH2 & NCH2), 4.83 (1H, s, pyran H4), 7.18 (2H, d, J = 8.4 Hz, 
ArH), 7.28 (1H, t, J = 7.6 Hz, ArH), 7.40 (2H, d, J = 8.4 Hz, ArH), 7.43 (1H, d, J = 
7.2 Hz, ArH), 7.80 (2H, s, exchangeable NH2), 7.91 (1H, d, J = 7.2 Hz, ArH). Anal. 
Calcd. for (C24H21N2O4Cl): C, 65.98; H, 4.84; N, 6.41. Found: C, 65.88; H, 4.71; N, 
6.25.  
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(2-bromophenyl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71l). Yield, 74 %; mp 248–249 °C. 1H NMR 
(DMSO-d6)  1.13 (3H, t, J = 6.8 Hz, Me), 1.96 (2H, m, CH2), 2.92 (2H, m, Ar-CH2), 
3.99 (4H, m, OCH2 & NCH2), 4.83 (1H, s, pyran H4), 6.84–6.88 (2H, m, ArH), 7.28 
(1H, t, J = 7.6 Hz, ArH), 7.35–7.39 (2H, m, ArH), 7.44 (1H, d, J = 7.2 Hz, ArH), 7.79 
(2H, s, exchangeable NH2), 7.91 (1H, d, J = 7.2 Hz, ArH). Anal. Calcd. for 
(C24H21N2O4Br): C, 59.89; H, 4.40; N, 5.82. Found: C, 59.74; H, 4.21; N, 5.89. 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(4-bromophenyl)-4H,5H,6H,9H-
pyrido[ij]pyrano[3,2-c]quinoline-3-carboxylate (71m). Yield, 82 %; mp 241–242 
°C. 1H NMR (DMSO-d6)  1.12 (3H, t, J = 6.8 Hz, Me), 1.96 (2H, m, CH2), 2.92 (2H, 
m, Ar-CH2), 3.99 (4H, m, OCH2 & NCH2), 4.83 (1H, s, pyran H4), 7.17 (2H, d, J = 
8.4 Hz, ArH), 7.27 (1H, t, J = 7.6 Hz, ArH), 7.39 (2H, d, J = 8.4 Hz, ArH), 7.44 (1H, 
d, J = 7.2 Hz, ArH), 7.79 (2H, s, exchangeable NH2), 7.91 (1H, d, J = 7.2 Hz, ArH). 
13C NMR (DMSO-d6)  14.2, 20.0, 26.8, 34.8, 41.8, 58.9, 76.8, 110.9, 112.5, 118.9, 
120.0, 121.6, 125.2, 130.2, 130.5, 130.6, 135.3, 145.4, 150.0, 159.5, 159.6, 167.7. 
Anal. Calcd. for (C24H21N2O4Br): C, 59.89; H, 4.40; N, 5.82. Found: C, 59.64; H, 
4.31; N, 5.99. 
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Ethyl-11-amino-7,8-dihydro-8-oxo-9-(2-methylphenyl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71n). Yield, 74 %; mp 229–230 °C. 1H 
NMR (DMSO-d6)  1.14 (3H, t, J = 6.8 Hz, Me), 1.95 (2H, m, CH2), 2.18 (3H, s, 
Me), 2.92 (2H, m, Ar-CH2), 3.99 (4H, m, OCH2 & NCH2), 4.87 (1H, s, pyran H4), 
7.16–7.19 (1H, m,  ArH), 7.23–7.27 (2H, m, ArH), 7.37–7.41 (2H, m, ArH), 7.40 
(1H, d, J = 7.2 Hz, ArH), 7.79 (2H, s, exchangeable NH2), 7.90 (1H, d, J = 7.6 Hz, 
ArH). Anal. Calcd. for (C25H24N2O4): C, 72.10; H, 5.81; N, 6.73. Found: C, 72.34; H, 
5.97; N, 6.67.  
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(3-methylphenyl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71o). Yield, 71 %; mp 208–209 °C. 1H NMR 
(DMSO-d6)  1.13 (3H, t, J = 6.8 Hz, Me), 1.95 (2H, m, CH2), 2.26 (3H, s, Me), 2.92 
(2H, m, Ar-CH2), 3.99 (4H, m, OCH2 & NCH2), 4.87 (1H, s, pyran H4), 7.15 (1H, s,  
ArH), 7.26–7.29 (2H, m, ArH), 7.35–7.39 (2H, m, ArH), 7.43 (1H, d, J = 7.2 Hz, 
ArH), 7.76 (2H, s, exchangeable NH2), 7.92 (1H, d, J = 7.6 Hz, ArH). Anal. Calcd. 
for (C25H24N2O4): C, 72.10; H, 5.81; N, 6.73. Found: C, 72.28; H, 5.94; N, 6.82. 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(4-methylphenyl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71p). Yield, 77 %; mp 222–224 °C. 1H 
NMR (DMSO-d6)  1.14 (3H, t, J = 6.8 Hz, Me), 1.95 (2H, m, CH2), 2.22 (3H, s, 
Me), 2.92 (2H, m, Ar-CH2), 3.99 (4H, m, OCH2 & NCH2), 4.87 (1H, s, pyran H4), 
7.17 (2H, d, J = 8.4 Hz, ArH), 7.25–7.29 (1H, m, ArH), 7.39 (2H, d, J = 7.6 Hz, 
ArH), 7.43 (1H, d, J = 7.2 Hz, ArH), 7.79 (2H, s, exchangeable NH2), 7.91 (1H, d, J = 
7.6 Hz, ArH). Anal. Calcd. for (C25H24N2O4): C, 72.10; H, 5.81; N, 6.73. Found: C, 
72.24; H, 5.99; N, 6.57.  
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(2-hydroxy-5-chlorophenyl)-4H,5H,6H,9H-
pyrido[ij]pyrano[3,2-c]quinoline-3-carboxylate (71q). Yield, 65 %; mp 213–214 
°C. 1H NMR (DMSO-d6)  1.06 (3H, t, J = 7.2 Hz, Me), 2.05 (2H, m, CH2), 2.99 (2H, 
m, Ar-CH2), 3.51 (1H, s, exchangeable OH), 3.99 (4H, m, OCH2 & NCH2), 5.32 (1H, 
s, pyran H4), 7.02–7.09 (2H, m, ArH), 7.25 (1H, t, J = 7.6 Hz, ArH), 7.36–7.40 (1H, 
m, ArH), 7.59–7.62 (3H, m, ArH & exchangeable NH2), 7.88 (1H, d, J = 7.6 Hz, 
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ArH). Anal. Calcd. for (C24H21N2O5Cl): C, 63.65; H, 4.67; N, 6.19. Found: C, 63.47; 
H, 5.01; N, 6.23. 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(4-hydroxy-3-methoxyphenyl)-
4H,5H,6H,9H-pyrido[ij]pyrano[3,2-c]quinoline-3-carboxylate (71r). Yield, 74 %; 
mp 224–225 °C. 1H NMR (DMSO-d6)  1.06 (3H, t, J = 7.2 Hz, Me), 2.07 (2H, m, 
CH2), 2.92 (2H, m, Ar-CH2), 3.65 (1H, s, exchangeable OH), 4.02 (4H, m, OCH2 & 
NCH2), 5.23 (1H, s, pyran H4), 7.02–7.10 (2H, m, ArH), 7.23–7.26 (1H, m, ArH), 
7.36–7.38 (1H, m, ArH), 7.59-7.64 (3H, m, ArH & exchangeable NH2), 7.88 (1H, d, J 
= 7.6 Hz, ArH). Anal. Calcd. for (C25H24N2O6): C, 66.95; H, 5.39; N, 6.25. Found: C, 
66.81; H, 5.24; N, 6.34. 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(furan-2-yl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71s). Yield, 62 %; mp 190–194 °C (dec.). 1H 
NMR (DMSO-d6)  1.19 (3H, t, J = 6.8 Hz, Me), 1.99 (2H, m, CH2), 2.93 (2H, m, Ar-
CH2), 4.03 (4H, m, OCH2 & NCH2), 5.04 (1H, s, pyran H4), 6.05 (1H, m, ArH), 6.26 
(1H, m, ArH), 7.26–7.28 (1H, m, ArH), 7.34–7.37 (1H, m, ArH), 7.43 (1H, d, J =7.2 
Hz, ArH), 7.75 (2H, s, exchangeable NH2), 7.89 (1H, d, J = 8 Hz, ArH). Anal. Calcd. 
for (C22H20N2O5): C, 67.34; H, 5.14; N, 7.14. Found: C, 67.44; H, 5.27; N, 7.02. 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-(thiophene-2-yl)-4H,5H,6H,9H-pyrido[ij] 
pyrano[3,2-c]quinoline-3-carboxylate (71t). Yield, 64 %; mp 189–190 °C. 1H NMR 
(DMSO-d6)  1.17 (3H, t, J = 6.8 Hz, Me), 1.99 (2H, m, CH2), 2.92 (2H, m, Ar-CH2), 
4.05 (4H, m, OCH2 & NCH2), 5.22 (1H, s, pyran H4), 6.83–6.86 (1H, m, ArH), 7.18-
7.19 (1H, m ArH), 7.24–7.28 (1H, m, ArH), 7.34–7.36 (1H, m, ArH), 7.43 (1H, d, J = 
7.2 Hz, ArH), 7.79 (2H, s, exchangeable NH2), 7.88 (1H, d, J = 8 Hz, ArH). Anal. 
Calcd. for (C22H20N2O4S): C, 64.69; H, 4.94; N, 6.86. Found: C, 64.78; H, 5.02; N, 
7.01. 
 
Ethyl-11-amino-7,8-dihydro-8-oxo-9-{spiro-[3-H-isatine]}-4H,5H,6H,9H-
pyrido[ij]pyrano[3,2-c]quinoline-3-carboxylate (74). Yield, 61 %; mp >290 °C. 1H 
NMR (DMSO-d6)  0.84 (3H, t, J = 7.2 Hz, Me), 1.93 (2H, m, CH2), 2.91 (2H, m, Ar-
CH2), 3.77 (4H, m, OCH2 & NCH2), 6.69–6.75 (2H, m, ArH), 6.84 (1H, d, J = 7.6 Hz, 
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ArH), 7.06 (1H, t, J = 8 Hz, ArH), 7.28 (1H, t, J = 8 Hz, ArH), 7.47 (1H, d, J = 8 Hz, 
ArH), 7.96 (1H, d, J = 8 Hz, ArH ), 8.04 (2H, s, exchangeable NH2), 10.24 (1H, s, 
exchangeable NH). Anal. Calcd. for (C25H21N3O5): C, 67.71; H, 4.77; N, 9.48. Found: 
C, 67.54; H, 4.86; N, 9.32.  
 
5.3 Conclusion 
We discovered that catalytic amount of piperidine (1–2 drop) can function as 
an effective catalyst for one-pot three-component Tendem Knoevenagel Michael 
addition reaction. This protocol has notable advantages, such as good to excellent 
product yields, efficient methodology, cleaner reaction profiles, ease of work-up, all 
of which make it a attractive strategy for the preparation of 4H,5H,6H,9H-
pyrido[ij]pyrano[3,2-c]quinoline derivatives. The biological study of newly 
synthesized compounds is underway. 
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5.4 Representative Spectra 
5.4.1 1H NMR Spectrum for compound 71a.  
 
 
 
D2O exchange 1H NMR Spectrum for compound 71a. 
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5.4.2 1H NMR Spectrum for compound 71d. 
 
 
 
D2O exchange 1H NMR Spectrum for compound 71d. 
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5.4.3 1H NMR Spectrum for compound 71m. 
 
 
D2O exchange 1H NMR Spectrum for compound 71m. 
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5.4.4 1H NMR Spectrum for compound 74. 
 
 
D2O exchange 1H NMR Spectrum for compound 74. 
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5.4.5 13C NMR Spectrum for compound 71a. 
 
5.4.6 13C NMR Spectrum for compound 71d. 
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5.4.7 135 DEPT 13C NMR Spectrum for compound 71d. 
 
5.4.8 13C NMR Spectrum for compound 71g. 
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5.4.9 13C NMR Spectrum for compound 71m. 
 
5.4.10 135 DEPT 13C NMR Spectrum for compound 71m. 
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Table 5.2  Elemental analysis of compounds 71a–t and 74. 
N
O
O NH2
COOC2H5
HN
O
74
N
O
O NH2
COOC2H5
R
71a-t  
Compd. MF MW 
CHN Calculated (%) CHN Found (%) 
C H N C H N 
71a C24H22N2O4 402.44 71.63 5.51 6.96 71.41 5.56 6.72 
71b C25H24N2O5 432.47 69.43 5.59 6.48 69.21 5.62 6.31 
71c C25H24N2O5 432.47 69.43 5.59 6.48 69.52 5.22 6.61 
71d C25H24N2O5 432.47 69.43 5.59 6.48 69.11 5.43 6.57 
71e C26H26N2O6 462.49 67.52 5.67 6.06 67.62 5.61 5.84 
71f C27H28N2O7 492.52 65.84 5.73 5.69 65.62 5.61 5.84 
71g C27H28N2O7 492.52 65.84 5.73 5.69 65.54 5.81 5.58 
71h C24H21N2O4F 420.43 68.56 5.03 6.66 68.24 4.88 6.53 
71i C24H21N2O4F 420.43 68.56 5.03 6.66 68.34 4.76 6.58 
71j C24H21N2O4Cl 436.89 65.98 4.84 6.41 65.86 4.75 6.28 
71k C24H21N2O4Cl 436.89 65.98 4.84 6.41 65.88 4.71 6.25 
71l C24H21N2O4Br 481.34 59.89 4.40 5.82 59.74 4.21 5.89 
71m C24H21N2O4Br 481.34 59.89 4.40 5.82 59.64 4.31 5.99 
71n C25H24N2O4 416.47 72.10 5.81 6.73 72.34 5.97 6.67 
71o C25H24N2O4 416.47 72.10 5.81 6.73 72.28 5.94 6.82 
71p C25H24N2O4 416.47 72.10 5.81 6.73 72.24 5.99 6.57 
71q C24H21N2O5Cl 452.89 63.65 4.67 6.19 63.47 5.01 6.23 
71r C25H24N2O6 448.47 66.95 5.39 6.25 66.81 5.24 6.34 
71s C22H20N2O5 392.40 67.34 5.14 7.14 67.44 5.27 7.02 
71t C22H20N2O4S 408.47 64.69 4.94 6.86 64.78 5.02 7.01 
74 C25H21N3O5 443.45 67.71 4.77 9.48 67.54 4.86 9.32 
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Section C 
 
Chapter 6. Introduction of (1H-
benzo[d]imidazol-2-yl)amino-
pyrimidine derivatives 
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6.0 Introduction 
Benzimidazole is a fused aromatic imidazole ring system where a benzene 
ring is fused to the 4 and 5 positions of an imidazole ring. Benzimidazoles are also 
known as benziminazoles and 1,3-benzodiazoles.1, 2 (Figure 1) They possess both 
acidic and basic characteristics. The NH group present in benzimidazoles is relatively 
strongly acidic and also weakly basic. Another characteristic of benzimidazoles is that 
they have the capacity to form salts. Benzimidazoles with unsubstituted NH groups 
exhibit fast prototropic tautomerism, which leads to equilibrium mixtures of 
asymmetrically substituted compounds.1 
 
The benzimidazole scaffold is a useful structural motif for the development of 
molecules of pharmaceutical or biological interest.3–5 Appropriately substituted 
benzimidazole derivatives have found diverse therapeutic applications such as in 
antiulcers,3 antihypertensives,6,7 anti-HIV,8 antiinflammatory,9 anticancers,10 
antioxidant,11 antitrichinellosis,12 and anxiolytics.13 The optimization of 
benzimidazole-based structures has resulted in various drugs which are currently in 
the market, such as omeprazole 1 (proton pump inhibitor), pimobendan 2 
(ionodilator), and mebendazole 3 (anthelmintic) (Figure 2).  
Figure 2
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6.1 Benzimidazoles 
Benzimidazole-derived alkaloids are rare in nature, and only few examples of 
these natural products can be found in the literature. On other hand, the occurrence of 
the imidazole skeleton in various natural sources is quite common.14–16 The 
benzimidazole alkaloid kealiiquinone (Figure 3) was isolated from a yellow button-
like Micronesian sponge species of Leucetta.16 
Recently, Nakamura et al. has successfully synthesized a regioisomer of 
kealiiquinone.17 The kealiiquinone 4 and its synthetic regioisomer 5 both have 
relatively weak activities against a panel of 39 human cancer cell lines but are 
considered to have a unique mechanism of action. 17 
Figure 3 Benzimidazole alkaloid and its regioisomer
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Makaluvamines (pyrroloiminoquinones) 6 (Figure 4) was isolated from a 
Fijian sponge in the early 1990s display in vitro cytotoxicity against human colon 
tumor cell lines and also inhibited human topoisomerase II in vitro. The 
benzimidazole analog of this indole-based marine natural product, 
imidazoquinoxalinone 7, has been synthesized by LaBarbera D.V. and co-workers.18 
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In comparison with the natural inositol 1,4,5-triphosphate, the adenophostins 8 
(Figure 5) exhibit higher receptor binding activity and Ca2+ mobilizing potencies and 
thus have significant biological importance. A total synthesis of a benzimidazole 
analog of adenophostin A 9 was described by Shuto et al.19 
N
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OPO3O
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OHO3PO
O3PO
OH
N
NO
OPO3O
OH
O
OHO3PO
O3PO
OH
8 9
Figure 5 Adenophostin and its benzimidazole analog  
 
6.2 Synthetic Methodologies for Benzimidazoles 
Most commonly benzimidazoles have been prepared from the reaction of 1,2-
diaminobenzenes with carboxylic acids under harsh dehydrating reaction conditions, 
utilized strong acids such as polyphosphoric acid, hydrochloric acid, boric acid, or p-
toluenesulfonic acid.20 However, the use of milder reagents, particularly Lewis 
acids,21 inorganic clays,22 or mineral acids,23 has improved both the yield and purity 
of this reaction.24 On the other hand, the synthesis of benzimidazoles via the 
condensation of 1,2-diaminobenzenes with aldehydes requires an oxidative reagent to 
generate the benzimidazole nucleus. Various oxidative reagents, such as nitrobenzene, 
benzoquinone, sodium metabisulfite, mercuric oxide, lead tetraacetate, iodine, 
copper(II) acetate, indium perfluorooctane sulfonates, ytterbium perfluorooctane 
sulfonates, and even air, have been employed for this purpose.25 Moreover, a variety 
of benzimidazoles could also be produced via coupling of 1,2-diaminobenzenes with 
carboxylic acid derivatives such as nitriles, imidates, orthoesters, anhydrides or 
lactones.26 
In recent years, some innovative and improved pathways for the synthesis of 
benzimidazoles have been developed and these are discussed in the following. 
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A palladium-catalyzed N-arylation reaction provided a novel synthesis of 
benzimidazoles from (o-bromophenyl)amidine precursors under microwave 
irradiation. The route was found to be flexible with respect to various substituents and 
allowed for the preparation of highly substituted benzimidazoles, including N-
substituted examples (Scheme 1).27 The method was later improved and optimized to 
achieve the rapid formation of benzimidazoles in high yield.28 It has been found that 
50% aqueous dimethyl ether (DME) is an optimal solvent for the reaction and that 
catalyst loading of palladium can be reduced to 1 mol%. 
Scheme 1
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Recently, 2-alkyl- and 2-aryl-substituted benzimidazole derivatives have been 
synthesized from 1,2-diaminobenzene and its corresponding acids in the presence of 
polyphosphoric acid using microwave assisted methods (Scheme 2).29 The reaction 
time required for the synthesis of benzimidazole derivatives was reduced to minutes 
by this method compared to conventional synthesis, which required up to four hours 
of heating to complete the reaction. Furthermore, it was found that the application of 
microwave irradiation increased yields by 10–50%. 
 
Conventional condensation of 1,2-diaminobenzene with 6-fluoro-3,4-dihydro-
2H-chroman-2-carboxylic acid under Phillip’s conditions or using Eaton’s reagent (1 : 
10 mixture of phosphorus pentoxide/methanesulfonic acid) yielded 2-(6-
fluorochroman-2-yl)-1H-benzimidazole (Scheme 3).30 
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Recently, microwave-assisted synthesis of 2-(alkyloxyaryl)-1H-benzimidazole 
derivatives related to the natural stilbenoid family has been reported (Scheme 4).31 
 
Recently, a facile, rapid one-pot procedure for the generation of 2-substituted 
benzimidazoles directly from 2-nitroanilines using a microwave procedure has been 
demonstrated (Scheme 5). An advantage of this approach is that the intermediate N-
acyl derivatives need not be isolated prior to cyclization.32 
Scheme 5
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Classical condensation-cyclization reactions using 1,2-diaminobenzenes, 2-
mercaptoacetic acid and appropriately substituted aromatic aldehydes in dry benzene 
under reflux required a long reaction time to afford the thiazobenzimidazoles, which 
are potent anti-HIV agents. (Scheme 6)33  
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Functionalization of C–H bonds of heterocycles to C-arylation is an important 
synthetic reaction and is used to build important bioactive structures. Palladium 
catalyst and copper-mediated C-2 arylations of benzimidazole with aryl iodides under 
ligandless and base-free conditions have been described by Bellina et al. (Scheme 
7).34 
 
 
6.3 Pharmacological profile of Benzimidazoles 
6.3.1 Antibacterial and Antifungal Agents 
2-substituted benzimidazole derivatives are known to possess varied biological 
activities.35 Recently, an efficient and rapid synthesis of novel benzimidazole 
azetidin-2-ones 10 has been established,36 and antibacterial screening revealed that all 
newly synthesized azetidin-2-ones 10 exhibited potent antibacterial activity against 
Bacillus subtilis, Staphylococcus aureus and Escherichia coli. Among all of the 
compounds investigated, 10i and 10j exhibited the greatest antibacterial activity 
against Gram-negative E. coli as compared to the antibiotic streptomycin.36 In 
addition, 5-fluoro benzimidazole carboxamide derivatives 1137 and benzimidazole 
isoxazolines 12 38 were reported to show antibacterial and antifungal activities. 
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6.3.2 Anthelmintic Agents 
Bearing in mind previous benzimidazole anthelmintics (e.g., albendazole, 
mebendazole), the search for new anthelmintic drugs is being actively pursued. 
Synthetic benzimidazole piperazine derivatives exhibited 50% anthelmintic activity in 
mice infected with Syphacia obvelata.39 Furthermore, piperazine derivatives of 5(6)-
substituted-(1H-benzimidazol-2-ylthio) acetic acids 13–15 40 and benzimidazolyl 
crotonic acid anilide 16 have shown good anthelmintic activity41 (Figure 7). 
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Figure 7 Benzimidazole anthemintic agents
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6.3.3 Anti-inflammatory and Antiulcer Agents 
Structure–activity relationship studies of the 5,6-dialkoxy-2-thiobenzimidazole 
derivatives 17 have revealed that compounds 17a–k possess pronounced anti-
inflammatory properties42 (Figure 10). Using the carrageenan model, the most 
significant anti-inflammatory effects were observed for compounds 17a, 17d, 17h, 
17i, and 17j. While using the bentonite model, the maximum activities were observed 
for compounds 17e and 17h. These results indicated that benzimidazoles are 
promising leads for the development of new anti-inflammatory agents.  
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Figure 8 Anti-inf lammatory benzimidazole derivatives
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In addition, N-benzoyl and N-tosyl benzimidazole compounds 18 showed 
significant anti-inflammatory activity, as indicated by ear swelling induced by xylene 
in mice, and their ulcer indices were all lower than those of aspirin.43 Furthermore, N-
morpholinomethylbenzimidazole 19 and its derivatives have been recently reported to 
show significant anti-inflammatory activity.44 
 
6.3.4 Cytotoxic and Antitumor Agents 
Novel bisbenzimidazoles with general formula 20–23 incorporating 
benzimidazole, pyridoimidazole, and imidazoquinone moieties as one of the units of 
bisbenzimidazole with a piperazinyl functional group have been synthesized (Figure 
9).45 The series of bisbenzimidazoles contains different leaving groups along with p-
methoxy substituents. The latter may be expected to have some influence on the 
nitrogen lone pair and consequently on the binding characteristics of the ligand. These 
novel bisbenzimidazoles are found to be actively cytotoxic against many human 
cancer cell lines, with GI50 values of between 0.01 and 100 μM, especially in the 
cases of renal cancer, CNS cancer, colon cancer, melanoma, and breast cancer cell 
lines. 
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Figure 9 Cytotoxic benzimidazole derivatives
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In addition, the alkyl-linked bisbenzimidazole 2446 and 
thiazolylbenzimidazole-4,7-diones 2547 exhibited cytotoxic activity against tumor cell 
lines (Figure 10). 
 
Moreover, novel head-to-head bisbenzimidazole compound 26 showed potent 
growth inhibition in human ovarian carcinoma cell lines (IC50 = 200–300 nM), with 
no significant cross-resistance in two acquired cisplatinresistant cell lines and a low 
level of cross-resistance in the p-glycoprotein over expressing doxorubicin-resistant 
cell line. In addition, compound 26 was found to have significant in vivo activity in 
the allowed fiber assay and tumor xenografts. 48-50 
Figure 11
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6.4 Introduction of Pyrimidine 
Pyrimidine is a heterocyclic aromatic organic compound similar to benzene 
and pyridine, containing two nitrogen atoms at positions 1 and 3 of the six-member 
ring.51 It is isomeric with two other forms of diazine. A pyrimidine has many 
properties in common with pyridine, as the number of nitrogen atoms in the ring 
increases the ring pi (π) electrons become less energetic and electrophilic aromatic 
substitution gets more difficult while nucleophilic aromatic substitution gets easier. 
Figure 12
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Azaheterocycles constitute a very important class of compounds. In particular, 
pyrimidine derivatives include a large number of natural products, pharmaceuticals, 
and functional materials (Figure 13).52 Several examples of pharmaceutically 
important compounds include trimethoprim 27,53 sulfadiazine 28,54 Gleevec (29, 
imatinib mesilate),55 and Xeloda (30,capecitabine).56  
Figure 13 Representative compounds containing a pyrimidine substructure.
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6.5 Pyrimidine Natural Products 
In nature, the pyrimidine ring is synthesized from glutamine, bicarbonate, and 
aspartate.57 These starting materials are converted to orotate (31, Figure 14). Several 
(mainly uracil, thymine and cytosine) pyrimidines have been isolated from the nucleic 
acid hydrolyses. The nucleic acid are essential constituent of all cell and thus of all 
living matter cytosine is found to be present in both types of nucleic acid i.e. 
ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) while uracil present only in 
RNA and thymine only in DNA.58 
 
In addition, Pyrimidine ring is also found in vitamin like thiamine 32, 
riboflavin 33 and folic acid 34.59 Barbitone1 35, the first barbiturate hypnotic sedative 
and anticonvulsant is a pyrimidine derivative.60 
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6.6 Synthetic Methodologies for Pyrimidines 
In 1818, Brugnatelli synthesized the first pyrimidine derivative, alloxan by 
nitric acid oxidative degradation of uric acid (Scheme 8).61 Another early report, by 
Frankland and Kolbe in 1848, described the first synthesis of a pyrimidine cyanalkine 
by heating propionitrile with potassium metal (Scheme 8).62 
Scheme 8 Early reports on the synthesis of pyrimidine
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Nitriles are a common N–C source and have been used to form pyrimidines in 
many syntheses. Cyanamide is a particularly useful nitrile derivative in the synthesis 
of pyrimidines as illustrated in Scheme 9.63 
 
The 4,6-di-substituted pyrimidines and 2-amino-4,6-di-substituted pyrimidines 
formed by the reaction of chalcone with thiourea and guanidine hydrochloride in 
presence of sodium hydroxide.(Scheme 10)64 
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Anilido compound are produced by treatment of different aryl amine with 
ethylacetoacetate which cyclized with various aromatic aldehyde and thiourea 
furnishing corresponding pyrimidinethione derivatives (Scheme 11).65 
 
Bag Seema et al. has reported single step reaction for 2,4-diaminopyrimidine 
from guanidine and orthoester in presence of sodium ethanoate in ethanol as solvent 
(Scheme 12).66 
 
 
4-Aryl-2-anilinopyrimidines and 2,4-dianilinopyrimidines (i.e., DAPYs) 
represent privileged structures67 found in an ever increasing number of drug-like 
molecules including VEGF68 and CDK69 inhibitors, reverse transcriptase inhibitors 
(e.g., dapivirine), and tyrosine kinase inhibitors (e.g., Gleevec). Brian I. Bliss et al. 
describe the convenient preparation of novel 4-aryl-2-(heteroarylamino)-pyrimidines 
and 4-anilino-2-(heteroarylamino)-pyrimidines.70 (Scheme 13) 
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Terry V. Hughes and co-workers have synthesized 4-Aryl-5-cyano-2-
aminopyrimidines as VEGF-R2 inhibitors.71 The key step involved reaction of a 
vinylogous amide with a guanidinium salt to form the pyrimidine ring. Specifically, 
conversion of an aryl methyl ester 3 (R1 = aryl) to the corresponding α-cyanoketone 
was achieved via formation of the lithium salt of acetonitrile by treatment with n-
BuLi at 78 0C followed by reaction with the ester at 45 0C. Subsequent treatment of 
the α-cyanoketone with N, N-dimethylformamide diethyl acetal (DMF-DEA) formed 
a vinylogous amide in situ that was reacted with guanidine nitrate in DMF at 100 0C 
to form the 2-amino-4-aryl-5-cyanopyrimidine. The Sandmeyer reaction of the 
aminopyrimidine was accomplished smoothly afford the 2-chloropyrimidine. The 
displacement of the Cl of pyrimidine with aliphatic amines proceeded at room 
temperature and with aromatic amines in refluxing THF to afford the pharmacophore. 
(Scheme 14) 
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Giblin et al.72 developed an efficient synthesis of 2-anilino pyrimidine 
derivatives has been achieved via reaction of 2-chloro-4-trifluoromethyl pyrimidine 
ester and aromatic amine in dioxane. (Scheme 15)  These compounds were found very 
potent analgesic in the FCA model of inflammatory pain and have a high therapeutic 
index and a promising pharmacokinetic profile in the rat.  
The prepared 2-anilino pyrimidine ester and amide derivatives showed 
micromolar potency at the CB2 receptor and good selectivity against CB1.73  
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Youssef et al.74 recently reported the synthesis and anticancer, antimicrobial 
activity of 4-amino-2-(benzo[d]thiazol-2-ylamino)pyrimidine-5-carbonitrile 
derivative. This compound was prepared from 2-guanidinobenzothiazole with 
ethoxymethylenemalononitrile in presence of anhydrous potassium carbonate reflux 
in absolute ethanol. (Scheme 16) 
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Sherif et al.75 has designed, synthesized and investigated the anti-HIV activity 
of some new 4-amino-2-(benzoxazol-2-ylamino)-pyrimidines-5-carbonitrile 
derivatives, which was found to inhibit the spread of the HIV infection by 95 % in 
MT4 cell culture. The 2-(benzoxazol-2-ylamino)-pyrimidines derivative was prepared 
by conventional method as described below. (Scheme 17) 
Chapter 6                                                                                            Introduction of… 
       
 
 
168
 
6.7 Pharmacological Profile of Pyrimidines 
6.7.1 Antineoplastics and anticancer agents 
There are a large number of pyrimidine-based antimetabolites. They are 
usually structurally related to the endogenous substrates that they antagonize. One of 
the early metabolites prepared was 5-fluorouracil76 (5-FU, 36a), a pyrimidine 
derivative. 5-Thiouracil 36b also exhibits some useful antineoplastic activities.77 
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36 a, b
a: X = O; R = F; R1 = H
b: X = O; R = SH; R1 = H
Figure 16  
There are many more in recent times, like nimustine 3778, uramustine 3879 and 
trimetrixate 3980. It is mainly used as an anticancer agent and also exhibits significant 
therapeutic effects in patients with herpes virus infections and herpes encephalitis. 
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6.7.2 Antibacterials and antiprotozoals 
In 1948, Hitchings made an important observation that a large number of 2,4-
diaminopyrimidines and some 2-amino-4-hydroxypyrimidines are antagonists of folic 
acid.81 Since then, a large number of 2,4-diaminopyrimidines have been synthesized 
as antifolates. It was eventually proved that these pyrimidines are inhibitors of the 
enzyme dihydrofolate reductase (DHFR).82 Notable amongst the 2,4-
diaminopyrimidine drugs are pyrimethamine 40, a selective inhibitor of the DHFR of 
malarial plasmodia; trimethoprim 41, an antibacterial drug which selectively inhibits 
bacterial DHFR. 
40 41
Figure 18
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6.7.3 Sulfa drugs 
Pyrimidine derivatives of sulfa drugs, namely sulfadiazine, sulfamerazine and 
sulfadimidine are superior to many other sulfonamides and are used in some acute UT 
infections, cerebrospinal meningitis and for patients allergic to pencillins83. 
Sulfonamide–trimethoprim combinations are used extensively for opportunistic 
infections in patients with AIDS84. Sulfadoxine85 42a, a short and intermediate acting 
sulfonamide with a half-life of 7–9 days is used for malarial prophylaxis. 
Sulfisomidine 42b with a halflife of 7 h is used as a combination sulfa therapy in 
veterinary medicine86. Sulfadiazine 43a, sulfamerzine 43b and sulfadimidine 43c 
possess good water solubility and therefore carry minimum risk of kidney damage, 
which makes them safe even for patients with impaired renal functions. 
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a: R = H; R1 = H; R2 = H
b: R = H; R1 = Me; R2 = H
c: R = H; R1 = Me; R2 = Me
Figure 19  
 
6.7.4 Antivirals and anti-AIDS 
Pyrimidine derivatives have generated widespread interest due to their 
antiviral properties. 5-Iododeoxyuridine87 44 is an antiviral agent of high selectivity. 
5-Trifluromethyl-2’-deoxyuridine (F3 TDR, 45) has been found useful against 
infections resistant to IDU therapy. 87 
Figure 20
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Several members of a series of acyclic nucleosides, which contain a 
pyrimidine ring, are found to be effective antiviral. (Figure 21) 
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Figure 21
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6.7.5 Antifungals 
Pyrimidines also exhibit antifungal properties. Flucytosine 5088 is a fluorinated 
pyrimidine used as nucleosidal antifungal agent for the treatment of serious systemic 
infections caused by susceptible strains of candida and cryptococcus.89 
Figure 22
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6.8 Research Aim 
Three component condensations with the participation of C–H acids, 
aldehydes or orthoesters, and N-containing mono- or binucleophiles lead to a variety 
of derivatives, which possess a wide spectrum of biological activity.90 For example, 
interaction of aromatic aldehydes, (thio)urea, and β-diketones in Biginelli conditions 
gave dihydro(thia)pyrimidones, which are calcium channel activators, antagonists of 
adrenoreceptors, etc. 91-93 
While development of important methodologies for the synthesis of 
pyrimidines enjoys a rich history, the discovery of new strategies for the convergent 
synthesis of pyrimidines remains a vibrant area of chemical research. 
At present there are no reports for the use of such reactions on guanidines, in 
this work, the three component condensation of benzoimidazole-2-guanidines with 
orthoesters and active methylene compounds containing a carbonyl function were 
studied. (Figure 23)  
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N
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Figure 23  
The chemical synthesis and characterization of Substituted-(1H-
benzo[d]imidazol-2-yl)amino-pyrimidine derivatives are described in Chapter 7. 
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Section C 
 
Chapter 7. Synthesis and 
Characterization of Some 
Substituted-(1H-benzo[d]imidazol-
2-yl)amino-pyrimidine derivatives 
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7.0 Chemistry 
The synthetic route for substituted 2-[(1H-benzo[d]imidazol-2-yl)amino]-
pyrimidine derivatives are shown in Scheme 2. The known 2-
benzimidazolylguanidine (53a,b) was synthesized from substituted o-
phenylenediamine (51a,b) and cyanoguanidine (52) by following literature 
procedure.94 Compound 53 was treating with tri ethyl orthoformate (CH(OC2H5)3) 
and active methylene compounds containing carbonyl function (54, 1,3-diketones) to 
furnish substituted 2-[(1H-benzo[d]imidazol-2-yl)amino]-pyrimidine (55a-h). The 
synthetic route for carboxamide derivatives are shown in Scheme 3. The substituted 
acetoacetanilide (57) was directly prepared from substituted aniline (56) by our 
laboratory established method.95 The compounds (57) were reacted with tri ethyl 
orthoformate (CH(OC2H5)3) and 2-benzimidazolylguanidine (53a,b) to give 
regioisomers intermediate (58a–n). The cyclization of regioisomers intermediate was 
carried out by heating in glacial acetic acid with sodium acetate to furnish 2-[(1H-
benzo[d]imidazol-2-yl)amino]-4-methyl-N-(substituted)-phenyl-pyrimidine-5-
carboxamide derivatives (59a–n). Table 7.1 and 7.2 show the yields and the physical 
data of these compounds. 
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7.1 Reaction Scheme  
7.1.1 Scheme 1 Synthetic route for 2-benzimidazolylguanidine (53a, b). 
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51a, b 52 53a, b
R1 R
1
a; R1 = H,
b; R1 = Cl  
 
7.1.2 Scheme 2 Synthetic routes for substituted 2-[(1H-benzo[d]imidazol-2-
yl)amino]-pyrimidine derivatives (55a–h). 
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7.1.3 Scheme 3 Synthetic routes for 2-[(1H-benzo[d]imidazol-2-yl)amino]-4-
methyl-N-(substituted)phenylpyrimidine-5-carboxamide derivatives (59a–n). 
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Table 7.1 Yields and physical data of the compounds 55a–h. 
 
 
Compd. 
Substitute Yield 
% 
MP °C Analysis 
R1 R2 R3 
55a H Me Me 88 > 300 CHN 
55b H Me OMe 79 210–211 CHN 
55c H Me OEt 76 221–222 CHN 
55d H CF3 OEt 72 214–215 CHN 
55e Cl Me Me 78 > 300 CHN 
55f Cl Me OMe 74 222–223 CHN 
55g Cl Me OEt 71 234–235 CHN 
55h H i-Pr OMe 79 218–219 CHN 
 
Table 7.2 Yields and physical data of the compounds 59a–n. 
 
N
H
N
NH
N
N
O
NHMe
R4
59a-n
R1
 
Compd. 
Substitute Yield 
% 
MP °C Analysis 
R1 R4 
59a H H 82 268–270 CHN 
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59b H 2-MeO 75 248–249 CHN 
59c H 4-MeO 77 240–241 CHN 
59d H 2-F 73 242–243 CHN 
59e H 4-F 79 247–248 CHN 
59f H 2-Cl 69 252–253 CHN 
59g H 3-Cl 71 240–241 CHN 
59h Cl 3-Cl 74 255–256 CHN 
59i H 4-Br 82 262–263 CHN 
59j H 2-Me 72 286–287 CHN 
59k Cl 2-Me 76 271–272 CHN 
59l H 2,6-di-Me 67 > 300 CHN 
59m H 3-CF3 63 265–266 CHN 
59n Cl 3-CF3 61 272–273 CHN 
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7.2 Experimental  
7.2.1 General methods and materials 
 
All commercial chemicals and solvents were reagent grade and used without 
further purification unless otherwise specified. Melting points were determined on a 
Fargo melting point apparatus and are uncorrected. Thin-layer chromatography was 
performed on silica gel G60 F254 (Merck) with short-wavelength UV light for 
visualization. All reported yields are isolated yields after chromatography or 
crystallization. Elemental analyses were done on a Heraeus CHN-O Rapid instrument. 
Mass spectra were recorded on Shimadzu GC-MS QP-2010 model using direct 
injection probe technique. The molecular ion peak was found in agreement with 
molecular weight of the respective compound. 1H NMR spectra were recorded on a 
400 MHz, Brucker Top-Spin spectrometers in the indicated solvent. The chemical 
shifts were reported in ppm () relative to TMS and coupling constants (J) in Hertz 
(Hz) and s, d, t, m, brs, refer to singlet, doublet, triplet, multiplet, broad respectively. 
 
All synthesized compounds were characterized by using 1H NMR, 13C NMR, 
Mass and Elemental analysis. For compounds 55a–h, the characteristic proton signals 
for pyrimidine ring (Ar-CH) appeared at the range of 8.96–9.09 δ ppm as singlet. The 
ethyl ester (OC2H5) proton appeared at the range of 1.31–1.35 and 4.30–4.34 δ ppm as 
triplet and quartet respective. The characteristic proton for benzimidazole ring and 
bridge (NH) appeared at the range of 11.87–12.24 δ ppm as singlet and D2O 
exchangeable single. While the compounds 59a–n, the characteristic proton signals 
for pyrimidine ring (Ar-CH) appeared at the range of 8.73–8.79 δ ppm as singlet and 
amide (CONH) proton appeared at the range of 10.19–10.51 δ ppm as singlet D2O 
exchangeable single. The characteristic proton for benzimidazole ring and bridge 
(NH) appeared at the range of 11.89–12.01 δ ppm as singlet and D2O exchangeable 
single. The molecular ion peak was found in agreement with molecular weight of the 
respective compound. The elemental analysis of the newly synthesized derivatives 
was within ±0.4% range of the calculated C, H, N data. 
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Synthesis of 2-benzimidazolylguanidine (53a). A mixture of o-phenylenediamine 
(51, 10.8 g, 100 mmol), cyanoguanidine (52, 8.4 g, 100 mmol) and concd HCl (20 
mL) in H2O (200 mL) was heated under reflux for 1 h. The reaction mixture was 
cooled at 0 °C and KOH (10%; 50 mL) was added slowly. The precipitates of 2-
guanidinobenzimidazole were collected by filtration, washed with H2O, dried, and 
used in next reactions without further purification. Yield 14 g (80 %); mp 240–242 °C 
(lit.94 mp 243–244 °C); MS m/z = 175 (M+). 
 
By following the same synthetic procedure as that for 53a, the following compounds 
were synthesized: 
 
5-Chloro-2-benzimidazolylguanidine (53b). Yield, 79 %; mp 258–259 °C. MS m/z 
= 209 (M+).  
 
1-[2-((1H-Benzo[d]imidazol-2-yl)amino)-4-methylpyrimidin-5-yl]ethanone (55a). 
A mixture of 2-guanidinobenzimidazole (53a, 1.75 g, 10 mmol), acetylacetone (54, 1 
g, 10 mmol) and tri ethyl orthoformate (15 mL) was stirred at reflux temperature for 
40 min. Upon the completion of the reaction (monitored by TLC, ethyl acetate:hexane 
(1:1)), the reaction mixture was concentrated under reduced pressure, and 1 mL of 
water was added. The separated solid product was collected by filtration and 
recrystallized from DMF to give 55a 2.3 g (88 %); mp > 300 °C (lit.96 mp > 300 °C); 
MS m/z = 267 (M+). Anal. Calcd. for (C14H13N5O4): C, 62.91; H, 4.90; N, 26.20. 
Found: C, 62.78; H, 4.98; N, 26.44. 
 
By following the same synthetic procedure as that for 55a, the following compounds 
were synthesized: 
 
Methyl-2-((1H-benzo[d]imidazol-2-yl)amino)-4-methylpyrimidine-5-carboxylate 
(55b). Yield, 79 %; mp 210–211 °C. 1H NMR (DMSO-d6)  2.78 (3H, s, Me), 3.85 
(3H, s, OMe), 7.09–7.11 (2H, m, 2 × ArH), 7.51–7.53 (2H, m, 2 × ArH), 8.96 (1H, s, 
ArH), 11.99 (2H, br s, exchangeable NH). MS m/z = 283 (M+). Anal. Calcd. for 
(C14H13N5O2): C, 59.36; H, 4.63; N, 24.72. Found: C, 59.69; H, 4.54; N, 24.88. 
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Ethyl-2-((1H-benzo[d]imidazol-2-yl)amino)-4-methylpyrimidine-5-carboxylate 
(55c). Yield, 76 %; mp 221–222 °C. 1H NMR (DMSO-d6)  1.34 (3H, t, J = 7.2 Hz, 
Me), 2.77 (3H, s, Me), 4.31 (2H, q, J = 7.2 Hz, OCH2), 7.08–7.10 (2H, m, 2 × ArH), 
7.47–7.49 (2H, m, 2 × ArH), 8.96 (1H, s, ArH), 11.87 (2H, br s, exchangeable NH). 
MS m/z = 297 (M+). Anal. Calcd. for (C15H15N5O2): C, 60.60; H, 5.09; N, 23.56. 
Found: C, 60.34; H, 5.31; N, 23.41. 
 
Ethyl-2-((1H-benzo[d]imidazol-2-yl)amino)-4-(trifluoromethyl)pyrimidine-5-
carboxylate (55d). Yield, 72 %; mp 214–215 °C. 1H NMR (DMSO-d6)  1.32 (3H, t, 
J = 7.2 Hz, Me), 4.31 (2H, q, J = 7.2 Hz, OCH2), 7.15–7.17 (2H, m, 2 × ArH), 7.45–
7.47 (2H, m, 2 × ArH), 9.09 (1H, s, ArH), 12.24 (2H, br s, exchangeable NH). 13C 
NMR (DMSO-d6)  13.7, 61.5, 112.6, 112.8, 1211.8, 133.3, 148.9, 161.5, 161.7, 
162.7.  MS m/z = 351 (M+). Anal. Calcd. for (C15H12N5O2F3): C, 51.29; H, 3.44; N, 
19.94. Found: C, 51.46; H, 3.57; N, 19.73. 
 
1-[2-((5-Chloro-1H-Benzo[d]imidazol-2-yl)amino)-4-methylpyrimidin-5-
yl]ethanone (55e). Yield, 78 %; mp > 300 °C. MS m/z = 301 (M+). Anal. Calcd. for 
(C14H12N5OCl): C, 55.73; H, 4.01; N, 23.21. Found: C, 55.46; H, 3.89; N, 23.34. 
 
Methyl-2-((5-Chloro-1H-benzo[d]imidazol-2-yl)amino)-4-methylpyrimidine-5-
carboxylate (55f). Yield, 74 %; mp 222–223 °C. MS m/z = 317 (M+). Anal. Calcd. 
for (C14H12N5O2Cl): C, 52.92; H, 3.81; N, 22.44. Found: C, 52.78; H, 3.98; N, 22.32. 
 
Ethyl-2-((5-Chloro-1H-benzo[d]imidazol-2-yl)amino)-4-methylpyrimidine-5-
carboxylate (55g). Yield, 71 %; mp 234–235 °C. MS m/z = 331 (M+). Anal. Calcd. 
for (C15H14N5O2Cl): C, 54.30; H, 4.25; N, 21.11. Found: C, 54.12; H, 4.47; N, 21.38. 
 
Methyl-2-((5-chloro-1H-benzo[d]imidazol-2-yl)amino)-4-isopropylpyrimidine-5-
carboxylate (55h). Yield, 79 %; mp 218–219 °C. MS m/z = 311 (M+). Anal. Calcd. 
for (C16H17N5O2): C, 61.72; H, 5.50; N, 22.49. Found: C, 61.40; H, 5.24; N, 22.38. 
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2-((1H-Benzo[d]imidazol-2-yl)amino)-4-methyl-N-phenylpyrimidine-5-
carboxamide (59a). A mixture of 2-guanidinobenzimidazole (53a, 1.75 g, 10 mmol), 
3-oxo-N-phenylbutanamide (57, 1.8 g, 10 mmol) and tri ethyl orthoformate (15 mL) 
was stirred at reflux temperature for 30 min. The precipitates were collected by 
filtration and recrystallized from dioxane to give (58a). Compound 58a was added 
into a mixture of anhydrous sodium acetate (3 g) in glacial acetic acid (30 mL) and 
the reaction mixture was boiled for 30 min. The reaction mixture was cooled to room 
temperature and dropped into cold water (100 mL). The precipitates was collected by 
filtration and recrystallized from DMF to give 59a 2.8 g (82 %); mp 268–270 °C; MS 
m/z = 344 (M+). Anal. Calcd. for (C19H16N6O): C, 66.27; H, 4.68; N, 24.40. Found: C, 
66.43; H, 4.47; N, 24.59. 
 
By following the same synthetic procedure as that for 59a, the following compounds 
were synthesized: 
 
2-((1H-Benzo[d]imidazol-2-yl)amino)-N-(2-methoxyphenyl)-4-methylpyrimidine-
5-carboxamide (59b). Yield, 75 %; mp 248–249 °C. MS m/z = 374 (M+). Anal. 
Calcd. for (C20H18N6O2): C, 64.16; H, 4.85; N, 22.45. Found: C, 64.38; H, 4.77; N, 
22.31. 
 
2-((1H-Benzo[d]imidazol-2-yl)amino)-N-(4-methoxyphenyl)-4-methylpyrimidine-
5-carboxamide (59c). Yield, 77 %; mp 240–241 °C. MS m/z = 374 (M+). Anal. 
Calcd. for (C20H18N6O2): C, 64.16; H, 4.85; N, 22.45. Found: C, 64.01; H, 4.67; N, 
22.28. 
 
2-((1H-Benzo[d]imidazol-2-yl)amino)-N-(2-fluorophenyl)-4-methylpyrimidine-5-
carboxamide (59d). Yield, 73 %; mp 242–243 °C. MS m/z = 362 (M+). Anal. Calcd. 
for (C19H15N6OF): C, 62.98; H, 4.17; N, 23.19. Found: C, 62.77; H, 4.02; N, 23.41. 
 
2-((1H-Benzo[d]imidazol-2-yl)amino)-N-(4-fluorophenyl)-4-methylpyrimidine-5-
carboxamide (59e). Yield, 79 %; mp 247–248 °C. 1H NMR (DMSO-d6)  2.66 (3H, 
s, Me), 7.06–7.10 (2H, m, 2 × ArH), 7.19–7.23 (2H, m, 2 × ArH), 7.46–7.49 (2H, m, 
2 × ArH), 7.73–7.77 (2H, m, 2 × ArH), 8.73 (1H, s, ArH), 10.51 (1H, br s, 
exchangeable CONH), 11.98 (2H, br s, exchangeable NH). MS m/z = 362 (M+). Anal. 
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Calcd. for (C19H15N6OF): C, 62.98; H, 4.17; N, 23.19. Found: C, 62.80; H, 4.30; N, 
23.01. 
 
2-((1H-Benzo[d]imidazol-2-yl)amino)-N-(2-chlorophenyl)-4-methylpyrimidine-5-
carboxamide (59f). Yield, 69 %; mp 252–253 °C. 1H NMR (DMSO-d6)  2.71 (3H, 
s, Me), 7.08–7.11 (2H, m, 2 × ArH), 7.28–7.32 (1H, m, ArH), 7.39–7.43 (1H, m, 
ArH) 7.51–7.58 (3H, m, 3 × ArH), 7.71–7.73 (1H, m, ArH), 8.79 (1H, s, ArH), 10.19 
(1H, br s, exchangeable CONH), 11.90 (2H, br s, exchangeable NH). 13C NMR 
(DMSO-d6)  23.1, 121.1, 121.9, 127.8, 127.9, 128.2, 129.0, 129.9, 134.9, 148.3, 
157.5, 158.5, 165.0, 168.0. MS m/z = 378 (M+). Anal. Calcd. for (C19H16N6OCl): C, 
60.24; H, 3.99; N, 22.19. Found: C, 60.41; H, 3.78; N, 22.03. 
 
2-((1H-Benzo[d]imidazol-2-yl)amino)-N-(3-chlorophenyl)-4-methylpyrimidine-5-
carboxamide (59g). Yield, 71 %; mp 240–241 °C. MS m/z = 378 (M+). Anal. Calcd. 
for (C19H15N6OCl): C, 60.24; H, 3.99; N, 22.19. Found: C, 60.08; H, 4.21; N, 22.33. 
 
2-((5-Chloro-1H-benzo[d]imidazol-2-yl)amino)-N-(3-chlorophenyl)-4-
methylpyrimidine-5-carboxamide (59h). Yield, 74 %; mp 255–256 °C. MS m/z = 
413 (M+). Anal. Calcd. for (C19H14N6OCl2): C, 55.22; H, 3.41; N, 20.34. Found: C, 
55.03; H, 3.21; N, 20.25. 
 
2-((1H-Benzo[d]imidazol-2-yl)amino)-N-(4-bromophenyl)-4-methylpyrimidine-5-
carboxamide (59i). Yield, 82 %; mp 262–263 °C. MS m/z = 423 (M+). Anal. Calcd. 
for (C19H16N6OBr): C, 53.91; H, 3.57; N, 19.86. Found: C, 53.74; H, 4.18; N, 19.73. 
 
2-((1H-Benzo[d]imidazol-2-yl)amino)-N-(2-methylphenyl)-4-methylpyrimidine-5-
carboxamide (59j). Yield, 72 %; mp 286–287 °C. MS m/z = 358 (M+). Anal. Calcd. 
for (C20H18N6O): C, 67.02; H, 5.06; N, 23.45. Found: C, 67.18; H, 5.19; N, 23.34. 
 
2-((5-Chloro-1H-benzo[d]imidazol-2-yl)amino)-N-(2-methylphenyl)-4-
methylpyrimidine-5-carboxamide (59k). Yield, 76 %; mp 271–272 °C. MS m/z = 
392 (M+). Anal. Calcd. for (C20H17N6OCl): C, 61.15; H, 4.36; N, 21.39. Found: C, 
61.34; H, 4.18; N, 23.47. 
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2-((1H-Benzo[d]imidazol-2-yl)amino)-N-(2,6-dimethylphenyl)-4-
methylpyrimidine-5-carboxamide (59l). Yield, 67 %; mp > 300 °C. MS m/z = 372 
(M+). Anal. Calcd. for (C21H20N6O): C, 67.73; H, 5.41; N, 22.57. Found: C, 67.58; H, 
5.29; N, 22.71. 
 
2-((1H-Benzo[d]imidazol-2-yl)amino)-N-(3-trifluoromethyl)-4-methylpyrimidine-
5-carboxamide (59m). Yield, 63 %; mp 265–266 °C. MS m/z = 412 (M+). Anal. 
Calcd. for (C20H15N6OF3): C, 58.25; H, 3.67; N, 20.38. Found: C, 58.37; H, 3.87; N, 
20.22. 
 
2-((5-Chloro-1H-benzo[d]imidazol-2-yl)amino)-N-(3-trifluoromethyl)-4-
methylpyrimidine-5-carboxamide (59n). Yield, 61 %; mp 272–273 °C. MS m/z = 
446 (M+). Anal. Calcd. for (C20H14N6OF3Cl): C, 53.76; H, 3.16; N, 18.81. Found: C, 
53.41; H, 3.48; N, 18.67.  
 
7.3 Conclusion 
In present chapter, first time reported three component condensations of 
benzoimidazole-2-guanidines, orthoester and active methylene carbonyl compounds 
leading to several novel new chemical entities substituted-(1H-benzo[d]imidazol-2-
yl)amino-pyrimidine derivatives. The biological activity of newly synthesized 
compounds is under investigation.  
Chapter 7                                                                    Synthesis & characterization of… 
       
 
 
185
7.4 Representative Spectra 
7.4.1 Mass Spectrum for compound 53a.  
 
 
 
7.4.2 1H NMR Spectrum for compound 55b. 
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7.4.3 1H NMR Spectrum for compound 55c. 
 
 
 
D2O exchange 1H NMR Spectrum for compound 55c. 
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7.4.4 1H NMR Spectrum for compound 55d. 
 
 
 
D2O exchange 1H NMR Spectrum for compound 55d. 
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7.4.5 1H NMR Spectrum for compound 57.  
 
 
 
7.4.6 1H NMR Spectrum for compound 59e. 
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D2O exchange 1H NMR Spectrum for compound 59e. 
 
 
 
7.4.7 1H NMR Spectrum for compound 59f. 
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D2O exchange 1H NMR Spectrum for compound 59f. 
 
 
 
7.4.8 13C NMR Spectrum for compound 55d. 
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7.4.9 13C NMR Spectrum for compound 59f. 
 
 
 
7.4.10 Mass Spectrum for compound 55a. 
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7.4.11 Mass Spectrum for compound 55g. 
 
 
 
7.4.12 Mass Spectrum for compound 55h. 
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7.4.13 Mass Spectrum for compound 59e. 
 
  
7.4.14 Mass Spectrum for compound 59g. 
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7.4.15 Mass Spectrum for compound 59j. 
 
 
 
7.4.16 Mass Spectrum for compound 59k. 
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7.4.17 Mass Spectrum for compound 59l. 
 
 
 
7.4.18 Mass Spectrum for compound 59m. 
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7.4.19 Mass Spectrum for compound 59n. 
 
 
N
H
N
NH
N
N
O
NHMe
MW: 446.81
CF3
Cl
Chapter 7                                                                    Synthesis & characterization of… 
       
 
 
197
Table 7.3  Elemental analysis of compounds 55a–h and 59a–n. 
 
 
   
Compd. MF MW 
CHN Calculated (%) CHN Found (%) 
C H N C H N 
55a C14H13N5O 267.29 62.91 4.90 26.20 62.78 4.98 26.44
55b C14H13N5O2 283.29 59.36 4.63 24.72 59.69 4.54 24.88
55c C15H15N5O2 297.31 60.60 5.09 23.56 60.34 5.31 23.41
55d C15H12N5O2F3 351.28 51.29 3.44 19.94 51.46 3.57 19.73
55e C14H12N5OCl 301.73 55.73 4.01 23.21 55.46 3.89 23.34
55f C14H12N5O2Cl 317.73 52.92 3.81 22.04 52.78 3.98 22.32
55g C15H14N5O2Cl 331.76 54.30 4.25 21.11 54.12 4.47 21.38
55h C16H17N5O2 311.34 61.72 5.50 22.49 61.40 5.24 22.38
59a C19H16N6O 344.37 66.27 4.68 24.40 66.43 4.47 24.59
59b C20H18N6O2 374.40 64.16 4.85 22.45 64.38 4.77 22.31
59c C20H18N6O2 374.40 64.16 4.85 22.45 64.01 4.67 22.28
59d C19H15N6OF 362.36 62.98 4.17 23.19 62.77 4.02 23.41
59e C19H15N6OF 362.36 62.98 4.17 23.19 62.80 4.30 23.01
59f C19H15N6OCl 378.82 60.24 3.99 22.19 60.41 3.78 22.03
59g C19H15N6OCl 378.82 60.24 3.99 22.19 60.08 4.21 22.33
59h C19H14N6OCl2 413.26 55.22 3.41 20.34 55.03 3.21 20.25
59i C19H15N6OBr 423.27 53.91 3.57 19.86 53.74 4.18 19.73
59j C20H18N6O 358.40 67.02 5.06 23.45 67.18 5.19 23.34
59k C20H17N6OCl 392.84 61.15 4.36 21.39 61.34 4.18 21.47
59l C21H20N6O 372.42 67.73 5.41 22.57 67.58 5.29 22.71
59m C20H15N6OF3 412.37 58.25 3.67 20.38 58.37 3.87 20.22
59n C20H14N6OF3Cl 446.81 53.76 3.16 18.81 53.41 3.48 18.67
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Summary 
 
The work represented in the thesis entitled “Studies on Some Oxygen, Nitrogen and 
Sulfur Containing Heterocycles” is divided into three sections with seven chapters 
which can be summarized as below. 
 
Section A deals with the potent antitumor DNA bifunctional alkylating agents and is 
further divided into three chapters. 
Chapter 1 comprises of the general introduction of the DNA bifunctional alkylating 
agents. Initially, the naturally occurring antitumor Mitomycin C (MMC), which 
possess two reactive nucleophilic centers are capable of cross-linking with DNA. The 
other synthetic antitumor bifunctional alkylating agents, 
bis(hydroxymethyl)pyrrolizines derivatives were also able to induce DNA cross-
linking via a similar mechanism of action of MMC. Based on the mechanism of 
action of these agents, in this chapter, we recently design several bis(hydroxymethyl) 
and bis(alkylcarbamates) pyrrolo derivatives. 
In Chapter 2, planned to synthesize Target Molecules (TMs). A series of linear 
bis(hydroxymethyl)-5,10-dihydropyrrolo[1,2-b]isoquinolin-1-yl derivatives and their 
bis(alkylcarbamate) derivatives were prepared. In this chapter, 53 compounds enlisted 
which are newly synthesized and bioactive compounds for various antitumor 
activities. 
Chapter 3, consists of antitumor activity of both bis(hydroxymethyl)pyrrolo[1,2-
b]isoquinoline and their bis(alkylcarbamate) derivatives. All the prepared derivatives 
show potent antitumor activity in various human tumor xenografts in vitro. Among 
these analogues, we discovered compound 81a, which was selected for antitumor 
studies in animal models, exhibits potent therapeutic efficacy against human breast 
MX-1 xenograft in nude mice, as complete tumor remission was observed. This agent 
is also able to significantly suppress human ovarian tumors (SK-OV-3) implanted in 
nude mice. The results reported herein warrant further investigation to optimize the 
schedule and dosage to get greater suppression of other human tumor growth in 
animal models. Studies on the DNA interstrand cross-linking suggested that the newly 
synthesized derivatives are potent bifunctional DNA cross-linking agents. 
Furthermore, these agents induced substantial G2/M phase arrested of the cell cycle. 
       
 
 
207
Section B encompasses the pyrano[3,2-c]quinolone derivatives and is further divided 
into two chapters. 
Chapter 4 covers the history and background of pyrano[3,2-c]quinolone analogues. 
Various biological activities like Antibiotic, Anticancer, Anti-HIV, Calcium Channel 
Blockers, Antiallergic, Antimicrobial etc are summarized. Various synthetic 
procedures for the synthesis of pyrano[3,2-c]quinolone core structure are also shown. 
In Chapter 5, attempts were made to generate small library of pyrano[3,2-
c]quinolone derivatives. The one-pot three-component Tendem Knoevenagel Michael 
addition reaction to furnish novel 4H,5H,6H,9H-pyrido[ij]pyrano[3,2-c]quinoline 
derivatives. The biological activity of newly synthesized compounds is under 
investigation. 
 
Section C deals with the (1H-benzo[d]imidazol-2-yl)amino-pyrimidine derivatives 
and is further divided into two chapters. 
Chapter 6 narrates the background and biological activity study of the Benzimidazole 
and Pyrimidine derivatives as well as in here including some recent synthetic 
strategies which have been employed to synthesize this class of compounds. The 
literature survey revealed that such class of which contains both heterocycles are 
show various biological activity. 
In Chapter 7, first time reported three component condensations of guanidines, 
orthoester and active methylene carbonyl compounds leading to several novels 
substituted-(1H-benzo[d]imidazol-2-yl)amino-pyrimidine derivatives. 22 new 
molecules are prepared and characterized in this chapter. The yield of these 
compounds is good to excellent.  
 
In all 96 derivatives have been synthesized in current work which are characterized by 
spectral data. Some of the compounds were tested for preliminary antitumor activity 
and advanced study. Other mechanistic studies like DNA interstrand cross-linking, 
cell cycle inhibition and rat plasma stability was also performed in the current work. 
The remaining synthesized compounds are also under screening for Anticancer, Anti-
tubercular as well as antimicrobial activity study, the results of which are awaited. 
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methylene compounds. Ravi Chaniyara, Bhavin Marvania, Nikhil Vekariya, 
Anamik Shah. (Manuscript under preparation). 
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Conferences/Seminars/Workshops Attended 
 
 “International conference on bridging gaps in discovery and development:  
chemical & biological science for affordable health, wellness & sustainability” 
jointly organized by ISCBC and Saurashtra University, Rajkot. February, 04-
07, 2011. 
 “The 7th International Symposium for Chinese Medicinal Chemists” (ISCMC) 
Kaohsiung, Taiwan, February, 01-05, 2010. 
 “2009 PST Medicinal Chemistry Symposium” Si-Tao, Taiwan, June 28-30, 
2009.  
 “International Conference On The Interface of Chemistry-Biology In 
Biomedical Research” jointly organized by ISCBC and Birla Institute of 
Technology & Science, Pilani. February, 22-24, 2008. 
 “A National Workshop On Updates In Process And Medicinal Chemistry” 
jointly organized by National Facility for Drug Discovery through New 
Chemicals Entities Development & Instrumentation support to Small 
Manufacturing Pharma Enterprises and DST FIST, UGC-SAP & DST-DPRP 
Funded Department of Chemistry, Saurashtra University, Rajkot March, 3-4, 
2009. 
 
 “National Conference On Selected Topics In Spectroscopy And 
Stereochemistry” organized by the Department of Chemistry, Saurashtra 
University, Rajkot, March, 18-20, 2009. 
 
 “National Workshop On Management And Use Of Chemistry Database And 
Patent Literature” organized by GUJCOST & Dept. of Chemistry of 
Saurashtra University, Rajkot, (Gujarat), February, 27-29, 2008. 
 
